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Chronic Lymphocytic Leukaemia (CLL) is the most common adult Leukaemia in the 
UK, Western Europe and America. It is a malignancy of naïve B-cells. The clinical 
course of patients with CLL is heterogeneous; some patients survive for years without 
treatment, others die of a chemotherapy resistant disease within two years of 
presentation. Genomic studies have found little variation in patients showing differing 
prognosis, suggesting that it is the same disease but with varying outcomes. At present 
there is no cost effective, reliable and routine clinical test which can distinguish patient 
prognosis and a “watch and wait” strategy is currently in clinical use. 
 
Studies have shown that patients who express mutated IgVH genes on the B-cell 
receptor (BCR) have a good prognosis, whereas patients who express unmutated IgVH 
genes have a poor prognosis. However IgVH gene mutational status is an expensive and 
time consuming test and would not be practical for routine clinical practice. If the B-cell 
has not been sensitised to a specific antigen (i.e. unmutated IgVH genes on BCR) it is 
hyper-responsive to stimulation through the BCR by antigen. Stimulation of the BCR 
may prevent apoptosis of malignant cells; therefore a hyper-responsive BCR is linked to 
poor prognosis. 
 
By artificially stimulating cells and using proteomic techniques we have investigated 
signaling pathways activated by the BCR to gain a greater understanding of the anti-
apoptotic nature of the malignant B-cells and to find potential prognostic biomarkers 
related to a hyper-active BCR. 
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Protein was extracted from stimulated and unstimulated cells from CLL patients 
categorised as having a poor prognosis (unmutated IgVH genes and hyper-responsive 
BCR). The extracts were separated using conventional two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE). The gels were stained with coomassie blue total protein 
stain and analysed with statistical software. Proteins with a two-fold (p<0.05) change in 
expression between stimulated and unstimulated samples were excised from the gels 
and analysed by matrix assisted laser desorption/ionisation with time of flight mass 
spectrometry (MALDI-TOF-MS). Antibody microarrays were used as a complimentary 
method to 2D-PAGE and immunoblotting was applied as a verification technique. 
 
Changes in protein expression were detected in response to prolonged BCR stimulation. 
Many of the proteins have had no previous connection with BCR signaling or leukaemia 
and give a greater insight to the mechanisms of the BCR. Targets found include ones 
which are associated with the activation of anaplastic lymphoma kinase (ALK), the 
plasma kallikrein-kinin system (KKS), the AKT-1 pathway, the MAPK pathways, the 
adenylate kinase system and involvement in the CD40-dependant activation of B-CLL 
cells. One of the protein targets found (kininogen) was increased by over two-fold in 
three independent clinical samples after sustained BCR stimulation. If we understand 
more about the BCR signaling pathways then we may be able to identify potential 
prognostic biomarkers and novel targets for therapeutic intervention that may inhibit 
survival of the malignant B-cells. 
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A Clinical Introduction to CLL 
 
1.1 Chronic Lymphocytic Leukaemia 
 
Chronic lymphocytic leukaemia (CLL) is a malignancy of naïve B-cells (Hamblin et al. 
1999). It is characterised by the progressive accumulation of mature B-cells with a 
characteristic immunophenotype (Hamblin et al. 1999; Lin et al. 2002). The clinical 
course of patients with B-cell CLL is heterogeneous; some patients survive for years 
without treatment, others die of a drug resistant disease in a year or two of presentation 
(Lin et al. 2002; Castro et al. 2005). However, it has been shown that CLL cases share a 
common mechanism of transformation and/or cell of origin, therefore CLL is one 




CLL is the most common adult leukaemia in the UK (Figure 1.1). An average of 2400 
people in the UK are diagnosed with the disease every year (CancerBacup. 2004).  
Incidence is dramatically increased in the over 60 age range (Figure 1.2). From 1971 to 
2001, deaths from CLL have shown a slight downward trend despite the increase in 
incidence, reflecting increased survival rates (Cancer Research UK. 2003). 
 





Figure 1.1: Chart to show numbers and proportions of leukaemias by type 
in the UK in 1999 (Cancer Research UK. 2003) 
Pie chart to show incidence of CLL. CLL is observed as the most common 
leukaemia and constitutes the greater proportion of the chart with 2310 cases 
reported in the UK in 1999, accounting for 35% of all leukaemias reported. 
(Office for National Statistics. 2002; ISD Online: Information and Statistics 
Division NHS Scotland. 2003; Welsh Cancer Intelligence and Surveillance Unit. 









Figure 1.2: Chart to show numbers of cases by age and leukaemia type in the 
UK in 1999 (Cancer Research UK. 2003) 
The chart shows that diagnosis of CLL increases with age. CLL is a disease of the 
elderly and rarely affects people under the age of 40 (Office for National Statistics. 
2002; ISD Online: Information and Statistics Division NHS Scotland. 2003; Welsh 





The aetiology of CLL is largely unknown, although it has been suggested that genetic 
factors may play a role (Chiorazzi et al. 2005; Crossen. 1997), it is primarily a disease 
of the elderly and it usually affects patients over the age of 55 (Kay et al. 2002). There 
is an overall excess of male diagnoses of CLL in a ratio of 2:1 to women (Leukaemia 
Research. 1996). Although the incidence in black and white populations are 
approximately equal, the disease in rarely seen in Asian origins irrespective of their 
residency or lifestyle. This suggests underlying differences in susceptibility (Leukaemia 
Research. 1996). 
 




1.2 Diagnostic Markers 
 
CLL cells share particular immunophenotypic features (Dighiero et al. 2008). The 
monoclonal population of B-cells in CLL express mature B-cell markers CD5 and 
CD23, weak expression of surface immunoglobulin and B-Lymphocyte surface antigen 
CD19 (Hamblin et al. 1999; Cochran et al. 2003; Chiorazzi et al. 2005). A positive 
expression of CD20 is also an indication of B-cell CLL. A total lymphocyte count of >5 
x 109 L is required for diagnosis (3.5 x 109 L is classed as a normal count). 
 
1.3 Clinical Staging 
 
The disease is said to have a variable course, some patients die within one year after 
diagnosis while others live for longer than ten years (Rai et al. 1975). The clinical 
staging of CLL is set by two accepted and measurable standardised parameters. These 
are called the Rai clinical staging method (Rai et al. 1975), which is mainly used in the 
USA, and the Binet prognostic classification (Binet et al. 1982), which is used 
throughout Europe. 
 
1.3.1 The Rai Clinical Staging Method 
 
The Rai clinical staging method puts the disease into five main classifications; 0, I, II, 
III and IV (Table 1.1). Table 1.1 shows clinical features and median survival. In the 
study anaemia (haemoglobin (Hb) levels less than 11g/100ml) and thrombocytopenia 
(platelets count less than 100,000mm3) were considered. The study was based on 125 
patients (Rai et al. 1975). 




Table 1.1: Table to show the five classification of CLL staging using the 
Rai staging method 
Rai 
Stage Clinical Feature 
Median Survival 
(months) 
0 Lymphocytosis (abnormal increase in number of lymphocytes) >150 
I As 0 + enlargement of lymph nodes 101 
II As 1 + enlargement of spleen or liver 71 
III As 2 + progressive compromise of  bone marrow function as revealed by anaemia 19 
IV As 3 + thrombocytopenia (abnormal decrease in number of circulating platelets) 19 
   
 
 
1.3.2 Binet Prognostic Classification 
 
The Binet prognostic classification stages the disease into three main classifications; A, 
B or C (Table 1.2). There are fewer stages than that of the Rai staging method and the 
system is simple, requiring only clinical examination and routine haematological 
analysis. Survivals of two series of CLL patients (99 from a retrospective series and 196 
from a prospective series) were studied (Binet et al. 1982).  
 
Group A was classed as patients with no anaemia (Hb levels above or equal to 
10g/100ml), no thrombocytopenia (a platelet count of 100,000-400,000/mm3) and less 
than three involved lymph node areas. Fifty-five percent of patients were categorised 
into group A and did not reach median survival after 10 years. 
 
Group B was classed as patients with no anaemia, no thrombocytopenia and three or 
more involved lymph node areas. Thirty percent of patients were categorised into group 
B and reached median survival at 7 years. 




Group C was classed as patients with anaemia (Hb less than 10g/100ml) and/or 
thrombocytopenia (platelets less than 100,000/mm3). Fifteen percent of patients were 
categorised into group C and reached median survival at 2 years. 
 
Table 1.2: Table to show the three classification of CLL staging using Binet 
staging method 





A <3 ≥10g/100ml ≥100,000mm3 >10 
B ≥3 ≥10g/100ml ≥100,000mm3 7 
C Any number <10g/100ml <100,000mm3 2 
 
 
1.4 Prognostic Factors 
 
Indications of bad prognosis include:  
 
1. Lymphocyte doubling time less than one year (Hamblin et al. 1999) 
2. Zeta associated protein 70 (ZAP-70), a critical T-cell receptor molecule 
(Packham et al. 2005), found in over 20% of leukaemic B-cells 
3. CD38, a cell surface enzyme involved in regulating B-cell activation (Hamblin. 
2004), found in over 30% of leukaemic B-cells 
4. Unmutated IgVH genes on B-cell receptor (see section 2.3) 
 
There is much controversy over using CD38 and ZAP-70 as prognostic markers. 
Expression of CD38 is known to change during the course of the disease (Chevallier et 
al. 2002) and CD38 expression conflicts with that of IgVH gene mutational status as a 
prognostic marker (Hamblin et al. 2002). Expression of ZAP-70 has also shown to 




conflict with IgVH gene mutational status (Rassenti et al. 2004). It has been shown that 
some patients show cells that lack ZAP-70, but also show cells with hyper-active B-cell 
receptors (see section 2.2) (Deglesne et al. 2006). ZAP-70 and CD38 are not fully 
standardised (Hamblin. 2007). There are disagreement as to what defines positivity, and 
expression levels are suggested to change, therefore further work is required with larger 
cohorts (Hamblin. 2007). At present IgVH status remains the strongest predictor of 
prognosis (Ghia et al. 2007; Hamblin et al. 1999; Maloum et al. 2000). To determine 
IgVH status requires a time consuming and expensive test, so at present there is no 
routine, cost effective, reliable clinical test to show how a patient diagnosed with CLL 
will progress. 
 
1.4.1 Chromosome Aberrations 
 
In CLL chromosome aberrations are detected in approximately 40-50% of tumours 
when using conventional chromosome banding analysis (Dohner et al. 1999), while 
fluorescence in-situ hybridisation (FISH) and molecular techniques reveal an even 
higher incidence (Crossen. 1997). 
 
 Chromosome 17 - Advanced disease is associated with a deletion in 17p. The 
tumour suppresser gene p53 is located on chromosome 17p13. and analysis 
shows that 10-15% CLL patients have mutations in p53 (Crossen. 1997). 
 Chromosome 11 - A deletion in 11q is also associated with bad prognosis. The 
myeloid/lymphoid or mixed-lineage leukaemia (MLL) gene is located on the 11q 
chromosome and is involved in pattern development during embryogenesis 
(Stanulla et al. 2001). 




 Chromosome 13 - Good prognosis is associated with 13q deletion as a sole 
aberration. 13q abnormalities are the most common structural abnormalities in 
B-CLL (Crossen. 1997). The gene encoding the retinoblastoma 1 (RB1) protein 
is located on the 13q chromosome and is a critical part of cell cycle control 
(Crossen. 1997). 
 Chromosome 12 - Trisomy 12 is the most frequent numerical chromosome 
abnormality in B-CLL (Dohner et al. 1999). The segment duplicated includes 
bands 12q13-q21.2, indicating that this region contains genes involved with the 




CLL is known as an incurable disease and patients are only recommended for treatment 
if the disease progresses or the symptoms become troublesome. Newly diagnosed 
patients with Binet stage A/B disease are monitored without therapy (Cheson et al. 
1996). At present there is no clinical test to show how a patient will progress; therefore 
patients must show symptoms before undergoing any form of treatment. A “watch and 
wait” procedure is implied, which is often termed by the patients as “watch and worry”. 
The National Cancer Institute Sponsored Working Group has published recommended 
criteria for starting treatment (Cheson et al. 1996). These include weight loss (greater 
than 10%) within 6 months, fevers for 2 weeks, night sweats, or extreme fatigue, as well 
as worsening anaemia and/or thrombocytopenia, autoimmune cytopenias (deficiency of 
certain elements in the blood caused by an immune response), progressive enlargement 
of the spleen (splenomegaly), progressive enlargement of the lymph nodes 
(lymphadenopathy) and lymphocyte doubling time of 6 months (Abbott. 2006).   




Oral chemotherapy is usually the first treatment recommended. Chlorambucil and 
Fludarabine are the most common drugs used. Table 1.3 shows the names and types of 
the most common drugs used in CLL. Some patients may need to be treated with 
intravenous chemotherapy, and if patients do not respond to a treatment, combination 
therapies can be used. Table 1.4 shows the most common combination therapies in 
CLL. 
 
Table 1.3: Table showing chemotherapy drugs 
used to treat CLL and mode of action 
Drug Type 
Chlorambucil Alkylating Agent 
Fludarabine Purine Analogue 
Cyclophosphamide Alkylating Agent 
Cladribine Purine Analogue 
Vincristine Vinca Alkaloid 
Prednisone Steroid 
Prednisolone Steroid 
Doxorubicin Anthracycline Antibiotic 
Rituximab Monoclonal Antibody 









Table 1.4: Table showing drugs used in chemotherapy 
combinations to treat CLL 
Combinations Drugs 
COP Cyclophosphamide, Vincristine and Prednisolone 
CHOP Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone 
CAP Cyclophosphamide, Doxorubicin, and Prednisolone 
FC Fludarabine and Cyclophosphamide 
FCR Fludarabine, Cyclophosphamide and Rituximab 
 
 
   
Chapter 2  - A Molecular Introduction to 
Chronic Lymphocytic Leukaemia 
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A Molecular Introduction to Chronic Lymphocytic Leukaemia 
 
CLL is an accumulation of mature B-cells (Hamblin et al. 1999) that have escaped 
apoptosis but do not proliferate (Bernal et al. 2001). 
 
2.1 The B-Cell 
 
The abbreviation “B” in B-cell stands for bursa-derived cells from the Bursa of 
Fabricius, which is a lymphoid organ found in birds were B-cells were first found to 
mature (Glick et al. 1964). B-cells are lymphocytes that mature in the bone marrow, 
travel through the lymphatic system in the blood and enter the lymph node. When in the 
germinal centre of the lymph node each cell is sensitised to a specific antigen 
(Stevenson et al. 2004), such as a toxin, bacterium or enzyme derived from outside the 
cell and from foreign cells (Figure 2.1). When an antigen is introduced into the body it 
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Figure 2.1: Diagram to show development of normal B-cells 
The B-cells become mature in the bone marrow, travel through the lymphatic system in 
the blood and enter the lymph node, where, in the germinal centre each cell is sensitised 
to a specific antigen. 
 
CLL is a tumour of mature B-cells (Hamblin et al. 1999) that have escaped apoptosis 
and do not proliferate (Bernal et al. 2001). The CLL B-cells are inert in vitro (Dighiero 
et al. 2008), suggesting that the cells rely on their microenvironment for survival 
(Burger. 2007). Most CLL research is therefore based on established Burkitt’s 
lymphoma B-cell lines such as RAJI, DAUDI and RAMOS. 
 
2.2 B-Cell Receptor 
 
B-cells express thousands of receptors on their surface, which bind to a targeted antigen 
if encountered to initiate cellular signaling pathways. Data has shown that stimulation of 
the B-cell receptor (BCR) (Figure 2.2) by antigen may prevent apoptosis of the 
malignant B-cells, and thus tumour behaviour relates to the differential ability of the 
BCR to respond to antigen (Stevenson et al. 2004). Good prognosis is associated with a 
BCR which is unresponsiveness (only responsive to it’s specific antigen) and bad 
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prognosis is associated with a BCR, which maintains the full capacity to respond to any 
antigen which the cells may be chronically exposed to (Scielzo et al. 2005). 
 
2.3 Mutations in the Variable Region of the Heavy Chain Immunoglobulin Genes 
 
The BCR consists of membrane bound Immunoglobulin (Ig) arranged in heavy and 
light chain loci (Figure 2.2). 
 
 
Figure 2.2: Diagram showing the BCR structure and membrane bound 
immunoglobulin 
B-cells express thousands of receptors on their surface, which bind to a targeted 
antigen to initiate cellular signaling pathways. 
Key: H: Heavy chain, L: Light chain V: Variable region, C: Constant region  
 
CLL may be divided into clinically distinct groups depending on whether the gene that 
controls the shape of the variable region of the heavy chain surface immunoglobin 
(IgVH) has under gone mutation or not (Cochran et al. 2003). The mutational status of 
the IgVH genes is an excellent prognostic indicator (Hamblin et al. 1999), but the 
analysis of the IgVH genes is a very time consuming expensive test and cannot routinely 
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be done in the clinic. CLL patients with mutated IgVH genes have a favourable 
prognosis over those with unmutated IgVH genes (Cochran et al. 2003). 
 
There are a few possible theories to explain IgVH gene mutational status as an indication 
of prognosis. One reason may be as follows: Genetic mutations occur in the germinal 
centre, which is situated in the lymph node. Here the cell is bombarded with antigens 
and the gene that controls the shape of the IgVH is mutated, so that the cell is sensitised 
to a specific antigen. A BCR which expresses unmutated IgVH genes has not been 
sensitised to a specific antigen. This suggests that it may not have entered the germinal 
centre, and therefore has not had the shape of the IgVH gene altered and is able to 
respond to a variety of non-specific antigens (Figure 2.3). Alternatively, the cell may 
have been exposed to antigen in the germinal centre but with insufficient stimulus 






Proteomic Analysis of Chronic Lymphocytic Leukaemia - A Molecular Introduction to 




Figure 2.3: Diagram to show theoretical development of the CLL B-cell which 
lacks IgVH mutation 
The B-cell has not entered the germinal centre in the lymph node, and has not had the 
shape of the IgVH gene altered. Therefore the BCR is not sensitised to a specific antigen 
and can trigger cell signaling in response to a variety of non-specific stimuli. 
 
Because the BCR is not sensitised to a specific antigen, it is hyper-responsive to 
stimulation from a variety of non-specific antigens. The over-active BCR will 
incessantly initiate cascades of cellular signaling pathways, which may support the 
survival of malignant B-cells (Bernal et al. 2001). This may be the reason why 
unmutated IgVH genes is related to a poor prognosis (Hamblin et al. 1999). It has also 
been shown that CLL patients share a common gene expression “signature” irrespective 
of IgVH gene mutational status (Rosenwald et al. 2001). 
 
2.4 B-Cell Receptor Signaling 
 
When an antigen stimulates the BCR, it translocates to lipid-enriched microdomains in 
the membrane termed lipid rafts (Figure 2.4) (Allsup et al. 2005). The lipid rafts are 
cholesterol-rich plasma membrane microdomains, and serve as a platform for B-cell 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - A Molecular Introduction to 
Chronic Lymphocytic Leukaemia 
 
 18
signaling (Cheng et al. 2001). Receptor stimulation induces phosphorylation of the 
receptor linked tyrosine (TYR) kinases (Stevenson et al. 2004). This leads to 
recruitment of other kinases that become phosphorylated. This results in the activation 




Figure 2.4: Figure to show BCR ligation into lipid rafts 
When an antigen stimulates the BCR, it translocates to lipid-enriched 
microdomains in the membrane. The lipid rafts act as a platform for 
B-cell signaling. 
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Figure 2.5: The complex signaling pathways associated with BCR activation (Dal 
Porto et al. 2004) 
BCR stimulation induces phosphorylation of kinases. This results in the activation of 
complex inter-connected signaling pathways which control cellular functions such as 
proliferation, differentiation and apoptosis. 
 
The mitogen activated protein kinase (MAPK) pathway is an example of one of the 
signaling pathways induced by BCR stimulation (Figure 2.6). When an antigen 
stimulates the BCR, auto-phosphorylation is triggered on the TYR (TYR) residues. 
Signaling molecules attach to the phosphorylated TYR (P-TYR). This binding 
stimulates the exchange of guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP), which activates a G protein (Kolch. 2000). The G protein is a protein found in 
the inner surface of the plasma membrane. They are called G proteins because they bind 
guanine nucleotides. The G protein activates a kinase cascade (Kolch. 2000). 
 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - A Molecular Introduction to 
Chronic Lymphocytic Leukaemia 
 
 20
The MAPK/extra cellular regulated kinase (MAPK/ERK) pathway (Figure 2.6) is an 
example of a MAPK signal transduction pathway. The pathway is very complex and 
regulates cellular activities such as cell proliferation, differentiation and importantly, 
apoptosis. This pathway has important implications in CLL due to survival capabilities 
of mature CLL B-cells in the blood. The G protein, Ras, is activated after BCR 
stimulation by an antigen. Ras recruits Raf, a cytosolic protein kinase (MAPKKK) 
(Dumaz et al. 2005) from the cytosol to the membrane. Raf is activated by kinases that 
phosphorylate the activating sites and de-phosphorylate the inhibitory sites. Activated 
Raf phosphorylates and activates mitogen activated ERK protein kinase (MEK). 
Phosphorylated MEK (P-MEK) activates ERK. Activated ERK then distributes into the 
cytosol and the nucleus. The activation of these proteins initiates other signaling 
pathways making the cascades interconnected and very complex. The result is the 
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Figure 2.6: Diagram of the MAPK pathway 
Upon antigen stimulation, kinases are phosphorylated 
resulting in the initiated of signaling pathways. 
Key 
p: Phosphorylation 
MAPKKK: Mitogen Activated Protein Kinase Kinase 
Kinase 
MAPKK: Mitogen Activated Protein Kinase Kinase 
MAPK: Mitogen Activated Protein Kinase 
MEK: Mitogen Activated ERK Protein Kinase 
ERK: Extra Cellular Regulated Kinase 
 
The BCR can be artificially stimulated to produce cascades of signals. Antibodies can 
be used that react with the light chain immunoglobulin (Ig) on the surface of the BCR, 
resulting in the clustering of BCR and initiating activation. Naïve and mature B-cells 
express the IgM antibody molecule, which has five base units covalently bonded with 
disulfide bonds. Each base unit has two binding sites. The B-cell can be artificially 
activated by cross-linking the BCR with an anti-IgM antibody in vitro (Haas et al. 
2000). By analysing the expression status of phosphoproteins downstream of the 
pathways, such as P-ERK, activation of the BCR can be confirmed. Chemicals such as 
phorbol 12-myristate 13-acetate (PMA) can also be used to stimulate B-cells. PMA 
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activates protein kinase C, which will subsequently lead to the activation of the MAPK 
pathway. Sole expression of IgG (an antibody with one base unit) is rare in CLL B-cells 
(Potter et al. 2006), therefore it can be used as an isotype control when activating cells 




Chronic lymphocytic leukaemia is the commonest leukaemia in the UK. The clinical 
course of patients with B-cell CLL is heterogeneous; some patients survive for decades 
without treatment, others die of a drug resistant disease in a year or two of presentation. 
There is no routine, cost effective clinical test to show how a patient will progress. IgVH 
gene mutational status has proven to be an excellent indication of prognosis, but the test 
is time consuming and expensive. The mutational status is related to the BCR 
responsiveness, which therefore can also be linked to prognosis. A bad prognosis is 
associated with unmutated IgVH genes and consequently a hyper-responsive BCR that is 
not sensitised to a specific antigen. A good prognosis is associated with mutated IgVH 
genes and a BCR that has been sensitised to a specific antigen to trigger a specific 
pathway. The signaling pathways which the hyper-active BCR is activating may be the 
key to understanding the survival skills of the mature B-cells in CLL. 
 
 
   
Chapter 3 - An Introduction to Proteomic 
Techniques 








The search for cancer-causing alterations within the whole genome is complicated by 
the different ways genes may be transcribed into a variety of functionally different 
proteins which can themselves undergo essential functional changes (Baak et al. 2005). 
The expression levels of all proteins would arguably provide the most relevant single 
data set characterising a biological system (Cox et al. 2007). There are many reasons 
why protein expression analysis (proteomics) is considered an alternative method to 
mRNA-based measurements (transcriptomics). For example proteins of interest in blood 
are mainly extracellular and transcriptomics is not directly relevant. Also proteomics 
delivers the desired end point, namely the protein expression level of a gene of interest 
(Cox et al. 2007). Proteins can also undergo post-translational modifications which 
affect the protein’s stability, localisation and function (Aebersold et al. 2003). Therefore 
proteomics gives a better reflection of the current state of the cell’s microenvironment 
than gene expression profiling (genomics) or transcriptomics. In 2001 Rosenwold et al 
used genomics to distinguish between CLL patients with good and bad prognosis. They 
found that CLL is characterised by a common gene expression “signature” irrespective 
of IgVH mutational status which is an accepted prognostic marker (see section 2.3) 
(Rosenwald et al. 2001). However, changes in protein expression have been found 
between CLL patients with differing prognosis (Scielzo et al. 2005; Cochran et al. 
2003), therefore, we have used proteomics as a technique to investigate B-cell receptor 
signaling, an indication of prognosis (see section 2.4) in CLL. 
 




Proteomics has been an important developing area of research for the past two decades 
(Aldred et al. 2004). The recent developments in mass spectrometry, such as high 
sensitivity and automation of protein identification has significantly increased the 
number of large scale proteomics projects (Stasyk et al. 2004). Although previously 
called ‘fishing expeditions’, today the term ‘discovery science’ is respectfully used for 
such large scale studies (Baak et al. 2005). Initial experiments using cell lines are now 
giving rise to the analysis of complex tissue and biological fluids to establish protein 
changes associated with disease (Aldred et al. 2004).  
 
3.1.1 One Dimensional Polyacrylamide Gel Electrophoresis 
 
One dimensional (1D) polyacrylamide gel electrophoresis (PAGE) is used to separate 
proteins in one dimension by molecular weight into a polyacrylamide gel in a tris-
glycine-sodium dodecyl sulphate (SDS) buffer (TGS buffer).  
 
Protein samples must be extracted or resuspended in a suitable buffer such as Laemmli 
buffer. Components of a Laemmli buffer are: 
 
 Detergent – (e.g. SDS) to solubilise membrane proteins and break down protein-
protein interactions 
 Reducing Agent – (e.g. β-mercaptoethanol) to reduce protein disulphide bonds 
prior to SDS-PAGE 
 Buffer – e.g. tris (hydroxymethyl) aminomethane-hydrochloride (Tris-HCl 
pH6.8) 




 Glycerol – to increase the density of a sample so that it sinks into the well when 
loading onto a gel 
 Protease Inhibitors – to inhibit the function of protease enzymes, which break 
down proteins. Protease inhibitor cocktails are available commercially 
 Phosphatase Inhibitors – to inhibit phosphates enzymes, which remove 
phosphate groups from proteins by hydrolysing phosphoric acid esters. It is 
important to use phosphatase inhibitors if studying phosphoproteins. 
Phosphatase inhibitor cocktails are available commercially 
 Dye – (e.g. bromophenol blue) to colour protein sample to enable visualisation 
 
The protein mixture is loaded into the gel and separated out into individual protein 
bands dependant on molecular weight (Figure 3.2). The proteins are then stained to 
visualise them using a dye such as coomassie blue (see section 3.1.3). A molecular 
weight marker is run in the gel. These are available to purchase ready made and contain 
a “ladder” of known proteins of specific weights, which are measured in Kilodaltons 
(KDa). The protein bands are compared to the known standard in the ladder to confirm 
their weight. Proteins can then be excised; digested and analysed as described in section 
3.1.4. It is an excellent technique if there are only a small number of proteins to be 
separated. However, if there are too many proteins, the bands will be masked by other 
proteins of a similar weight. By separating the proteins in a second dimension according 
to pH (see section 3.1.2) resolution is improved and a large number of proteins can be 
visualised and accurately excised. 
 
 




3.1.2 Two Dimensional Polyacrylamide Gel Electrophoresis 
 
Two dimensional polyacrylamide gel electrophoresis (2D-PAGE) is a method widely 
used to separate proteins. Proteins are first separated horizontally onto an immobilised 
pH gradient (IPG) strip on the basis of their pH dependant, net charges (pI) by 
isoelectric focusing (IEF). This is known as the first dimension of separation. They are 
then separated vertically on the basis of their molecular masses by electrophoresis into a 
polyacrylamide gel in a TGS buffer. This is the second dimension of separation. 
Proteins spots on the gel are visualised using a stain (Figure 3.1). 
 
 
Figure 3.1: Picture of a 2D gel stained with coomassie blue protein stain 
The picture is from a complex protein mixture extracted from a blood sample, which 
has been separated out into individual protein spots. Proteins where first separated 
horizontally dependant on there pI on an IPG strip. The IPG strip was then placed into a 
gel, where and the proteins ran out of the IPG strip and separated vertically dependant 
on their molecular weight. A molecular weight marker was included in the gel and the 
gel was stained with coomassie blue to visualise the proteins. 
 




When the protein spots are visible, they are cut from the gel, digested into peptides 
using an enzyme such as trypsin, and mass spectrometry (MS) is then used to generate a 
peptide mass fingerprint (PMF) which can be used to identify the protein. 
 
Throughout the 2D-PAGE experimental workflow it is vital that the sample is not 
contaminated by foreign proteins. The sample must be handled with nitrile gloves to 
prevent polymer contaminations from latex gloves, and extra care must be taken to 
avoid keratin contamination from skin and hair throughout the experiment. New, clean 
equipment should be used. Proteins samples should be frozen at -80oC or in liquid 
nitrogen in the presence of protease inhibitors (Beranova-Giorgianni. 2003). 
 
3.1.2.1 First Dimension: Separation by pH 
 
To prepare the sample for gel electrophoresis the protein sample needs to be extracted 
in, or resuspended in a solubilisation/denaturation (SD) buffer (Beranova-Giorgianni. 
2003). This is used to ensure reliable running of the IEF. Components of the SD buffer 
are: 
 
 Chaotrophe – (e.g urea/thiourea) to disrupt hydrogen bonded structures in the 
sample protein and increase solubility 
 Reducing Agent – (e.g. dithiothreitol (DTT)) to reduce disulphide bonds, so that 
all proteins in the sample have the same linear shape 
 Detergent – (e.g 3-((3-Cholamidopropyl)Dimethylammonio)-1-
propanesulphonate (CHAPS)) to solubilise membrane proteins and break down 
protein-protein interactions 




 Ampholytes – (e.g. Bio-Lyte® (Bio-Rad)) to establish a stable pH gradient for 
use in IEF  
 Protease Inhibitors – to inhibit the function of protease enzymes 
 Phosphatase Inhibitors – to inhibit phosphatase enzymes 
 Dye – (e.g. bromophenol blue) to colour protein sample 
 
In order to separate out the proteins, a pH gradient must be established. The proteins are 
placed in a medium with a pH gradient and an electric field is applied. The proteins will 
migrate towards the electrode with the opposite charge and will pick up or lose protons. 
The net charge and the mobility will decrease and eventually the proteins will slow 
down. Each protein will stop at the point in the pH gradient that is equal to its pI. 
An IPG is commonly used for IEF. Immobilines are buffering acrylamide derivatives 
immobilised within a polyacrylamide gel, which produce a pH gradient that does not 
drift. An IPG is stable for IEF as the gel is plastic backed and the pH gradient is fixed. 
Also an IPG can be applied to larger protein samples without gradient degeneration and 
decreased batch variability. The disadvantage of an IPG is that membrane and 
hydrophobic proteins can be poorly represented in SDS-PAGE. This could be due to 
protein/gel interactions during IEF. However the advantages of using an IPG outnumber 
the disadvantages. 
 
IPG strips are pre-packed from suppliers and arrive dehydrated and in a variety of pH 
ranges. Before they are used they must be rehydrated. If the strip is rehydrated in the 
presence of the sample (in-gel rehydration) the resolution is improved, and large sample 
volumes can be handled (Rabilloud et al. 1994). 
 




3.1.2.2 Second Dimension: Separation by Molecular Weight 
 
When the proteins have been separated by IEF they can be further separated by 
molecular weight by SDS-PAGE. The IPG strips must be equilibrated before they can 
be used for SDS-PAGE to further denature proteins, maintain solubility, and establish 
an appropriate pH for SDS-PAGE analysis. DTT is added to reduce any re-formed 
disulphide bonds and iodoacetamide (IAA) is added to alkylate the sulphydryls, 
converting them to carboxyamidocysteine residues so that they cannot recombine to 
form disulfides. It is important that in the second dimension the proteins are treated with 
SDS to give them a negative charge and to denature them (Garfin. 2003). The 
equilibrated IPG strip is placed onto the top of the polyacrylamide gel and an electric 
field is applied. The proteins migrate into the gel and separate out according to their 
molecular weight.  
 
3.1.3 Visualising Proteins 
 
After the SDS-PAGE has been performed the proteins must be visualised in order to 
excise them, so the proteins are stained. There are various different staining methods, 
the most popular being coomassie blue staining as it is relatively cheap, quick and easy. 
This stain can detect down to 80ng of protein (Figure 3.2) and it is compatible with MS. 
 





Figure 3.2: Picture of a 1D gel showing the sensitivity of coomassie blue protein 
stain 
The picture shows a 1D gel loaded with different concentrations of pure protein 
standard, cytochrome C (12KDa). The protein was stained with coomasie blue to 
visualise and a molecular weight ladder was included to confirm protein band 
weights. The result shows that coomassie can detect down to 80ng of protein. 
 
Silver staining is another popular option. The stain can detect 0.5-1.2ng protein, which 
makes it more sensitive than coomassie. However, it is relatively time consuming, 
messy and expensive. Silver stain is not usually compatible with MS; however, some 
suppliers now produce a range suitable for MS. The quantification of protein spots is 
unreliable with silver staining because of its lack of dynamic range. 
 
Fluorescent stains are becoming more popular. This is because they can detect 1-2ng of 
protein, they are selective and quantitative. They range in price and most are quick and 
easy to use. Commercially available total protein fluorescent stains include Sypro Ruby 
(Molecular Probes), Flamingo (Bio-Rad) and Krypton (Pierce) (Table 3.1) 
 




Table 3.1: Table to show cited ranges and excitation/emission maxima of total 
protein fluorescent stains. 
Fluorescent Stain Protein Detection Excitation/Emission Maxima 
Sypro Ruby 0.25ng-1ng 450/610nm 
Flamingo 0.5ng-1µg 532/605nm 
Krypton >0.25ng 520/580nm 
   
 
 
These are total protein stains but there are fluorescent stains which only stain specific 
proteins, such as phosphoproteins, membrane proteins and glycoproteins. Pro-Q 
Diamond phosphoprotein gel stain (Molecular Probes) is a selective stain for 
phosphorylated proteins. Pro-Q Diamond stain can detect 1-16ng of protein and has an 
excitation/ emission maxima of ~555/580nm. A robotic system is an advantage for spot 
excision as visualising fluorescently stained proteins can be a problem. However, the 
fluorescent stain can be excited by a UV light source and the spots can then be cut out 
manually. Fluorescent stains are light sensitive which makes handling them a problem. 
Fluorescent stains are excellent for visualising low amounts of proteins, however, if the 
proteins are to be identified, the technique used for identification must retain a similar 
level of sensitivity. 
 
3.1.4 Protein Identification 
 
The protein spots of interest are individually cut out of the gel. The proteins must then 
be de-stained to prevent the stain interfering with the analysis. The proteins are too big 
to be removed from the gel; therefore they are digested within the gel into small 




peptides for analysis. This can be done using an enzyme, such as trypsin, which cleaves 
the protein at the C-terminal side of lysine and arginine (Beranova-Giorgianni. 2003). 
 
The sample may need to be de-salted before MS analysis. This can be done by diluting 
the sample with buffer or with the use of desalting tips such as Zip Tips (Millipore). The 
pipette tips contain immobilised C18, C4 or another resin attached to the tip. The 
sample is drawn into the tip and the peptides bind to the resin. The peptides can then be 
washed and eluted. However, 100% recovery of peptides cannot be guaranteed.  It is not 
always necessary to desalt samples when using a MALDI-TOF-MS and it may depend 
on the instrument. 
 
When the samples have been prepared they can then be analysed by MS to determine 
the peptide mass fingerprint. The sequenced peptides are traced back to the parent 
protein by using bioinformatics. 
2D-PAGE coupled with MS is a very popular method for identifying biomarkers and 
differences in protein expression between samples; however, it does have its limitations. 
The main problem is contaminations from abundant proteins such as keratins. Hair and 
skins cells can fall into tubes and samples, which will be digested with the sample when 
trypsin is added. The result is a mixture of sample peptides and contaminating peptides 
which cause high intensity MS peaks. These peaks can shroud lower abundant proteins 
resulting in insignificant identifications. However, an experienced analyst will be able 
to edit the MS data to disregard the contaminating peaks (see Appendix H). Co-
migration of proteins causes problems when excising and identifying as there maybe 
more than one protein present in the gel piece excised. In addition 2D-PAGE may 
exclude highly hydrophobic, very acidic, very basic, very small, very large, and low 




abundant proteins. However, apart from the restrictions mentioned, the technique is 
global and there is no method at present which is equivalent. 
 
3.2 Mass Spectrometry 
 
The two main types of ionisation techniques used in proteomics for MS are: 
 
 Matrix assisted laser desorption ionisation (MALDI) (Aebersold et al. 2001; Lin 
et al. 2003) 
 Electrospray ionisation (ESI) (Aebersold et al. 2001; Lin et al. 2003) 
 
3.2.1 Matrix Assisted Laser Desorption Ionisation 
 
MALDI uses energy from a laser to ionise biomolecules (Lin et al. 2003). The sample 
to be analysed is mixed with small, energy absorbing, organic matrix molecules, such as 
2, 5 dihydroxybenzoic acid (DHB) or -cyano-4-hydroxycinnamic acid (CHCA). The 
matrix and sample are mixed in an appropriate solvent to prevent aggregation of the 
sample. The mixture is spotted onto a MALDI sample plate, which is a flat stainless 
steel surface containing hydrophilic anchors on the surface (Figure 3.3). The solvent is 
removed under vacuum conditions or by evaporation, leaving co-crystallized peptides 
homogeneously dispersed within matrix molecules.  
 





Figure 3.3: Picture of a MALDI sample plate 
Picture of an AnchorChip™ MALDI Target (#209515; Bruker Daltronics). The sample 
plate is a made from stainless steel and contains spotting areas with hydrophilic anchors 
on the surface which are arranged on a coordinate grid. The spotting areas and 
hydrophilic anchors come in a range of sizes and shapes dependant on the amount and 
type of sample used. 
 
Ionisation occurs when the matrix molecules absorb energy from the photon energy 
provided by the laser and transfers it into excitation energy (Figure 3.4) (Lin et al. 
2003). When the pulsed laser beam is tuned to the appropriate frequency, the energy is 
transferred to the matrix, which is partially vaporised, carrying intact peptides into the 
vapour phase and charging the amino acid chains. MALDI produces mainly singly 
charged ions, which allows the mass to charge (m/z) value to be determined.  
 





Figure 3.4: Schematic of a MALDI source 
A laser is used to transfer energy to the matrix carrying it and the peptides towards the 
mass analyser. 
 
Multiple laser shots are used to improve the signal-to-noise ratio and the peak shapes, 
which increases the accuracy of the molecular mass determination. The user can 
determine how many shots the laser will fire per acquisition. Usually this range is 
between twenty and fifty laser shots per spectra acquirement. Multiple spectra are 
acquired and summed to give “averaged” spectra. Good quality spectra should have a 
minimum of 200 laser shots combined from each acquirement to give the final spectra. 
However, if more spectra are acquired and combined, the peaks will be better defined 
making peak picking/editing and the protein identification process easier. This is more 
relevant to DHB matrix rather than CHCA, as the DHB/sample mixture is not a 
homogenous mixture due to the large size of the DHB crystals. Peptides are not 
distributed equally in the co-crystallisation on the sample plate, which means that the 
user may need to “hunt” for the peptides. CHCA dries to form a fine powder, making it 
easier to gain spectra as the mixture is homogenous. 
 




3.2.2 MALDI-TOF Mass Analyser 
 
Time of flight (TOF) mass analysers are used with MALDI-MS (Aebersold et al. 2001). 
MALDI-TOF-MS is a favoured technique for generating peptide mass fingerprinting to 
allow the identification of unknown proteins (Beranova-Giorgianni. 2003) as it is a 
robust, sensitive technique (to femtomole levels) which can analyse a large mass range. 
The mass analyser is responsible for separating the ions by their mass to charge ratios 
(Lin et al. 2003). The ions travel the same distance down an evacuated field-free flight 
tube; the smaller ions arrive at the detector in a shorter amount of time than the larger 
ions. Separated ion fractions arriving at the end of the drift region are detected by a 
recorder that produces a signal upon impact of each ion group. By adding an ion 
reflector at the end of the flight tube, the mass resolution can be improved. The ion 
reflector is essentially a mirror which increases the distance at which the ions have to 
travel, therefore correcting for small energy differences among ions (Figure 3.5). The 









Figure 3.5: Schematic of a MALDI-TOF mass spectrometer 
Ions travel through the flight tube at different speeds according to their mass. The 
detector records the data produced and send the information to a computer. 
 
The TOF mass spectrum is a recording of the detector signal as a function of time. The 
time of flight for a molecule of mass (m) and charge (z) to travel this distance is 
proportional to (m/z) ½. Therefore, t ~ (m/z) ½ can be used to calculate the mass of the 
ion. By using this calculation, the conversion of the TOF mass spectrum to a 
conventional spectrum of m/z vs. ion intensity can be achieved (Figure 3.6).  
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Figure 3.6: PMF of glyoxalase domain containing 4 (GLOD4). 
Spectra shows intensity (y-axis) vs. m/z (x-axis). 
 
3.2.3 MALDI-TOF-MS Analysis 
 
Differentially expressed proteins in biological research are often low abundant proteins, 
the identification of which can be shrouded by more abundant contaminants such as 
keratins and trypsin autolysis peaks; even if the analyst has taken precautions to avoid 
contaminations (see section 3.1.2) (Keller et al. 2008).  Common contaminating peaks 
can be determined by performing experimental controls by digesting blank pieces of gel 
and digesting known proteins standards. The resultant peptides can then be analysed by 
MS to obtain the background peaks which are individual to each user and to each 




laboratory. When the analyst has performed this analysis multiple times and is confident 
that the peaks obtained are true background peaks, they can then be taken out of future 
spectra by editing the peak list in the MS software. It is also important to carefully 
check the spectra and make sure the software had correctly selected peaks and to edit 
accordingly. It is important to spend time inspecting the PMF as the risk of false 
positive results will be decreased if this is done correctly. 
 
The PMF peak list is submitted to a database search, which compares the peptide in the 
sample to the peptides in the database of theoretically digested proteins. If enough 
peptides from the PMF match the database PMF then a protein identification will be 
given based on the ion score and the percentage of sequence covered by the PMF to the 
database PMF (see Appendix H: Mascot Search Results – Beta Galactosidase (LacZ 
Protein)). The ion score is a calculation based on probability: 
-10*log(P) 
Where P is the probability that the match is a random event. Protein scores that are 
classed as significant will have p<0.05 (see Appendix H: Mascot Search Results – Beta 
Galactosidase (LacZ Protein)). The theoretical protein’s pI and molecular weight can 
then be matched to location of the protein spot on the 2D gel. 
 
One disadvantage of using a PMF database is that proteins which have undergone post-
translational modifications (e.g. phosphorylation) may not be identified. This is because 
peptides from a modified protein will not match those of the unmodified protein in the 
database, making a positive identification very difficult. Another problem is the 
presence of more than one protein in the digested sample. For example, if two proteins 
migrate to the same point on the gel they will be excised together and digested together. 




The result would be a PMF mixture from more than protein, making a positive 
identification unfeasible. It is also worth remembering that a large percentage of 
proteins are not yet in the databases, and that small proteins may not generate a 
sufficient amount of peptides to gain a significant identification. However, in these 
cases the amino acid sequence for an individual peptide in the PMF can be gained by 
subjecting selected ions to further fragmentation by tandem mass spectrometry 
(MS/MS) (see section 3.2.6).  
 
3.2.4 Electrospray Ionisation 
 
ESI-MS/MS is often used in a two-tier protein identification strategy (Beranova-
Giorgianni. 2003), MALDI-TOF-MS is used primarily to identify the peptide mass 
fingerprint data, and database searching is used to try and identify the parent protein. 
However, if the protein is still not identified then ESI-MS/MS or MALDI-TOF-MS/MS 
can be used to generate product ion data (see section 3.2.6) (Beranova-Giorgianni. 
2003). 
ESI produces charged solvent droplets when a high electric potential is set between a 
capillary and the inlet to a mass spectrometer (Lin et al. 2003). Typically peptides or 
proteins are analysed as positive ions using the capillary as an anode and the MS inlet as 
the cathode. The sample to be analysed is suspended in an appropriate solvent such as 
50:50 acetonitrile: water with 1% acetic acid and injected directly into the instrument. 
ESI produces mainly doubly charged ions which allows for the determination of the m/z 
value. The ions are generated directly from the solution by a fine spray. As the droplet 
size decreases, the electric charge density on the surface increases. Mutual repulsion 
between the like charges on the surface exceeds the forces of the surface tension, and 




ions begin to leave the droplet through a "Taylor cone" (a jet of charged particles 
emanating above a threshold voltage) (Figure 3.7). Ions are electrostatically directed 
into mass analyser. ESI is readily coupled to high performance liquid chromatography 
(HPLC) as it uses a steady stream of solvent to produce a continuous beam of ions (Lin 
et al. 2003). The peptide mixture is first separated by liquid chromatography (LC), 
which is coupled on-line to the ESI-MS. This technique is used to gain product ion data 
(Beranova-Giorgianni. 2003). The flow rate on the ESI-MS is usually set to µl per 
minute, but if the flow rate is lowered to nanolitres per minute, the signal is greatly 
improved. This technique is called nano-electrospray. 
 
 
Figure 3.7: Schematic of an ESI Source.  
The sample is injected through the syringe pump directly into the machine. Ions are 
generated by applying a high electric potential, and are sprayed from the capillary to the 
mass analyser. 
 
3.2.5 ESI Mass Analyser 
 
The ESI source is readily coupled to a quadrupole ion trap (QIT) mass spectrometer and 
tandem mass spectrometry (see section 3.2.6). A QIT mass analyser uses a combination 
of radio frequency (RF) and direct current (DC) voltages to select ions of a particular 
m/z (Khalsa-Moyers et al. 2006).  The ions are then trapped in an electric or magnetic 




field and stored by decreasing their kinetic energy. The ions are sequentially ejected into 
a detector by increasing their kinetic energy by ramping RF voltages (Khalsa-Moyers et 
al. 2006). A population of variable charged ions produced by ESI generate the spectra 
(Figure 3.8). The peaks observed are due to multiple charging effects. The spectra can 
then be used to pick individual peptides to be subjected to tandem mass spectrometry. 
 
 
Figure 3.8: Spectra obtained from ESI-MS of cytochrome C digested 









3.2.6 Tandem Mass Spectrometry 
 
Tandem mass spectrometry is brought about by multiple series of mass spectrometry. 
The first course of MS isolates individual peptides. The second round fragments the 
selected peptides further. The fragmentation is brought about when the precursor ion 
collides with a gas in the vacuum of the mass spectrometer. This is called collision-
induced dissociation (CID). The peptide sequence tag generated by MS/MS can be used 
to identify the peptide in a database. 
 
3.3 Antibody Microarrays 
 
An antibody microarray is a collection of antibodies spotted onto a nitrocellulose coated 
glass slide. Antibody microarrays can be used to compare protein expression profiles of 
two samples (e.g. test vs. control). Each protein sample is labelled with a different dye 
(cy3 or cy5) and is incubated on the antibody microarray. The expression of a protein 
can be detected when it binds to its corresponding antibody spotted on the slide (Figure 
3.9). The fluorescent signal intensity for each sample is recorded individually at the 
wavelength corresponding to the dye label of the sample and control. The protein 










Figure 3.9: Picture of an antibody microarray slide 
Left: picture of an antibody microarray slide spotted with 725 antibodies. The slide has 
been incubated with two separately labelled protein samples. 
Right: enlarged image of the highlighted area. The protein expression is represented by 
the colour of the spot. If more protein is expressed in the control sample (labelled with 
cy3) then the spot will be green, if more protein is expressed in the more test sample 
(labelled cy5) then the spot will be red. If equal amounts of protein are expressed in 
both samples the spot will be yellow. 
 
Antibody microarrays are a quick way of generating vast amounts of data, but replicates 
can become expensive. However, by purchasing some of the antibodies separately to the 
array kit, results can be confirmed using immunoblotting. This allows the antibody 
microarray to be used as a preliminary screening method. The array only takes 
approximately 3 days to run, which is an improvement to 2D-PAGE which takes 5-6 
weeks; however, protein identifications will always be limited to what antibodies are 
spotted on the slide. There are many antibody microarrays commercially available on 




the market, each with a different number of antibodies and different protein targets. 
Pathway specific arrays are also available for more focused research. 
 
3.4 Western Blot Analysis 
 
Western Blot analysis is a method to detect a particular protein in a biological sample 
and can be used to confirm identifications by MS.  
 
 One dimensional gel electrophoresis is used to separate proteins in a gel (3.1.1 One 
Dimensional Polyacrylamide Gel Electrophoresis). The proteins are then transferred to a 
nitrocellulose membrane by applying a current between two electrodes and placing the 
gel and the membrane in between the electrodes. The charged proteins move from the 
gel onto the membrane in the same orientation as they were on the gel. The membrane 
is then washed with a blocking solution to prevent non-specific protein interactions 
when it is probed with an antibody. Bovine serum albumin (BSA) or non-fat dried milk 
powder can be used to block non-specific binding sites on the proteins.  
 
The proteins immobilised on the membrane are then probed with a specific primary 
antibody. If the primary antibody is not horseradish peroxidase (HRP) conjugated, a 
secondary HRP conjugated antibody is needed to visualise the proteins. Secondary 
antibodies bind to the primary antibody. A chemiluminescent agent is used to initiate a 
reaction with the HRP, which produces luminescence in proportion to the amount of 
protein. The luminescence can be used to visualise the protein bands by exposing the 
membrane to a photographic film. Densitometry can then be used to give a ratio of the 
level of protein between samples. To ensure that equal amounts of protein have been 




loaded onto the gel the membrane is probed for a “housekeeping” such as GAPDH or 
beta-actin, which should demonstrate constant levels of expression and acts as a loading 
control (Figure 3.10). Densitometry can be used to compare the intensity of the bands 
from each sample. If the bands have an equal level of intensity then it can be assumed 
that equal amounts of protein have been loaded. Western blotting can be used as a 
confirmation method for targets found by 2D-PAGE/MS or as a technique to identify 
levels of a specific protein. 
 
 
Figure 3.10: Western blot of phosphorylated ERK (P-ERK) with a GAPDH 
loading control. 
The picture shows that each lane has a similar amount of protein loaded as the GAPDH 
band (40KDa) shows a similar intensity for all samples. However, the samples have 
varying amounts of P-ERK protein (42/44KDa) between them. 
 
 





The clinical course of patients with CLL is heterogeneous; some patients survive for 
years without treatment, others die of a chemotherapy resistant disease within two years 
of presentation. There is no routine, cost effective clinical test to show how a patient 
will progress.  
 
The aim of this project is to identify potential biomarkers which could be used in a 
clinical test to predict patient prognosis. IgVH gene mutational status has proven to be a 
good prognostic marker but the test is expensive and time consuming and can not be 
used routinely in clinical practice. If the B-cell has not been sensitised to a specific 
antigen (i.e. unmutated IgVH genes on BCR) it is hyper-responsive to stimulation 
through the BCR by antigen. Stimulation of the BCR may prevent apoptosis of 
malignant cells; therefore a hyper-responsive BCR is linked to poor prognosis.  
 
By using proteomics we will investigate signaling pathways activated by the BCR to 
gain a greater understanding of the anti-apoptotic nature of the malignant B-cells and to 
find potential prognostic biomarkers related to a hyper-active BCR. If we understand 
more about the BCR signaling pathways then we may be able to identify novel targets 
for therapeutic intervention. These may inhibit survival of the malignant B-cells. 
 
Intravenous blood samples will be collected from patients with CLL who have not 
received treatment for three months prior to sampling. Peripheral blood mononuclear 
cells (PBMCs) will be extracted from the blood and the samples will be classified 
according to IgVH genes mutational status and BCR responsiveness. Cells will be 
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artificially stimulated to induce BCR signaling cascades and to categorise BCR 
responsiveness by western blotting. RAJI B-cells will be used for optimisation and to 
obtain preliminary results. 
 
Selected samples which have been categorised as having a poor prognosis (hyper-active 
BCR and unmutated IgVH genes) will be taken forward for further analysis. Protein will 
be extracted from stimulated and unstimulated cells and the protein profiles of the two 
groups will be compared using 2D-PAGE. Protein spot editing software will be used to 
identify statistical changes between the two groups and these proteins will be excised 
from the gel and digested into peptides using trypsin. MALDI-TOF-MS will be used to 
generate a PMF and identify the excised proteins. Potential protein targets will be 
confirmed by western blotting and antibody microarrays will be used as a 
complementary method to 2D-PAGE. Proteins found may be utilised as potential 
prognostic biomarkers related to a hyper-active BCR, and data obtained should give a 
greater understanding of the anti-apoptotic nature of the malignant B-cells. 
   
Chapter 4 - Materials and Methods 
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Materials and Methods 
 
All chemicals were of the highest quality or proteomics grade. All solution components 
and details of suppliers can be found in Appendix A. 
 
4.1 Culturing B-Cells Lines 
 
Established suspension B-cell lines RAJI, DAUDI and RAMOS-EHRB derived from 
patients with Burkett’s lymphoma were cultured for preliminary experiments and to 
optimise techniques.  
 
When culturing cells it is vitally important that everything is sterile and clean to avoid 
contaminations. All work was carried out in a sterile tissue culture (TC) hood and 70% 
alcohol was used to sterilise equipment before it was placed in the hood. Cells were 
cultured in an incubator set at 37C with 5% CO2. On average cells were passaged three 
times a week. Cells were grown in a T25 or a T75 tissue culture flask (Sarstedt) 
depending on the number of cells. Contaminated waste was soaked in Virkon 
disinfectant for 24hrs before discarding. 
 
4.1.1 Passaging Cells 
 
Cells were taken out of the flask with a pipette and transferred into a 30ml screw top 
tube (Scientific Laboratory Supplies). The cells were centrifuged (Sigma-Aldrich 2-5; 
SciQuip centrifuge) at 1600rpm for 3mins. The media was discarded to leave the pellet 
of cells. 
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Cells were resuspended in at least 5ml of tissue culture media (see Appendix C) pre-
warmed to 37C, and transferred to appropriate number of new tissue culture flasks. 
Each flask was made up to an appropriate volume (dependant on the number of cells) 
with warmed tissue culture media. Flasks were placed in an incubator maintained at 
37°C with 5% CO2. 
 
4.1.2  Cryopreservation of Cells 
 
Cells were resuspended slowly (2-3mins) in tissue culture freezing media, which 
contained 10% dimethyl-sulphoxide (DMSO) (see Appendix C), at a density of between 
1x106 cells/ml to 1x108 cells/ml, and transferred into 2ml cryovials (Scientific 
Laboratory Supplies) and frozen at -80C. Cells were later transferred to liquid nitrogen 
for long term storage. 
 
4.1.3 Thawing Cells 
 
Samples were taken out of the freezer, thawed quickly in a water bath set to 37C and 
transferred to a 30ml screw top tube. The  DMSO was diluted out with 10ml of tissue 
culture media warmed to 37C. DMSO is toxic to thawed cells if left in too long, 
however, it needs diluting out slowly (dropping media in over a period of 2-3mins) to 
avoid the cells going into shock. The cells were centrifuged (Sigma-Aldrich 2-5; 
SciQuip centrifuge) for 3mins at 1600rpm and the supernatant was discarded. Fresh 
tissue culture was added and the cells were transferred to a T25 or T75 tissue culture 
flask and placed in an incubator maintained at 37°C with 5% CO2. 
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4.2 Clinical Sample Collection 
 
4.2.1 Ethical Approval 
 
The study was approved by Hull and the East Riding Local Research Ethics committee 
and Hull and East Yorkshire NHS Trust Research and Development department 
05/Q1104/33. 
 
4.2.2 Mononuclear Cell Isolation 
 
Following informed consent 50ml of blood was taken from patients diagnosed with 
CLL who had not received chemotherapy treatment in the previous 3 months. The 
peripheral blood mononuclear cells (PBMCs) were separated using Histopaque® 
(#10771; Sigma-Aldrich). Histopaque® contains polysucrose and sodium diatrizoate 
adjusted to a density of 1.007g/ml.  By centrifuging whole blood, layered onto 
Histopaque®, the PBMCs form a layer at the plasma/Histopaque® interface. The white 
blood count (WBC) from the patient was needed before the PBMCs were stored. Each 
cryovial of cells stored contained at least 1x107cells/ml. For example, if the WBC was 
80x109cells/L then 100 vials at a concentration of 4x107cells/ml were stored. If the 
WBC was 20x109cells/L then 50 vials at a concentration of 1x107cells/ml were stored. 
 
Six ml of ice cold Histopaque® was added to four 50ml centrifuge tubes (Sarstedt). One 
50ml blood sample was split between the four tubes, i.e. 12.5ml of blood was layered on 
top of the Histopaque®. The tubes were centrifuged (Rotanta 96R; Hettich centrifuge) 
at 1700rpm for 20mins at 4C and set to ramp down slowly to avoid the interfaces 
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mixing (Figure 4.1). The cloudy mononuclear layer in the middle of the tube was 
carefully removed using a 1ml pipette and the PBMCs from the four tubes were 
combined into a new 50ml centrifuge tube. The combined cells were washed in 10-20ml 
of ice-cold tissue culture media and centrifuged (Rotanta 96R; Hettich centrifuge) at 
1700rpm for 10mins at 4C. The supernatant was discarded and the PBMCs were 
resuspended in an appropriate amount of ice-cold tissue culture media (see Appendix C) 
(1/2 the total volume needed to freeze). For example, if a patient had a WBC of 
80x109cells/L, and the sample was to be stored into 100 vials, the cells would be 








Figure 4.1: Picture of cellular layers obtained by centrifuging whole blood, layered 
onto Histopaque® 
The pictures show, from left, Histopaque is placed in tube (1), blood is layer on to the 
Histopaque (2), tube is centrifuged and four layers are produced, plasma, PBMCs, 
Histopaque and red cells (3). The PBMCs can then be extracted with a pipette. 
 
Fifty ml of 20% DMSO freezing media (Appendix C) was then added slowly (over 3-
5mins) to make the total volume to 100ml. The sample was mixed thoroughly and 
aliquoted into 1ml cryovials. As DMSO is toxic to the cells, once added the samples had 
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to be frozen within 15mins. Vials were stored at -80C and transferred to liquid nitrogen 
for long term storage. 
 
4.2.3 IgVH Gene analysis 
 
Approximately 1x107 cells from each sample were sent to the Haematological 
Malignancy Diagnostic Service (HMDS) at St. James’s Institute of Oncology, Leeds for 
IgVH gene analysis.  
 
RNA was extracted from PBMCs using the Qiagen RNeasy mini kit (Qiagen, Crawley, 
UK) and complementary DNA was synthesised using the Reverse-iT kit according to 
the manufacturer’s instructions (ABgene).  The IgVH gene was amplified using 
polymerise chain reaction (PCR) (Hamblin et al. 1999) and sequenced using the BIG 
dye terminator sequencing kit version 3 according to the manufacturer’s instructions 
(Applied Biosystems).  Sequences were compared to accepted germline sequences using 
IgBLAST (National Centre for Biotechnology Information, Bethesda, Maryland; 
http://ncbi.nih.gov/igblast/). A <5% difference in standard germline sequence was 
classed as an unmutated IgVH gene and a >5% difference in standard germline sequence 
was classed as a mutated IgVH gene (Allsup et al. 2005).  
 
4.3 Cell Counting 
 
A Neubauer haemocytometer was used to determine the cell concentration per millilitre 
of tissue culture media in cell lines and in clinical samples. 
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Cells were centrifuged to remove dead cells. The cell pellet was resuspended in a 
volume of tissue culture appropriate for the size of the pellet. The volume could be 
adjusted later if there were too many or too few cells in the counting chamber. 
 
Twenty-five µl of thoroughly mixed cells were taken and added to 25µl of 0.4% trypan 
blue (Sigma-Aldrich). Trypan blue stains non-viable cells (dead cells) blue because the 
chromophore is negatively charged and reacts with damaged cell membranes. The 
solution was thoroughly mixed by pipetting and left for 5mins to allow the cells to 
absorb the dye. Twenty-five µl of the solution was then carefully pipetted into the 
haemocytometer chamber underneath a glass cover slip. The haemocytometer was then 
placed onto a microscope stage. 
 
The haemocytometer consists of nine 1mm x 1mm squares, which can each hold a 
volume of 10-4ml (Figure 4.2). It is important that each 1mm square has between 70-150 
cells as this will give a more accurate cell count. If there are too many or too few cells 
on the haemocytometer, the original stock solution must be diluted or resuspended in 
the correct volume and the procedure repeated. Cells in five of the squares (Figure 4.2) 
were counted separately. The cell numbers were then averaged. 
 




Figure 4.2: Figure showing Neubauer haemocytometer grids 
Grid system of a Neubauer haemocytometer showing the five 1mm squares counted to 
determine cell concentration. 
 
The following equation was used to calculate the cell concentration: 
 




Square 1 = 118 cells 
Square 2 = 114 cells 
Square 3 = 120 cells 
Square 4 = 116 cells 
Square 5 = 122 cells 
Average = 118 cells per 10-4ml   
 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Materials and Methods 
 
 58
The trypan blue dilution factor needs to be taken into account (solution is 50% trypan 
blue and 50% cells) therefore this number must be multiplied by 2. 
 
118 cells x 2 = 236 cells per 10-4ml 
= 236 x 104 cells/ml 
 
4.4 BCR Stimulation 
 
The stimulation protocol was followed for both B-cell lines and clinical cells. 
 
Cells were taken from the freezer and thawed as described in 4.1.3 Thawing Cells. Cells 
were centrifuged for 3mins at 1600rpm and resuspended in an appropriate amount of 
tissue culture media (dependant on number of cells). They were transferred into a T25 
or T75 flask and left in an incubator for 3 hours at 37C with 5% CO2 to acclimatise. 
 
After the incubation period cells were centrifuged for 3mins at 1600rpm and 
resuspended in 10-20ml of tissue culture media. A cell count was then performed on the 
sample (4.3 Cell Counting). Cells were resuspended at a final concentration of 
5x106/mL for CLL cells and 5x105/mL for B-cell lines (the cells of the B-cell lines were 
bigger than the PBMCs and fewer cells were needed). An appropriate volume of cells 
(at least 1ml for Western blot analysis, and 15ml for 2D-PAGE analysis) were 








10g/ml of AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5  fragment 
specific (#109-006-129 Jacksons Immuno Research Laboratories Inc) 
2. Isotype Control 
10g/ml ChromPure Goat IgG, F(ab’)2 fragment (#005-000-006 Jacksons 
Immuno Research Laboratories Inc) 
3. Positive Control 
100nmol/L of phorbol 12-myristate 13-acetate (PMA) (#P1585 Sigma-Aldrich) 
(which activates protein kinase C and causes widespread protein 
phosphorylation) 
4. Neutral/Negative Control 
Nothing added 
 
All the tubes were incubated at 37°C with 5% CO2 for either 5 minutes (see section 
7.1), 8hrs (see section 7.3), or 5.5hr (see sections 9.3 and 10.1). Cells were transferred 
to a 30ml screw top tube and centrifuged for 3mins at 1600rpm. The supernatant was 
discarded and the cells were washed in ice cold phosphate buffered saline (PBS). At 
least three cycles of PBS washes and centrifugations were completed in order to wash 
away all of the stimulant and media. Samples which were to be analysed by 2D-PAGE 
were washed at least five times to remove any proteins from the supernatant such as 
fetal calf serum (FCS) in the media. On the final wash the samples were transferred to 
1.5ml polypropylene microfuge tubes (Scientific Laboratory Supplies). All of the PBS 
was removed by using a fine pipette and the stimulation was terminated by adding 
Laemmli buffer (see Appendix F) or 2D-PAGE lysis buffer (see Appendix D). 
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4.5 Western Blot Analysis 
 
4.5.1 Protein Extraction 
 
Cells were resuspended in Laemmli buffer (125l-300l dependant on number of cells) 
(see Appendix F). Samples were vortexed for 5mins at room temperature and sonicated 
for 5mins at room temperature to disrupt the cells. The tubes were then placed on an 
end-over-end rotator at 4C overnight. Samples were centrifuged at 16,000xg for 
15mins at 4C to pellet cell debris and the supernatant was transferred into new, cold 
1.5ml polypropylene microfuge tubes. Extracts were stored at -80C. 
 
4.5.2 Protein Quantification for Western Blot 
 
The RCDC kit (#500-0122; Bio-Rad) was used for the quantification, which allows 
proteins to be quantitatively precipitated whilst washing away contaminants. The 
technique is based on the Lowry assay, which is a colorimetric assay for determining 
the protein concentration (Lowry et al. 1951). Copper (II) ions react with the protein 
samples in alkaline conditions to form complexes which react with folin phenol 
(phospho-molybdic-phosphotungstic) reagent. The product is reduced to 
molybdenum/tungsten blue. The higher the concentration of protein, the more 
molybdenum/tungsten blue is produced, and the darker the solution (Lowry et al. 1951). 
All samples must be in the same volume and protein standards of known concentrations 
are required to produce a graph of optical density vs. protein concentration. The RCDC 
kit is compatible with protein extraction buffer containing detergents such as SDS, and 
reducing agents such as β-mercaptoethanol. 
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Four dilutions of protein standards were prepared using a 2mgml stock of bovine serum 







Some samples required dilution (1:2, 1:5 or 1:10 in DH2O) as the detection limits of the 
kit range from 0.2mg/ml to 1.5mg/ml. 
 
RC Precipitation/Clean Up 
 
Twenty-five µl of BSA standards and samples were pipetted into 1.5ml microfuge 
tubes. One hundred and twenty-five µl of RC Reagent 1 (from the kit) was added. 
Samples were vortexed and incubated at room temperature for 1 min. One hundred and 
twenty-five µl of RC Reagent 2 was added and the samples were vortexed. Samples 
were centrifuged at 15,000xg for 5mins and the supernatant was discarded. Tubes were 
inverted on absorbent tissue paper to allow the liquid to completely drain leaving only 
the protein pellet. 
 
DC Quantification Assay 
 
Reagent A’ (Working Colour Reagent) was prepared following the manufacturers 
instruction by adding 5l of DC Reagent s to every 250l of DC Reagent A. 
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One hundred and twenty seven µl of Reagent A’ was added to each tube. The samples 
were vortexed for 5mins at room temperature to ensure the pellet had fully dissolved. 
One ml of DC Reagent B was added to each tube, samples were vortexed immediately 
and tubes were incubated at room temperature for 15mins. Two hundred µl of each 
sample and standard were placed into individual wells of a 96 well plate. Two hundred 
µl of DH2O was used as a blank. The absorbance was read at 690nm on a Multiscan MS 
plate reader (Thermoelectron, UK).  
 
The BSA standard protein optical density was used to produce an optical density vs. 
concentration graph, which was then use to determine the protein concentrations of the 









Figure 4.3: Graph of optical density vs. protein concentration using a BSA protein 
standard and the RCDC Kit (Bio-Rad) 
The equation from this graph can be used to calculate the protein concentration of a test 




Twenty g of protein was loaded into one well on a 1D gel as this amount generally 
gave visible bands that were not saturated. 
 
Protein samples (20µg) were diluted with Laemmli buffer to a volume of 25µl in order 
to ensure that equal amounts were loaded. The phosphatase and protease inhibitors were 
not added to the Laemmli buffer, as these cocktails are only beneficial when storing 
samples. Twenty-five µl of diluted protein sample was placed in 0.5ml microfuge tube. 
The samples were heated at 95C in a thermocycler for 5mins to denature. The β-
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Materials and Methods 
 
 64
mercaptoethanol in the Laemmli buffer cleaves the disulphide bonds in the proteins, 
thus allowing peptides to migrate to the correct point in the gel according to its chain 
length, with no influence from the secondary structure. The tubes were placed 
immediately on ice, vortexed for 30sec and centrifuged briefly to collect sample at 
bottom of tube. A homogenous Novex® 12% Tris-Glycine gel (1.0mm, 8x8cm, 10 
well) (#EC6005box; Invitrogen) was placed in a vertical electrophoresis unit and 
approximately 120ml and 1120ml of 1x running buffer (see Appendix F) was added to 
the upper and lower chambers respectively. One or two pre-cast gels could be run 
simultaneously in the electrophoresis unit. 
 
Ten µl of Precision Plus Dual Colour Molecular Protein Standard (#161-0374; Bio-Rad) 
was added to the last well of the gel for visibility on the gel and membrane (Figure 4.4). 
Ten µl of Cruz Marker™ molecular weight standards (#sc-2035; Santa Cruz) was added 
to the first well for visibility after chemiluminescence (Figure 4.5). Twenty µl of the 
25µl protein sample was loaded into each well and SDS-PAGE was performed at a 








Figure 4.4: Precision Plus Dual Colour Protein Standard 
The Dual Colour Protein standard consists of ten precise recombinant pre-stained 
protein standards (10-250KDa) for electrophoresis and western blotting. The marker is 
visible on the gel and on the membrane. 
 
 
Figure 4.5: Cruz Marker™ Molecular Weight Standards 
The Cruz Marker ladder consists of six bands (23-132KDa) which appear on the final 
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4.5.4 Transfer to Membrane 
 
The gels were taken out of their plastic cassettes and placed in a tray containing chilled 
transfer buffer (see Appendix F) to equilibrate them and to wash off any running buffer. 
For each gel to be transferred, two Mini Trans-Blot filter papers (#1703932; Bio-Rad), a 
Trans-Blot nitrocellulose membrane (0.45m) (#162-0115; Bio-Rad) cut to the size of 
the gel and two foam pads were also soaked in chilled transfer buffer. The fibre pads, 
filter papers, gel and membrane were layered on the transfer cassette as shown in Figure 
4.6. Care was taken to ensure no air bubbles were trapped between the gel and the 
membrane, as they would interfere with the transfer. 
 
 
Figure 4.6: Schematic of the Transfer Layers in a Western Blot 
The transfer cassette has a black side and a red side. To ensure a successful transfer of 
proteins from the gel to the membrane the first foam pad must be layered onto the 
black side. This is followed by filter paper followed by the gel. The nitrocellulose 
membrane is placed directly onto the gel and filter paper is placed onto the 
membrane. At this point it is important to get out any air bubbles trapped between the 
membrane and the gel. This can be done by using a glass pipe or pipette to roll over 
the filter paper. The final foam pad is placed onto the filter paper before closing the 
cassette. 
 
The cassette was closed and placed in the Mini Trans-Blot electrophoretic transfer cell 
(Bio-Rad). The transfer cell could transfer one or two gels onto a membrane 
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simultaneously. The transfer cell was filled with approx 900ml of chilled transfer buffer 
which was stirred throughout the transfer to keep cool. Electrophoretic transfer was 
performed at 400mA for 1hr at 4C. The transfer works on the same principle as that of 
electrophoresis. A charged protein can travel through an electric field whether that is 
through a gel, or from a gel onto a membrane support. The negatively charged proteins 
travel to the positive electrode (from black side of cassette to the red side), but they are 
blocked by the membrane which binds them. After the transfer the gel can be stained to 
make sure the proteins have completely transferred. In an efficient transfer there should 




Proteins, including antibodies, bind readily to the nitrocellulose membrane. To ensure 
the antibodies do not bind non-specifically, the membrane is incubated in a solution of 
protein such as BSA or casein (milk protein). This blocks all the binding sites on the 
membrane leaving only the bound transferred proteins exposed to the antibodies. The 
membrane was transferred to a Nalgene staining box (Scientific Laboratory Supplies) 
containing 20ml of 5% milk blocking solution (see Appendix F) and incubated for 1hr 
on an orbital rocker at room temperature. Nalgene staining boxes were used to prevent 
the antibodies from sticking onto the surface of the plastic. It was important that the 
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4.5.6 Antibody Probing 
 
Each antibody needs optimising for concentration and incubation time before use. The 
optimised amount of primary antibody was added to 10ml of 5% milk blocking solution 
(Table 4.1). The membrane was incubated in the antibody for the optimised time on an 
orbital rocker. Incubations over 2hrs were performed at 4C°. The membrane was 
washed 3 times for 5mins each wash in tris buffered saline mixed with 0.05% TWEEN 
20 detergent (TBS/TWEEN) (see Appendix F). It was important to ensure that all 
unbound primary antibody was washed off to avoid non-specific binding of the 
secondary antibody. The primary antibody was not HRP conjugated therefore a 
secondary HRP conjugated antibody, which is specific to the primary antibody’s 
species, is required. The secondary antibody was used at a 1:1000 dilution in 10ml 5% 
milk blocking solution (Table 4.2). The membrane was incubated in the secondary 
antibody for 1hr on an orbital rocker at room temperature. 
 
Table 4.1: Table of western blot primary antibody details 
Antibody Type Catalogue Number & Supplier Dilution Molecular Weight 
P-ERK Mouse Monoclonal #sc-7383 Santa Cruz 1:100 P-ERK 1: 44KDa P-ERK 2: 42KDa 
ERK Rabbit Polyclonal #sc-154 Santa Cruz 1:1000 ERK 2: 42KDa 
GAPDH Rabbit Polyclonal #ab9485 Abcam 1:10000 40KDa 
Β-Actin Rabbit Polyclonal #ab8227 Abcam 1:2500 47KDa 
Bcl-2 AB-3 Mouse Monoclonal #MS-597-P0 Thermo Scientific 1:200 25/26KDa 
AK5 Rabbit Polyclonal #Ap8131a Abgent 1:100 22KDa 




Proteomic Analysis of Chronic Lymphocytic Leukaemia - Materials and Methods 
 
 69
Table 4.2: Table of western blot secondary HRP conjugated antibody details 
Antibody Supplier Dilution 
Goat anti mouse IgG HRP #sc-2031 Santa Cruz 1:1000 





The membrane was washed three times (5mins each) on an orbital rocker in 
TBS/TWEEN before the two components of the Supersignal West Pico 
Chemiluminescence kit (#34078; Pierce Biotechnology) were added. Eight ml of Stable 
Peroxide Solution and 8ml Luminol/Enhancer Solution were mixed to obtain the West 
Pico Supersignal Working Solution. The membrane was incubated in the working 
solution in the dark for 5mins with gentle agitation. The chemiluminescence agents 
react with the HRP (conjugated to the secondary antibody) to produce light in 
















Figure 4.7: Schematic of antibody probing on a Western blot membrane  
The membrane is first incubated with a dilute solution of protein such as casein or BSA 
to block any non-specific binding sites (A). The membrane is then incubated with a 
primary antibody (B), followed by incubation with a HRP conjugated, species specific 
secondary antibody (C). A chemiluminescence agent is then exposed to the HRP to 
produce luminescence in proportion to the amount of target protein bound to the 
membrane (D). 
 
Membranes were exposed to SuperSignal CL-Xposure film (Pierce Biotechnology) for 
5mins. Films were developed by gentle agitation in GBX developer (Kodak), then 2% 
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rinsed with water and air-dried. The membrane was stored in PBS at 4C prior to 




Films were scanned using a GS-800 laser densitometer (Bio-Rad) into the Quantity One 
software (Bio-Rad). Target bands were normalised to a loading control such as GAPDH 
or β-actin to account for protein loading variability, and the optical density of the target 











Figure 4.8 Normalised western blot image scanned into Quantity One software 
(Bio-Rad) 
The picture shows a western blot of a 22KDa protein target and a 47KDa protein 
loading control. The target bands have been normalised to the loading control bands. 
The western blot is of a protein extract from treated cells and a untreated cells. The 
normalised optical density of the target bands is shown so the target protein expression 
can be compared in the treated sample and the untreated sample. This result shows a 
fold change of -1.9 of the target protein in the treated sample. 
 
4.5.9 Stripping Membranes 
 
Sometimes membranes need to be re-probed with different antibodies. Other antibodies 
can include loading controls or other related proteins of interest. If the original protein is 
a similar molecular weight to the new protein of interest, then the antibody from the 
first experiment has to be removed to avoid overlapping bands. Stripping buffers are 
available commercially. 
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The membrane was incubated in 15ml of Restore Plus Western Blot Stripping Buffer 
(#46430; Pierce) for 10mins at room temperature for a mouse antibody or 15mins at 
37C for a rabbit antibody on an orbital rocker.  
 
The membranes were then washed, briefly re-blocked (see section 4.5.5) for 30mins and 
incubated in the 2 antibody used prior to stripping. Films were developed as described 
in 4.5.6 and 4.5.7 to ensure that the primary antibody had been completely removed. If 
the antibodies had been successfully removed then the membrane was re-probed with a 
new primary antibody. Repeated stripping of a membrane will eventually remove bound 
proteins, therefore membranes were stripped a maximum of three times. 
 
4.6 Two Dimensional Gel Electrophoresis 
 
Protein extracts intended for 2D-PAGE/MS analysis must be handled correctly to avoid 
contaminations and to prevent loss of sample. Polypropylene tubes were used to avoid 
proteins and peptides sticking inside, nitrile gloves were worn as opposed to latex 
gloves which cause protein contaminations and clothing and hair were covered to avoid 
keratin contaminations. All reagents used were proteomic/MS grade. 
 
It is important that a minimum of three technical replicates of the same sample are done 
to acquire reliable results. For cell line work, protein should be extracted on three 
consecutive days to account for day to day variation in the cells, and a clinical sample 
should be divided into three and at processed the same time. 
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4.6.1 Protein Extraction 
 
Cells were resuspended in 2D-PAGE lysis buffer (1ml) (see Appendix D). Samples 
were vortexed for 5mins at room temperature and sonicated for 5mins at room 
temperature to disrupt the cells. The tubes were then placed on an end-over-end rotator 
at 4C overnight. Samples were centrifuged at 16,000xg for 15mins at 4C to pellet cell 
debris and the supernatant was transferred into new, cold 1.5ml polypropylene 
microfuge tubes. Extracts were stored at -80C. 
 
4.6.2 Protein Quantification for 2D-PAGE 
 
The 2-D Quant Kit (#80-6453-56; Amersham Biosciences) was used to quantify 
proteins for 2D-PAGE. The assay quantitatively precipitates proteins whilst leaving the 
contaminants in solution. This assay is a colorimetric assay and is compatible with 
CHAPS, urea, thiourea and DTT used in the preparation of protein samples for 2D-
PAGE. The assay works by resuspending precipitated proteins in a copper containing 
solution. The copper ions bind specifically to the proteins and the assay measures any 
unbound copper. If lots of free copper ions are present, then the solution will become a 
darker orange colour. Therefore a lighter solution indicates more protein than a darker 
solution. A graph of optical density vs. amount of protein can be generated by using 
known amounts of a protein standard. 
 
Six standard protein samples were prepared in 1.5ml microfuge tubes from a stock 
solution of BSA at 2mg/ml. The standards contained 0g, 10g, 20g, 30g, 40g and 
50g of BSA. 





Five µl of protein sample was transferred into 1.5ml microfuge tubes. Two technical 
replicates were performed for each sample. Five hundred µl of 2-D Quant Kit 
Precipitant was added to each tube. Tubes were vortexed briefly to mix and left to stand 
at room temperature for 2mins.  Five hundred µl of 2-D Quant Kit Co-precipitant was 
added to each tube and solutions were vortexed. The proteins were centrifuged at 
10,000xg for 5min and the liquid was discarded. Tubes were centrifuged again for 30sec 
to enable small amounts of excess liquid to be discarded with a fine pipette. This step 




One hundred µl of Copper Solution and 400l of DH2O was added to each tube. The 
tubes were thoroughly vortexed for 5min at room temperature to ensure the protein 
pellet was fully suspended. One ml of Working Colour Reagent (100 parts Colour 
Reagent 1 with 1 part Colour Reagent b, from the kit) was added and the tubes were 
vortexed immediately to ensure instantaneous mixing. Samples were incubated at room 
temperature for 15 min and 200l of each sample and standard was added to a 96 well 
plate. The absorbance was read at 492nm on a plate reader. The BSA standard protein 
results were used to produce an optical density vs. protein amount graph, which was 
used to determine the protein amounts of the samples (Figure 4.9). 
 




Figure 4.9: Graph of optical density (y-axis) vs. protein amount (x-axis) using  BSA 
protein standards and the 2-D Quant Kit (Amersham) 
The equation from this graph can be used to calculate a protein sample’s quantity when 
the optical density is known. 
 
4.6.3 2D-PAGE Sample Preparation and Clean Up 
 
Protein samples were removed from the -80C freezer and left to thaw on ice. Two 
hundred µg of protein was used for 2D-PAGE. This amount has been optimised for use 
with Coomassie Blue protein stain, if more protein was to be used the gels would be 
too streaky, if less protein was to be used the spots would be too faint. From the data 
obtained from the 2D quantification (see section 4.6.2), 200µg of sample was placed in 
a 1.5ml polypropylene microfuge tube and the sample was diluted to 200µl with 2D 
sample buffer, therefore a minimum of 1mg/ml protein is needed from the extraction. 
Protein samples were vortexed thoroughly and the ReadyPrep 2-D Cleanup Kit (#163-
2130; Bio-Rad) was used to remove contaminants such as salts, lipids, nucleic acids 
and ionic detergents that may interfere with IEF and produce streaky gels. The kit is a 
precipitation based clean up, so it can also concentrate dilute samples. The kit is 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Materials and Methods 
 
 77
compatible with 1-500µg of protein per reaction but can only be used with a volume of 
100µl (or 200µl if reagents are scaled up as described in the kit protocol). When the 





For a 200µl sample: Three hundred µl of Precipitation Agent 1 was added to each 
sample. Tubes were mixed and left on ice for 15mins. Three hundred µl of Precipitation 
Agent 2 was added and tubes were mixed and centrifuged at 16,000xg for 5mins at 
room temperature. The liquid was discarded and the tube was centrifuged again to 




Forty µl of Wash Reagent 1 was added to the pellet and tubes were vortexed. Samples 
were centrifuged as before for 5mins and excess liquid was discarded. Forty µl of 
DH2O was added and samples were vortexed for 20secs. One ml of cold Wash Reagent 
2 and 5l of Wash Additive 2 were added and samples were vortexed for 1min. 
Samples were incubated for 30mins at -20C and vortexed every 10mins for 30sec. 
Tubes were centrifuged as before for 5mins. The liquid was discarded and the tubes 
were centrifuged until the all the excess liquid could be removed with a fine pipette. 
The pellets were air dried for 4mins or until the pellet appeared translucent.  
 
 





The samples were resuspended in the appropriate amount of 2D buffer. For 11cm IPG 
strips, 200µg of protein was resuspended in 210µl of 2D buffer. The samples were 
mixed with a pipettor and then vortexed for 1min. Tubes were incubated at room 
temperature for 5mins, vortexed for 1min and centrifuged for 5mins. 
 
If the correct protocol is followed and Wash Reagent 2 is added cold, then the kit 
should recover over 95% of the protein. 
 
4.6.4 Isoelectric Focusing 
 
An 11cm ReadyStrip IPG strip (#163-2015; Bio-Rad) can absorb 180µl of solution; 
therefore 180µg of protein will be loaded from a 1mg/ml solution. The Bio-Rad 
ReadyPrep IPG strips come as 7cm, 11m or 17cm long, the equivalent sized 2D gel 
must also then be used. For this project 11cm IPG strips were used, this is because 
17cm gels are fragile and difficult to handle, and 7cm gels do not separate out the 
proteins enough. The IPG strip’s pH ranges used in this project were 3-10 and 4-7. An 
11cm pH3-10 strip does not separate the proteins enough and gels are usually streaky 
making the spots difficult to excise. Therefore it is best to do an experiment in two 
sections. Firstly separate and analyse protein in the pH4-7 region, then (sample quantity 
permitting) analyse proteins in the pH7-10 region. The pH7-10 region does not yield as 
many proteins as the pH4-7 region and gels are very streaky. Between pH7-9, 
disulphide groups on the protein are prone to unspecific oxidation causing extra spots 
and streaking (Figure 4.10).  
 




Figure 4.10: 2D Gel of proteins separated on a pH3-10 IPG strip 
The picture shows a 2D gel of E.coli run on a pH3-10, 11cm, non-linear ReadyStrip 
IPG strip (#163-2016; Bio-Rad) (see section 5.5.1). The gel shows how streaky the 
proteins spots become at a high pH (red) making proteins difficult to excise. The gel 
also shows more proteins in the lower pH region (green). 
 
Loading the IEF Tray 
 
The protein sample was carefully pipetted along the back edge of a new rehydration tray 
(#165-4025; Bio-Rad). Care was taken to avoid getting the sample on the sides of the 
tray. When all the protein had been loaded the coversheet was peeled off a thawed 11cm 
IPG strip. The strip was placed gel side down in the channel containing the protein. 
Care was taken to avoid getting any air bubbles trapped between the protein sample and 
the IPG strip, and that all the protein solution was in contact with the strip. Three ml of 
mineral oil (#163-2129; Bio-Rad) was layered onto each strip to prevent evaporation 
and the strips drying out. The samples tray was covered over and the IPG strips were 
left to absorb the protein for 16hrs at room temperature. 





Electrode wicks were placed over the electrodes in a clean, dry IEF tray (#165-4020; 
Bio-Rad). Eight µl of DH2O was added onto each wick. The IPG strips were taken out 
of the rehydration tray with forceps and held vertically for 7secs over blotting paper and 
blotted to remove any excess oil and unabsorbed protein which can lead to streaky gels. 
The strips were placed in the IEF tray gel side down and ensuring that the positive side 
of the strip corresponded with positive end of the tray. Three ml of mineral oil was 
added to each strip to prevent the strips from drying. The lid was placed on the tray and 
the tray was placed in the Protean IEF cell (Bio-Rad). The cell was programmed with 
the method suggested for an 11cm IPG strip (Table 4.3). The completed method takes 
approximately 5.5hrs. The strips are first subjected to 250V for 20mins on a linear 
ramp, then 8000V for 2.5hrs and then 8000V on rapid ramp for 20,000 Volt Hours (V 
hrs). Finally the strips are held at 500V. 
 
Table 4.3: Method for the Protean IEF Cell for an 11cm IPG strip 
Step Voltage (V) Ramp Time (hrs:mins & V hrs) 
1 250 Linear 00:20 
2 8000 Linear 02:30 
3 8000 Rapid 20,000 V hrs 
4 500 Linear Hold 
 
 
The strips were removed from the IEF tray and held vertically for 7 sec over blotting 
paper and blotted to remove excess liquid. The strips were then placed in a rehydration 
tray gel side up. The tray was wrapped in saran wrap and stored at -80C. The IPG 
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Stock equilibration buffer (see Appendix D) was made up and stored in 40ml aliquots at 
-20C. Equilibration buffers 1 and 2 were prepared fresh (see Appendix D). 
Equilibration buffer 2 is light sensitive and was kept in the dark. The protein loaded IPG 
strips were taken from the freezer and thawed in laminar flow hood at room temperature 
until translucent. The strips were not left to thaw longer than 15mins. They were then 




Four ml of equilibration buffer 1 (containing DTT) was added to each IPG strip in the 
tray and the tray was placed on an orbital rocker at room temperature for 10mins. 




Four ml of equilibration buffer 2 (containing IAA) was added to each strip. The tray 
was placed on an orbital rocker for 10mins at room temperature in the dark and 
equilibration buffer 2 was discarded. 
 





Pre-cast 13.3 x 8.7cm, 8-16% Criterion Tris-HCl gels (#345-0105; Bio-Rad) were 
removed from their packaging and the comb was removed. The wells were rinsed three 
times in DH2O and the excess water was blotted off using filter paper. The IPG strips 
were washed in running buffer (taking care not to introduce any air bubbles on the 
surface of the strip) and placed on the back of the gel, gel side up. Molten agarose 
solution (see Appendix D) was pipetted in the IPG strip well, and the IPG strip was 
gently pushed into the well ensuring contact with the gel, and making sure no air 
bubbles were present. The gel was left for 5mins to let the agarose solution set. The gel 
was then placed into a Criterion Cell (Bio-Rad), which was subsequently filled with 
running buffer (upper buffer chambers filled with ~60ml and lower chamber filled with 
~800ml). The Criterion Cell could run one or two Criterion pre-cast gels 
simultaneously. Ten µl of Precision Plus Dual Colour Molecular Protein Standard 
(#161-0374; Bio-Rad) was added to the molecular weight standard well. The lid was 
placed on the tank and electrophoresis was performed at a constant 200V for 65mins. 
The gel was taken out of the plastic cassette and placed in a Nalgene staining box. Gels 
were washed for 5mins with approximately 300ml of DH2O three times. The water was 
discarded and the gels were stained as detailed in section 4.8. 
 
4.7 One Dimensional Gel Electrophoresis 
 
Proteins were separated as described in section 4.5.3; however the Cruz Marker™ was 
not required. After the gel had run it was removed from the plastic casing, transferred to 
a clean Nalgene staining box and washed for 5mins in approximately 100ml of DH2O 
three times. It was important to keep western blot staining boxes and coomassie blue 
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staining boxes clean and separate, as the blocking solution used for westerns binds to 
the sides of the boxes and will be stained by a protein stain. The water was discarded 
and the gels were stained as detailed in section 4.8. 
 
4.8 Protein Staining 
 
Stains that have been used and compared for this project are Bio-Safe™ Coomassie 
stain (#161-0787; Bio-Rad), SYPRO® Ruby protein gel stain (#s-12000; Invitrogen), 
Krypton protein stain (#46629; Pierce), Flamingo™ fluorescent gel stain (#161-0492; 
Bio-Rad) and Pro-Q® Diamond phosphoprotein gel stain (#p-33300; Invitrogen). The 
fluorescent stains and the fluorescent stained gels were handled in the dark throughout 
the protocols. 
 
4.8.1 Coomassie Protein Stain 
 
After the gels were washed with DH2O, enough Bio-Safe™ Coomassie stain was added 
to the Nalgene staining box to cover the gel (approximately 50ml for a 1D gel and 
150ml for a 2D gel). The staining box was placed on an orbital rocker for 1hr at room 
temperature. The staining solution was discarded and the gels were placed in DH2O 
(approximately 100ml for a 1D gel and 250ml for a 2D gel) for 16hrs to destain. Gels 
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4.8.2 SYPRO Ruby Protein Stain 
 
For a 1D gel, 100ml of fix solution (see Appendix E) was added to the gel in a Nalgene 
staining box, which was agitated on an orbital rocker for 30mins. This step was repeated 
with fresh fix solution. Sixty ml of SYPRO® Ruby protein gel stain was added to the 
gel, which was left for 16hrs at room temperature on an orbital rocker in the dark. The 
gel was transferred to a clean staining box and 100ml of wash solution (see Appendix 
E) was added and left on for 30mins on an orbital rocker in the dark. The gel was 
washed in DH2O before being scanned into Quantity One with a PharosFX Molecular 
Imager System (Bio-Rad) fitted with a 532nM laser and a 605nM bandpass filter. 
 
4.8.3 Krypton Protein Stain 
 
For a 1D gel 100ml of fix solution (see Appendix E) was added to the gel in a Nalgene 
staining box and agitated on an orbital rocker for 30mins. The fix solution was 
discarded and the procedure repeated with fresh fix solution. The gel was washed with 
DH2O on an orbital rocker for 5mins. The water was discarded and 5ml of Krypton 
stain was diluted in 45ml DH2O and was added to the gel. The gel was left for 16hrs at 
room temperature on an orbital rocker in the dark. The stain was discarded and the gel 
was incubated in 50ml destaining solution (see Appendix E) on an orbital rocker in the 
dark for 5mins. The gel was transferred to a clean staining box and 100ml of DH2O was 
added which was left on for 15mins on an orbital rocker in the dark. The wash was 
repeated before the gel was scanned into Quantity One with a PharosFX Molecular 
Imager System fitted with a 532nM laser and a 605nM bandpass filter. 
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4.8.4 Flamingo Protein Stain 
 
For a 1D gel 100ml of fix solution (see Appendix E) was added to the gel in a Nalgene 
staining box and agitated on an orbital rocker for 16hrs. Five ml of Flamingo™ 
fluorescent gel stain was diluted in 45ml DH2O and was added to the gel, which was left 
for 3hrs at room temperature on an orbital rocker in the dark. The gel was transferred to 
a clean staining box and 100ml of DH2O was added which was left on for 10mins on an 
orbital rocker in the dark. The gel was washed in again in DH2O before being scanned 
into Quantity One with a PharosFX Molecular Imager System fitted with a 532nM laser 
and a 605nM bandpass filter. 
 
4.8.5 Pro-Q Diamond Phosphoprotein Gel Stain 
 
For a 1D gel 100ml of fix solution (see Appendix E) was added to the gel in a Nalgene 
staining box and agitated on an orbital rocker for 30mins. The fix solution was 
discarded and the procedure repeated with fresh fix solution for 16hrs. The gel was 
washed with 100ml DH2O on an orbital rocker for 15mins. The wash step was repeated 
a further two times. The water was discarded and 60ml of Pro-Q® Diamond 
phosphoprotein gel stain was added to the gel, which was left for 90mins at room 
temperature on an orbital rocker in the dark. The stain was discarded and the gel was 
incubated in 100ml destaining solution (see Appendix E) on an orbital rocker in the 
dark for 30mins. The destaining step was repeated a further two times. The gel was 
transferred to a clean staining box and 100ml of DH2O was added which was left on for 
5mins on an orbital rocker in the dark. The wash was repeated before the gel was 
scanned into Quantity One with a PharosFX Molecular Imager System fitted with a 
532nM laser and a 555nm longpass filter. To re-stain the proteins with a total protein 
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stain, the gel was washed in DH2O twice for 5mins and the total protein stain was added 
(see sections 4.8.1 and 4.8.3) without a fixing step. 
 
4.9 Data Analysis 
 
Two software packages, which identify differentially expressed spots in 2D gels, were 
compared for use in the project. The software packages were PDQuest 2-D Analysis 
software (Bio-Rad) and Progenesis SameSpots (Nonlinear Dynamics). The two 
software packages were compared for; 
 
 Reliability 
 Ease of use 
 Accuracy of results 
 Time for analysis 
 
Based on the finding PDQuest 2-D analysis software was used to analyse gels (see 
section 5.6). 
 
4.9.1 PDQuest 2-D Analysis Software 
 
Three replicate gels were run for the test sample and the control sample. The six gels 
were uploaded from the Quantity One scanned images (in .1sc format) to PDQuest 2-D 
analysis software which creates the experimental file (in .ms format). Version 8.0 was 
used in this project which includes a wizard guide to setting up the experiment. The 
software asks the user to define a small spot and a faint spot. Spots should be selected 
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which are not too faint or too small to be excised. The software runs automatic detection 
and matching based on the spot information given and de-speckles the gels to discard 
non-specific spots. The software picks the gel with the most spots and creates a master 
gel from it. The master gel contains all the spots from all the gels which have been 
detected and matched. Each spot is given a corresponding letter (A-Z) so that it is easy 
to recognise individual spots on each gel. When the software has analysed the gels it 
then opens up the results box. 
 
However, it is necessary to manually edit the analysed gels as the software is unable to 
give 100% accuracy. This requires removing false spots (which maybe water bubbles 
from scanning) and clustered spots/streaks (which may be impossible to excise and take 
up analysis time), adding in missing spots, and identifying incorrect matching (Figure 
4.11 and Figure 4.12). This procedure usually takes up to five days if done thoroughly. 
Only if time and dedication is spent manually editing the automatically analysed gels 
will the results be true, and this will reduce false positive Western blot results after MS 
identification. The Dual Colour protein standards must also be added and assigned a 
molecular weight. 
 




Figure 4.11: Screenshot of PDQuest Editing 
The picture shows in a zoomed in area of the gel where editing is needed. Spots which 
have a red circle around them have not been automatically matched and added to the 
master gel and need manually matching. When the spots have been manually matched it 
will show a purple square on it. There are also spots in this area which need adding 
because the automatic detection has not picked them up, and spots which need deleting 
because they are in streaks and clusters and are un-excisable. To visualise the spots 
better a transform tool increases or decrease the contrast of the picture, this does not 
affect the results. 
 




Figure 4.12: PDQuest 3D Viewer 
A 3D viewer allows the gel to be seen geographically, showing the proteins like hills on 
the gel. The picture shows a very large, dark spot highlighted in the red box. The 3D 
viewer clearly shows that this is two proteins overlapping. 
 
When the editing is complete, the gels can be analysed. Only protein spots present in all 
3 replicates are included in the analysis therefore it is important to make sure that if a 
spot is present in one gel, it is highlighted in all the replicates or it will not be counted in 
the results. The “total quantity in valid spot” normalisation method is used, which 
divides the raw quantity of each spot in the member set by the total quantity of all spots 
in the gel, which have been included in master gel (this is recommended when little is 
known about sample variation). A Boolean analysis set is created by taking into account 
a quantitative 2-fold analysis set and a statistical Students t-test (P<0.05) analysis set 
(Figure 4.13). Proteins which are differentially expressed between the two groups are 
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identified by intersecting the two analysis sets. Histograms of the replicates are shown 
in the results to allow the analyst to discard any ambiguous results (Figure 4.14). 
 
 
Figure 4.13: PDQuest Analysis Sets 
The picture shows a Boolean analysis set. From the data shown above, 66 spots were 
found to have p<0.05 and 83 spots had a 2 fold quantitative change. Of these 149 spots, 
23 of them had both p<0.05 and a 2 fold quantitative change. 
 




Figure 4.14: PDQuest Spot Review Results 
Spots which are shown to be differentially expressed by the Boolean analysis set are 
shown in the spot review tool box, complete with histograms of the replicate gels. A 
print out of the gel with the differentially expressed spots highlighted is then used to 
manually excise spots from the gels. 
 
A print out of the gel highlighting the differentially expressed spots to be excised, the pI 
and the molecular weights is used to excise and to subsequently help with MS 
identification. For manual excision of the spots, it is helpful to have printouts of 
zoomed-in images of the gel and spots. 
 
4.9.2 Progenesis SameSpots 
 
Gels were uploaded into the software (in .tif format) and categorised into their groups. 
The software asks the user to pick a gel which could represent the experiment (usually 
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the one with the most spots on). The software works by aligning the pictures of the gels 
to the representative gel (Figure 4.15). The gels (coloured green) are placed on top of 
the representative gel (coloured pink) one at a time, and are aligned by the addition of 
vectors. The analyst first adds vectors manually until they are confident that the 
software has been trained sufficiently to add vectors automatically (Figure 4.16). 
Vectors need to be added in all regions of the gel if the automatic vectors are to be 
placed correctly. It is important that time is spent at this stage in the analysis if well 
aligned gels pictures are to be obtained. When enough vectors have been placed 
manually, and the software has correctly added automatic vectors, the gel images can be 
aligned (Figure 4.17). When this stage has been done for each replicate gel the software 
can analyse the gels to identify any differentially expressed spots (Figure 4.18). 
 
 
Figure 4.15: Unaligned gels from Progenesis SameSpots 
The representative gel (coloured pink) is layered on one of the replicate gels (coloured 
green). It is possible to see from the picture the similarities between the gels. The gels 
need to be aligned for analysis. To do this vectors are placed on the picture to show 
where the gels need to be moved to. The spots are good landmarks for placing the 
vectors. 
 




Figure 4.16: Unaligned gels with vectors from Progenesis SameSpots 
Vectors are added to train the software where to pull the gel image to. The manually 
added vectors are shown in red. When enough vectors have been added by the analyst 
the software can then add vectors in automatically, these vectors are shown in blue. The 
screen shot shows four gel images. Top left is a zoomed in area of the gel showing 
vectors. Bottom left is the full gel image. Top right pictures alternates between the 
representative gel and one of the replicate gels. Bottom right is the checkerboard effect 
from overlying the two images. The contrast and size of zoomed area can be altered. 
 




Figure 4.17: Aligned gels from Progenesis SameSpots 
When all the vectors have been added, the images can be aligned. The checkerboard 
image (bottom right) is a good indication of a successful alignment. The image at the 
top right of the screen shot will still alternate between the representative gel and one of 
the replicate gels but changes should be less noticeable. The picture top left shows the 
manually added vectors (red) and the automatic vectors (blue). 
 




Figure 4.18: Results from Progenesis SameSpots 
The software creates a table of all spots detected in the gels, the fold change between 
groups and the Anova p value. It is possible at this point in the software to edit the 
automatic spot detection. The spot list is analysed by the user and spots are either 
included or discounted from the final report. A print out of the gel with the differentially 
expressed spots highlighted is then used to manually excise spots from the gels. 
 
4.10 In-Gel Digestion 
 
4.10.1 Excision and Washing of Gel Pieces 
 
Stained 2D gels (see section 4.8) were washed with distilled water and transferred to gel 
cutting sheets (#165-7018; Bio-Rad). Protein spots of interest were excised with a 
scalpel using a magnifying glass and print outs of the gels with the differentially 
expressed spots highlighted. The gel spots were cut into small pieces to increase the 
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surface area for trypsin digestion. Each spot was pooled from all of the replicate gels 
into a labelled EZ polypropylene 1.5ml microfuge tube (#223-9480; Bio-Rad) 
containing 500l DH2O. By using polypropylene tubes, the risk of peptides sticking to 
the surface and of polymer contaminants is greatly reduced. The gel pieces were 
centrifuge at 16000xg for 30sec.  
 
4.10.2 Reduction and Alkylation 
 
The following procedures were carried out in a laminar flow hood. A 0.1M ammonium 
bicarbonate NH4HCO3 (AMBIC) solution was prepared fresh. Acetonitrile (ACN) was 
filtered into a clean, sterile bottle before use. 
 
The DH2O was removed with a fine pipette and 200l of ACN was added to dehydrate 
the gel pieces. The tubes were vortexed and left to stand at room temperature for 
15mins. The samples were centrifuged at 16000xg for 30sec and the ACN was removed 
with a fine pipette. The open tubes were placed in a vacuum-centrifuge (Uniequip) to 
dry for 30mins. Sixty µl of DTT/0.1M AMBIC solution (see Appendix D) was added to 
each tube and the tubes were vortexed and placed in an oven for 30mins at 56C to 
reduce any disulphide bonds. The samples were checked every 10mins to ensure they 
were fully covered by the DTT/0.1M AMBIC solution and to ensure the gel pieces were 
not sitting in an air bubble at the bottom of the tube. The tubes were centrifuge for 
30sec at 16,000xg and the DTT/0.1M AMBIC solution was removed with a fine pipette. 
Two hundred µl of ACN was added and the samples were vortexed and left to stand at 
room temperature for 15mins to dehydrate. The ACN was removed with a fine pipette 
after centrifuging the samples at 16000xg for 30secs. Sixty µl of IAA/0.1M AMBIC 
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solution was added to each tube and the samples were stored in the dark at room 
temperature for 20mins to alkylate. Samples were centrifuged at 16000xg for 30sec and 
the IAA/0.1M AMBIC solution was removed with a fine pipette. Two hundred µl of 
0.1M AMBIC was added to the gel pieces. Tubes were vortexed for 15mins. Samples 
were centrifuged at 16000xg for 30sec and the 0.1M AMBIC solution was removed 
with a fine pipette. Two hundred µl of ACN was added to dehydrate the gel. Samples 
were vortex for 15mins. Samples were centrifuged at 16000xg for 30sec and the ACN 
solution was removed with a fine pipette. The gel pieces were vacuum centrifuged for 
30mins. 
 
4.10.3 Washing and Destaining of Gel Pieces 
 
One hundred and fifty µl of 0.1M AMBIC solution was added. Tubes were vortexed for 
15mins. One hundred and fifty µl of ACN was added to the samples in the 0.1M 
AMBIC solution. Samples were vortexed for 15mins, centrifuged at 16000xg for 30sec 
and the ACN/0.1M AMBIC solution was removed. A further 200l of ACN was added 
and the samples were vortex for 15mins centrifuged at 16000xg for 30sec. The ACN 
was removed with a fine pipette. The gel pieces were dried in a vacuum centrifuge for 
30mins. 
 
If the gel pieces were blue at this point (i.e. still had coomassie stain in them), the 




Proteomic Analysis of Chronic Lymphocytic Leukaemia - Materials and Methods 
 
 98
4.10.4 Trypsin Digestion 
 
Trypsin Gold, Mass Spectrometry Grade (#V5280; Promega) was reconstituted in 
50mM of acetic acid to 1µg/µl. The reconstituted trypsin was aliquoted and stored at -
80°C. Digest buffer 1 (which contained reconstituted trypsin) and digest buffer 2 were 
prepared fresh prior to digestion (see Appendix D).  
 
When all the stain had been washed out of the gel pieces 30µl of digest buffer 1 
(containing trypsin) was added to each tube and they were incubated at room 
temperature for 1hr. During this time the gel pieces would absorb the solution. Larger 
gel pieces would absorb more trypsin than the smaller ones. The excess of trypsin digest 
buffer 1 was removed with a pipette after 1hr. Trypsin is a protein and if in excess will 
digest itself causing contaminating trypsin peptides. By removing the excess solution 
and only allowing the gel pieces 1hr to absorb the solution, the risk of trypsin autolysis 
is minimised. 
 
When the excess of digest buffer 1 was removed 50µl of digest buffer 2 was added to 
the samples. Digest buffer 2 keeps the gel pieces hydrated during the digestion and also 
acts as a suitable volatile solvent for the peptides to diffuse into. The samples were 
incubated in an oven at 37°C for 16hrs. 
 
4.10.5 First Peptide Extraction 
 
The following procedures were carried out in a laminar flow hood. A 0.025M AMBIC 
solution (see Appendix D) was prepared fresh. ACN was filtered before use. During the 
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peptide extraction, lids on the microfuge tubes were sealed with parafilm prior to all 
vortexing and shaking steps. 
 
Fifteen µl of 0.025M AMBIC solution was added to the tubes. Samples were shaken for 
15mins at 37°C. Fifty µl of ACN was added to the tubes and samples were shaken again 
for 15mins at 37°C. The gel pieces were centrifuged at 16000xg for 30sec and the 
supernatant (containing peptides) was transferred to new 1.5ml polypropylene 
microfuge tubes. Care was taken not to transfer any gel pieces with the supernatant. The 
gel pieces were retained in the original microfuge tubes for the second peptide 
extraction step on the gel pieces. 
 
Second Peptide Extraction Step 
 
A second peptide extraction step was necessary to retrieve a maximal yield of peptides 
for MS. Lids on the microfuge tubes were sealed with parafilm prior to vortexing and 
shaking. 
 
Fifty µl of 5% formic acid was added to the gel pieces which were vortexed for 15mins 
at 37°C. Tubes were centrifuged for 30sec at 16000xg and 50µl of ACN was added to 
the gel pieces in 5% formic acid. Samples were shaken for 15mins at 37°C. The tubes 
were centrifuged for 30sec at 16000xg and the supernatant was combined with the 
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4.10.6 Preparation for Mass Spectrometry 
 
The combined extracts from section 4.6.1 were dried down in a vacuum centrifuge until 
approximately 1-2µl of solvent was remaining (approximately 40min). It was important 
not to dry the solution completely as the peptides may stick to the tube and become 
difficult to get back into solution. Fifteen to twenty µl of ACN/DH2O (50:50) with 1% 
formic acid was added to the tubes which were vortexed and sonicated for 5mins at 
room temperature to ensure all peptides have been resuspended. It is necessary to 
resuspend the peptides in a minimum volume of 15µl to ensure the solvent mixes with 
the peptides in the vortexing step. 
 
An AnchorChip™ MALDI Target (#209515; Bruker Daltronics) (Figure 3.3) was 
cleaned by sonicating in methanol:DH2O (50:50). A saturated solution of DHB 
(#85707; Sigma-Aldrich) in ACN:DH2O (50:50) with 1% formic acid was prepared 
fresh. 
 
Two µl of sample was mixed with 1l of DHB saturated solution in a polypropylene 
0.5ml microfuge tube by gentle pipetting. The remaining peptide extracts could be 
stored at -20°C for up to 5 days or dried down in a vacuum centrifuge and stored at -
20°C for long term storage. Three µl of sample/matrix solution was loaded onto the 
MALDI sample plate, with a fine, gel loading pipette tip. Each sample was loaded onto 
a separate sample spot on the plate and the coordinates of each sample was recorded. 
The samples were left to air dry. It was sometimes necessary to re-spot certain samples 
if they had not dried well. For example, if the room temperature was high, the solvent 
would evaporate away too quickly, leaving the matrix/peptide crystals clumped and too 
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thick. The crystals need to be spread out enough to be thin enough for the MS laser to 
be able to penetrate through. This is only a cause for concern when using DHB matrix. 
 
4.11 Matrix Assisted Laser Desorption/Ionisation, Time of Flight Mass 
Spectrometry 
 
A Bruker Daltronics Reflex IV MALDI-TOF MS fitted with a 337nm nitrogen laser in 
reflectron mode was used to acquire PMFs. Ions were accelerated through a potential of 
20Kv into the TOF mass analyser and ions within m/z 950-2500 were detected. Laser 
power was set between 19 and 35%. A minimum of 200 laser shots were used to acquire 
the averaged spectra and 20 shots were fired in a single acquisition. Analysis was 
performed using the Bruker software suite and acquisition of spectra was obtained with 
Flex Control. Spectra were processed using Flex Analysis and Biotools. Peaks were 
edited in Flex Analysis (small undetected peaks were added and multiple isotopic peaks 
were deleted); however keratin contaminants were kept in at this point. 
 
PMFs were searched against the NCBInr database using MASCOT search engine 
(www.matrixscience.com). Taxonomy was restricted to human. Fixed carbamidomethyl 
modifications and variable methione and oxidation modifications were selected. The 
search allowed for two missed cleavage and a +/- 0.1% mass tolerance for monoisotopic 
peak. The MOWSE scoring was used by MASCOT to determine whether protein 
identifications were significant (P<0.05). 
 
The spectra were first submitted to the database search without taking out any keratin 
peaks. Any results which matched the molecular weight and the pI of the protein spot of 
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interest were investigated. If a significant score had not been achieved the first set of 
contaminant peaks (see section 5.7.2 and Appendix H) were taken out. 
 
Prior to starting the project a list of contaminants was obtained from the internet which 
included keratin contaminants and trypsin autolysis peaks. A blank piece of 
polyacrylamide gel was digested to obtain background peaks. Multiple digests of 
standard, commercially available proteins were analysed on the MALDI-TOF-MS and 
the spectra was compared to reference spectra. This allows the analyst to obtain their 
own personal contaminants list. Therefore it is vital that the analyst conducts their own 
work throughout (see section 5.7.2). 
 
It is important not to take all contaminants out at once as some peaks may overlap with 
real peptide peaks. Therefore four sets of contaminant peaks (see Appendix H) were 
taken out sequentially if a protein match (significant score and correct pI and MW) was 
not shown. These sets have been derived by myself over the past four years and range 
from the first set containing peaks which have a high intensity and are present in over 
90% of experiments, to the fourth set of peaks which have lower intensities and are 
present in less than 60% of experiments. 
 
If a significant score had not been achieved the first set of contaminant peaks were 
taken out and the search was submitted again. If a significant protein still did not show 
then the second set of contaminant peaks were taken out, and so on. After the fourth set 
of contaminant peaks were taken out and there was still no protein of interest then that 
protein spot was listed as unidentified. A protein can be unidentified for many reasons, 
such as: 
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 Protein not listed in database 
 Too many keratin contaminants masking small peptides peaks 
 Not enough protein present in gel spot (spot too faint/small) 
 Contaminated with neighbouring spot on gel during excision  
 Small number of peptides present in digest, which requires all peptide peaks to 
be seen in spectra  
 Large number of peptides present in digest, which results in a large number of 
protein matches 
 
4.12 The Sigma-Aldrich Panorama® Antibody Microarray – XPRESS Profiler725 
Kit 
 
The Panorama® Antibody Microarray – XPRESS Profiler725 (#XP725; Sigma-
Aldrich) contains 725 different antibodies each spotted in duplicate on a nitrocellulose-
coated glass slide. By labelling the protein extracts with fluorescent dyes, the expression 
of a protein can be detected when it binds to its corresponding antibody spotted on the 
slide. The fluorescent signal intensity for each sample is recorded individually at the 
wavelength corresponding to the dye label of the sample and control. The protein 
expression for the two samples can then be compared. 
 
4.12.1 Protein Extraction for Antibody Microarray 
 
Approximately 1.2x108 cells from clinical sample 003 were stimulated (see section 4.4) 
for 5.5hrs, and approximately 1.2x108 cells were exposed to an isotype control for 
5.5hrs (see section 4.4). Cells were washed twice in cold PBS and 20% were lysed in 
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Laemmli buffer (see section 4.5) for Western blot confirmations, and 80% were lysed in 
1ml of Buffer A from the XPRESS Profiler725 kit. The antibody microarray samples 
were vortexed for 30secs and incubated on ice for 5mins. Samples were centrifuged for 
10secs at 10,000xg, and the supernatant was transferred to a new 1.5ml microfuge tube. 
 
4.12.2 Protein Quantification for Antibody Microarray 
 
The Bradford Assay was used to determine the protein quantification as recommended 
by Sigma-Aldrich. At least 1ml of protein at 1mg/ml was needed for the experiment. 
The Bradford assay is a colorimetric assay based on the formation of a complex 
between the dye (Coomassie Brilliant Blue G) and the proteins in solution. When the 
dye (originally coomassie red) binds to the protein, it stabilises to coomassie blue. The 
assay uses the shift in the absorbance from 465nm (red) to 595nm (blue) to measure 
protein. The amount of absorption is proportional to the protein present. 
 
Three technical replicates of differing dilutions were used for the stimulated extract and 
isotype control extract in the assay. An undiluted sample and dilutions of 1:2.5 and 1:5 
were used. 
 
One hundred µl of samples were place into a 96 well plate along with 100µl of four 
BSA standards of 0.1, 0.5, 1.0 and 1.4mg/ml. The linear range of the assay is 0.1-
1.4mg/ml. 
 
Three ml of Bradford Reagent (#B6916; Sigma-Aldrich) was added to each of the wells 
and the plate was vortexed gently. Samples were incubated at room temperature for 
15mins and the absorbance was read at 595nm on a Multiscan MS plate reader 
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(Thermoelectron, UK). A plot of absorbance vs. standard concentrations was used to 
determine the concentration of the samples. 
 
4.12.3 Protein Labelling 
 
The following procedures were carried out in the dark. 
 
Extracts were diluted to 1mg/ml with Buffer A from the XPRESS Profiler725 kit. One 
ml of protein extracted from stimulated cells was added to the Cy5 dye (#PA25001; GE 
Healthcare) and 1ml of protein extracted from unstimulated cells was added to the Cy3 
dye (#PA23001; GE Healthcare). The dyes were supplied in a lyophilised form. The 
Cy5 dye was a blue powder and the Cy3 dye was a pink powder. 
 
The dye vials were mixed thoroughly by briefly vortexing. The samples were incubated 
at room temperature for 30mins with vortexing briefly every 10mins. The unlabeled 
dyes were removed by using a Sigma-AldrichSpin column (provided with the XPRESS 
Profiler725 kit). The Sigma-AldrichSpin column was first placed in a collection tube 
and centrifuged at 750xg for 2mins to remove any excess buffer. The eluate was 
discarded and the column was placed in a new collection tube. One hundred and fifty µl 
of dye labelled protein was then carefully pipetted directly onto the centre of the Sigma-
AldrichSpin column. The remaining labelled protein was stored at -80°C. The Sigma-
AldrichSpin column and collection tube were centrifuged for 4mins at 750xg. The 
Sigma-AldrichSpin column was discarded and the eluate was retained. 
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The protein quantification was determined using the Bradford assay (see section 4.12.2) 
but this time samples did not need diluting. This was to ensure there was still 1mg/ml 
protein. The labelled protein could then be stored short term at 2-8°C. 
 
4.12.4 Determination of Dye to Protein Molar Ratio 
 
The following procedures were carried out in the dark. 
 
In accordance with the XPRESS Profiler725 kit the dye to protein ratio (D/P) should be 
above 2. A lower ratio may affect the array and produce a higher background. The D/P 
was calculated by the following equation: 
 
D/P ratio = Dye Concentration (µM) 
Protein Concentration (µM) 
 
The protein concentration (µM) is calculated by the following equation: 
 
Protein Concentration (µM) = (Protein Concentration (mg/ml)/60,000) X106 
 
The dye concentration is calculated by the following equations: 
 
Cy3 concentration (µM) = A552/0.15 
(CY3: εµM(552nm) = 0.15µM-1cm-1) 
 
Cy5 Concentration (µM) = A650/0.25 
(CY5: εµM(552nm) = 0.25µM-1cm-1) 
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Therefore the absorbance of the samples was read at 552nm for Cy3 and 650nm for 
Cy5. A Libra S11 Spectrophotometer (Biochrom) was used to measure absorbance. A 
1:10 dilution of each labelled sample was used and 100µl of sample was added to the 
cuvette. The cuvette was thoroughly washed with DH2O in between each reading and 
the spectrophotometer was blanked with Buffer A from the XPRESS Profiler725 kit. 
 
4.12.5 Sample Incubation on the Array 
 
The following procedures were carried out in the dark. 
 
The slide was washed by dipping briefly in PBS in a 50ml tube. Using the protein 
quantification results, 50ug of each of Cy3 and Cy5 labelled samples (at equal 
concentrations) were mixed with 5ml of Array Incubation Buffer from the kit. The 
samples were mixed well by inverting the tubes several times. The mixture was added 
to well 1 of the Incubation Tray supplied with the kit. The slide was immersed into well 
1 and was incubated at room temperature for 30mins with gentle agitation on an orbital 
rocker. Five ml of Wash Buffer was added to wells 2, 3, and 4 in the Incubation Tray. 
The slide was carefully taken out of well 1 and placed into well 2 and incubated at room 
temperature for 5mins with gentle agitation on an orbital rocker. This step was repeated 
by transferring into wells 3 and 4. The liquid was decanted from well 4 and 5ml of 
DH2O was added. The slide was incubated for 2mins on the bench and then allowed to 
air dry for 40mins on an incline to allow excess liquid to drain. The slide was not 
covered over so it was essential to let it dry in a dust and debris free environment. It was 
essential that the slide was absolutely dry before scanning to avoid water marks. 
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4.12.6 Scanning the Antibody Microarray 
 
The slide was kept in the dark at all times. 
 
The microarray slide was scanned using a GenePix Personal 4100A Microarray scanner 
(Axon Instruments) using a 532nm laser for the excitation of Cy3, and a 635nm laser 
for the excitation of Cy5. Analysis was performed using the GenePix Pro software 
package 4.1 (Axon Instruments). 
 
The microarray was scanned at a resolution of 5µm/pixel. The laser photomultiplier 
tube (PMT) gains were manually set for each dye to ensure a normal count ratio of 1 
(±0.1) across the whole array (Figure 4.19).  
 




Figure 4.19: Histogram from an antibody microarray scan 
The picture shows the count ratio of 0.97. The PMT gains should be adjusted until this 
value is as close to 1 as possible. 
 
Scanned microarray images (in .tif format) were set in a grid (Figure 4.20) and linked to 
the protein print array list included in the kit so that each spot could be linked back to a 
specific protein. Any features which were not correctly aligned or sized were altered 
manually using the manipulation tool. The result files were imported into Acuity 4.0 
(Axon Instruments) and differentially expressed proteins were highlighted. The 
antibody microarray was normalised using the Lowess method. Unreliable data was 
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removed from the analysis. Only spots with less than 3% of saturated pixels, spots that 
were not flagged bad or absent, spots with relatively uniform intensity and uniform 
background and spots that are detectable above background were included in the 
analysis. Proteins showing a 2 change in expression were classed as significant. 
 
 
Figure 4.20: Scanned image of the Sigma-Aldrich Panorama® Antibody 
Microarray – XPRESS Profiler725 slide 
The image shows the scanned slide containing 725 antibodies and bound, dye labelled 
protein samples. The mixture of the two labelled protein extracts (test and control) will 
appear orange if they are in the same concentration, but if a protein is over expressed in 




   
Chapter 5 - Establishment and Optimisation of 
the Western Blot Signaling Assay and 2D-
PAGE/MS to Analyse BCR Signaling 
 
Aims: 
Establish and Optimise: 
 A method to artificially stimulate the BCR in RAJI B-cells to induce 
kinase pathways 
 A western blot based BCR signaling assay  
 A 2D-PAGE/MS method for the analysis of a protein extract 
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Establishment and Optimisation of the Western Blot Signaling Assay and 2D-
PAGE 
 
5.1 Optimisation of the BCR Stimulation with a Surrogate Antigen 
 
B-cell lines and clinical samples were artificially stimulated through the BCR as 
described in section 4.4.  The number of cells, the concentration of antibody fragment 
and the incubation time needed to be optimised, so initial experiments were set up on 
RAJI, DAUDI and RAMOS-EHRB B-cell lines to find the optimum stimulation 
conditions. 
 
5.1.1 Optimisation of Stimulation Incubation Time 
 
After cell counting (section 4.3) RAJI B-cells were suspended in a concentration of 
5x105cells/ml (Allsup et al. 2005). Cells were incubated for 5, 25, 45 and 60mins with 
10g/ml of AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5 fragment specific 
(see section 4.4) (Allsup et al. 2005). Cells incubated with 100nM PMA for 5mins were 
included as a positive control and cells incubated with 10g/ml of ChromPure Goat IgG 
F(ab’)2 fragment for 60mins were included as an isotype control (see section 4.4) 
(Allsup et al. 2005). Incubations were performed at 37°C with 5% CO2. 
 
Protein was extracted as described in section 4.5.1 and western blots were performed as 
described section 4.5. P-ERK was used as a primary antibody and GAPDH was used as 
a loading control (see Table 4.1 and Table 4.2). 
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The western blot showed that 5mins incubation with 10g/ml of the anti-human IgM 




Figure 5.1: Western blot showing ERK phosphorylation over different B-cell 
stimulation times 
The western blot showed that a 5mins incubation with 10g/ml of AffiniPure F(ab’)2 
fragment goat anti-human IgM, Fc5 fragment specific antibody is sufficient to activate 
the BCR and induce the MAPK pathway. The isotype control shows that after 5mins the 
cells were negative for P-ERK, providing evidence that P-ERK levels were purely 
induced by the anti-human IgM antibody. The PMA positive control shows that after 
5mins the cells are viable and have reacted to stimulation. 
 
5.1.2 Optimisation of Stimulant Concentration 
 
After cell counting (see section 4.3) RAJI B-cells were suspended in a concentration of 
5x105cells/ml (Allsup et al. 2005). Cells were incubated with 1.0, 10, 50 and 100 g/ml 
of AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5 fragment specific for 5mins 
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(see section 4.4). Cells incubated with 100nM PMA for 5mins were included as a 
positive control and cells incubated with 100g/ml of ChromPure Goat IgG F(ab’)2 
fragment for 5mins were included as an isotype control (see section 4.4). Incubations 
were performed at 37°C with 5% CO2. 
 
Protein was extracted as described in section 4.5.1 and Western blots were performed as 
described section 4.5. P-ERK was used as a primary antibody and GAPDH was used as 
a loading control (see Table 4.1 and Table 4.2). 
 
The concentration to be used throughout the project was chosen as 10µg/ml as this 
concentration corresponded with the literature (Allsup et al. 2005; Petlickovski et al. 
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Figure 5.2: Western blot showing ERK phosphorylation over different 
concentrations of the B-cell stimulant 
The western blot shows that incubation with all of the chosen concentrations of 
AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5 fragment specific antibody 
activated the BCR and induced the MAPK pathway as indicted by phosphorylation of 
the ERK protein. The isotype control shows that at concentration of 100µg/ml cells 
were negative for P-ERK, providing evidence ERK phosphorylation was induced by the 
anti-human IgM antibody. The PMA positive control shows that after 5mins the cells 
are viable and have reacted to stimulation. 
 
5.1.3 Stimulant Concentration and Incubation Time Optimisation Summary 
 
For the western blot signaling assay, B-cell lines were incubated in 10µg/ml F(ab’)2 
fragment goat anti-human IgM, Fc5 fragment specific antibody for 5mins to induce 
BCR signaling as shown in Figure 5.1 and Figure 5.2. 
 
5.2 Western Blot Gel Optimisation 
 
There are many pre-cast 1D gels on the market. To decide which gels to use for the 
assay gels from the two market leaders, Bio-Rad and Invitrogen were compared. 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Establishment and 
Optimisation of the Western Blot Signaling Assay and 2D-PAGE 
 
 116
12% Tris-HCl Ready Gels (#161-1120; Bio-Rad) were compared to homogenous 
Novex® 12% Tris-Glycine gel (1.0mm, 8x8cm, 10 well) (#EC6005box; Invitrogen). 
Samples were randomly selected from stimulated and unstimulated CLL clinical 
samples. Twenty micrograms of protein extract were run on the two gels 
simultaneously. Gels were probed with a P-ERK antibody (see Table 4.1 and Table 4.2). 
Samples should show varying levels of P-ERK depending on their response to 
stimulation. The experiment was performed in duplicate on separate days with different 
samples. 
 
The Invitrogen gels were a much better quality then the Bio-Rad Gels and were 
consistently reliable producing good quality data, whereas the Bio-Rad gels had batch 
variability and produced unreliable results. Therefore the Homogenous 12% NuPAGE 
Tris-Glycine gels (Invitrogen) were used for western blots and 1D gels throughout this 
project. 
 
5.3 Optimisation of Stripping Buffers for Western Blot on a Nitrocellulose 
Membrane 
 
Western blots were used to determine if a CLL clinical sample was a responder to BCR 
stimulation. PBMCs were extracted from blood as described in section 4.2.2. Protein 
was extracted from stimulated PBMCs as described in sections 4.4 and 4.5.1 Protein 
Extraction and quantified as described in section 4.5.2. Western blots were performed as 
described in section 4.5. 
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Expression of P-ERK was used to assess BCR activation. If a BCR is activated 
successfully then the MAPK pathway will be triggered, causing the ERK protein to 
become phosphorylated (see section 2.4). The increase in phosphorylation of ERK can 
be used to determine the BCR responsiveness. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a loading control. GAPDH is an enzyme used to 
break down glucose. It is stable, and constitutively expressed at high levels in most cells 
therefore is considered a housekeeping gene, making it an ideal loading control for 
western blots. Dilutions of the P-ERK and GAPDH antibodies were optimised prior to 
assay (see Table 4.1 and Table 4.2). 
 
It is sometimes necessary to strip a primary antibody off a membrane in order to re-
probe with another primary antibody of a similar molecular weight. Western blots of 
randomly selected clinical samples were used for the stripping optimisation. The blots 
were probed for P-ERK raised in a mouse (see Table 4.1 and Table 4.2). Membranes 
were stripped using two different types of stripping buffer, a homemade stripping buffer 
and a commercially available stripping buffer (Restore PLUS Western Blot Stripping 
Buffer #46430; Pierce). The two buffers were compared to see which would give the 
best results. The membranes were stripped as described in section 4.5.8. 
 
Homemade Western Blot Stripping Buffer 
 
The homemade stripping buffer comprised of 2% SDS, 100mM β-mercaptoethanol and 
50nM Tris pH 6.8. A western blot of P-ERK (see 4.5) on stimulated RAJI B-cell lysates 
(see section 4.4) was run and developed (see Figure 5.3 (A)). The nitrocellulose 
membrane was then incubated in 15ml of buffer with gentle agitation for 5mins, 
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15mins, 30mins, 45mins and 60mins, at room temperature, 50°C and 70°C. The 
membrane was then incubated for 1hr with a secondary mouse HRP conjugated 
antibody and the blot was developed to show any unstripped primary antibody (see 
Figure 5.3 (B)). The primary antibody was only successfully removed by incubating at 
70C for 60mins.  The membrane was probed again for P-ERK to compare the amount 
of protein with the original blot. There was a significant loss in signal intensity (see 
Figure 5.3 (C)). The stripping buffer had successfully removed the primary antibody, 
but had also removed protein sample. Therefore, although this buffer was efficient at 
removing the antibody, the method was too harsh to be used in this project. 
 
 
Figure 5.3: Western blot which has been incubated with a homemade stripping 
buffer for 60mins at 70°C 
The Western blot was probed for P-ERK with a mouse antibody (A). After stripping 
the membrane in 15ml of homemade stripping buffer for 60mins at 70C it was 
incubated with a secondary mouse HRP conjugated antibody and the blot was 
developed to show any unstripped primary antibody (B). The membrane was re-
probed for P-ERK as before and developed to compare the signal intensity with the 
original blot (C). The blots show that the stripping buffer had successfully removed 










+ + + - 
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Pierce Restore Western Blot Stripping Buffer 
 
The Restore PLUS Western Blot Stripping Buffer (#46430; Pierce) is advertised as an 
effective buffer that is not as harsh as a homemade stripping buffer and so less protein is 
removed.  
 
Two western blots of P-ERK (see 4.5) on stimulated RAJI B-cell lysates (see section 
4.4) were run and developed (Figure 5.4 (A)). The nitrocellulose membranes were 
incubated in 15ml of Restore PLUS Stripping Buffer. One membrane was incubated for 
5mins and the other for 10mins at room temperature with gentle agitation (The protocol 
given by the manufacturer suggests an incubation time of 5-15mins). The membranes 
were incubated in a secondary mouse HRP conjugated antibody for 1hr and developed.  
 
The results show that an incubation time of 5mins was not sufficient, and an incubation 
time of 10mins was necessary to completely remove the primary antibody (Figure 5.4 
(B)). The membrane which had been incubated in Restore PLUS Stripping Buffer for 
10mins was then re-probed for P-ERK to determine if protein sample had also been 
stripped off the membrane. The western blot shows that little protein sample had been 
lost (Figure 5.4 (C)). 
 
To see if this membrane could be stripped repeatedly, it was incubated again for a 
further 10mins in the Restore PLUS Stripping Buffer, and as before all the primary 
antibody was removed (Figure 5.4 (D)). The membrane was re-probed for P-ERK as 
before, but the signal intensity showed that protein had been lost on the second stripping 
(Figure 5.4 (E)). The loss of protein appeared to be less of a problem when compared 
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Figure 5.4: Western blot which has been repeatedly incubated with Restore 
PLUS Stripping Buffer (#46430 Pierce) for 10mins at room temperature 
The Western blot was probed for P-ERK with a mouse antibody (A). After stripping 
the membrane in 15ml of Pierce Restore PLUS Stripping Buffer for 10mins at room 
temperature it was incubated with a secondary mouse HRP conjugated antibody and 
the blot was developed to show any unstripped primary antibody (B). The membrane 
was re-probed for P-ERK as before and developed to compare the signal intensity 
with the original blot (C). The membrane was stripped in 15ml of Pierce Restore 
PLUS Stripping Buffer for 10mins at room temperature it was incubated with a 
secondary mouse HRP conjugated antibody and the blot was developed to show any 
unstripped primary antibody (D). The membrane was re-probed for P-ERK as before 
and developed to compare the signal intensity with the original blot (E). The blots 
show that a 10mins incubation period with Restore Plus stripping buffer is sufficient 
to remove the primary antibody (B and D). Little protein is lost upon the first 
stripping (C) but repeated stripping results in a loss (E). 
 
Because of its gentle stripping properties and ease of use, the Pierce Restore Stripping 
Buffer was used to strip all membranes in the project. Anti-P-ERK is a mouse antibody 
and was successfully removed under the condition described. A membrane was only 
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Antibodies raised in rabbits such as Anti-GAPDH and Anti-ERK proved to be more 
difficult to remove and required heating to 37C and incubating for 15-30mins, which 
resulted in significant loss of protein sample. Therefore a strategy was adopted whereby 
antibodies raised in mouse were applied first and then stripped before the application of 
a rabbit antibody. This meant that the stripping of antibodies raised in rabbits was not 
necessary. 
 
5.4 Optimisation of Protein Stains for 2D-PAGE 
 
Coomassie blue visible stain and three fluorescent stains were compared for ease of use 
and sensitivity. The stains that were used and compared for this project were Bio-Safe™ 
Coomassie total protein stain (#161-0787; Bio-Rad), SYPRO® Ruby total protein gel 
stain (#s-12000; Invitrogen), Krypton total protein stain (#46629; Pierce), Flamingo™ 
fluorescent total protein gel stain (#161-0492; Bio-Rad) and Pro-Q® Diamond 
phosphoprotein gel stain (#p-33300; Invitrogen). 
 
The total protein stains were investigated first. A 1D gel of different cytochrome C 
concentrations was run in quadruplicate according to the protocol described in section 
4.7. Eight concentrations of cytochrome C were used at 10µg, 2µg, 400ng, 80ng, 16ng, 
3.2ng, 0.64ng and 0.25ng. Each gel was stained with a different total protein stain 
(Figure 5.5) and scanned as described in section 4.8. 
 
Krypton protein stain was the most sensitive fluorescent stain and gave the cleanest gel. 
Coomassie is not as sensitive as Krypton stain however the advantage of coomassie is 
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that it is visible without the use of a fluorescent scanner. Krypton fluorescent protein 
stain and Coomassie visible stain were chosen to be used in the project. 
  
  
Figure 5.5: 1D gels of varying concentration of cytochrome C stained with Bio-Safe 
Coomassie stain, SYPRO Ruby protein gel stain, Flamingo fluorescent gel stain and 
Krypton protein stain 
Gel stained with Coomassie (A). Gel stained with Sypro (B). Gel stained with Flamingo 
(C). Gel stained with Krypton (D). The gels show that Krypton protein stain is the most 
sensitive and gave the cleanest gel, the stain detected 16ng of protein. SYPRO Ruby stain 
streaked across the dye front making it difficult to distinguish individual bands. Flamingo 
protein stain saturated bands at higher concentrations. Coomassie blue stain was the only 
visible stain compared and detected 80ng of protein. 
 
Krypton is a fluorescent total protein stain so it needed to be compatible with Pro-Q 
Diamond phosphoprotein fluorescent gel stain if phosphoproteins were to be visualised. 
The literature on Pro-Q Diamond stain specified that it was only compatible with 
A B 
C D 
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SYPRO ruby stain. A 1D gel was run to determine if Krypton stain was compatible with 
Pro-Q Diamond stain. 
 
PeppermintStick phosphoprotein molecular weight standard (#P33350; Invitrogen) is a 
mixture of phosphorylated and non-phosphorylated proteins ranging from 14.4 – 
116.25KDa. A 1D gel of varying PeppermintStick concentrations was run according to 
the protocol described in section 4.7. Separation by polyacrylamide gel electrophoresis 
resolves the standard mixture into two phosphorylated protein bands and four non-
phosphorylated protein bands (Figure 5.6). 
 
 
Figure 5.6 Peppermint Stick Molecular Weight Marker from Invitrogen 
The picture shows a scanned image of the PeppermintStick molecular weight marker. 
The bands on the left show phosphorylated proteins. The bands on the right show 
unphosphorylated proteins. Proteins are as follows: β-galactosidase 116.3KDa, BSA 
66.2KDa, ovalbumin (phosphorylated) 45KDa, β-casein (phosphorylated) 23.6KDa, 
avidin 18KDa, and lysozyme 14.4KDa. 
 
Nine different concentration of PeppermintStick were loaded onto a gel, they were 
500ng, 250ng, 125ng, 62.5ng, 31.3ng, 15.6ng, 7.8ng, 3.9ng and 1.95ng. The gel was 
then stained with Pro-Q Diamond and scanned as described in section 4.8.5. The 
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Phosphoprotein stain was then washed off and the gel was stained with Krypton protein 
stain and scanned as described in section 4.8.3. Results show that Krypton total protein 
stain is compatible with Pro-Q Diamond phosphoprotein stain which can detect protein 
at 15.6ng (Figure 5.7). 
 
  
Figure 5.7: 1D gel stained with Pro-Q® Diamond Phosphoprotein Gel and then 
stained with Krypton Total Protein Stain 
The picture shows a 1D gel of nine concentrations of PeppermintStick Phosphoprotein 
Molecular Weight standard (#P33350; Invitrogen). Ten µl of Precision Plus Dual 
Colour Marker (#161-0374; Bio-Rad) was placed in lane 1 as a visible marker. The gel 
was stained first with Pro-Q Diamond Phosphoprotein Stain (A), and then stained with 
Krypton Total Protein Stain (B). The gels show that the two stains are is compatible. 
The Pro-Q Diamond stained image (A) shows the two phosphoprotein bands in the 
PeppermintStick Standard. The Krypton stained image (B) shows all protein bands in 
the PeppermintStick Standard with the exception of the 14.4KDa band which has run 
off the gel during electrophoresis. Proteins can be visualised by Pro-Q diamond at 
15.6ng, Krypton total protein fluorescent stain can detect high molecular weight 
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5.5 Optimisation of 2D-PAGE 
 
5.5.1 2D-PAGE of E.coli Protein Standard 
 
To gain experience in running a 2D gel and to check the optimised running conditions 
the ReadyPrep 2-D starter kit (#163-2105; Bio-Rad) was used. The kit contained a 
prepared E.coli protein sample (#163-2110; Bio-Rad) and allowed the analyst to focus 
on the technique rather than the sample and reagent preparations. The kit included step 
by step instructions and tips for first time users. 
 
The protein extract from E. coli from the kit was separated using the methods described 
in sections 4.6.4, 4.6.5 and 4.6.6. ReadyStrip IPG strips of 11cm, pH 3-10 (#163-2016; 
Bio-Rad) were used. The gel was comparable to that of example shown in the Bio-Rad 
starter kit. Spots would have been better defined if the protein extract had been 
separated across a smaller pH range such as pH4-7 and pH7-10 (Figure 5.8). 
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Figure 5.8: 2D gel of an E.coli protein extract from the ReadyPrep 2-D starter 
kit (Bio-Rad) 
The gel was comparable to that of reference image in the Bio-Rad starter kit. The 
proteins were separated by pH on an 11cm, pH3-10 ReadyStrip IPG strip (Bio-Rad) 
and then separated by molecular weight on a Criterion 8-16% gel (Bio-Rad). The gel 
is cleaner at a lower pH because the disulphide groups on the protein at a higher pH 
are prone to unspecific oxidation causing extra spots and streaking. The separation of 
spots in the middle of the gel is quite poor; this is because the protein was separated 
across a large pH range. 
 
5.6 2D Gel Analysis Software 
 
Two software packages, which identify differentially expressed spots in 2D gels, were 
compared for use in the project. The software packages were PDQuest 2-D Analysis 
software V8.0 (Bio-Rad) and Progenesis SameSpots V1.01 (Nonlinear Dynamics). The 
two software packages were compared for; 
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 Ease of use 
 Accuracy of results 
 Time for analysis 
 
PDQuest had been used for previous work at our laboratory but is time consuming 
(takes one week to analyse an experiment) and relies greatly on human intervention 
which may lead to biased results. Progenesis SameSpots is advertised as giving reliable 
data as human intervention is not required, and takes only one day to complete the 
analysis. 
 
Protein extracts from stimulated and unstimulated RAJI B-cells (see sections 4, 4.4 and 
4.5.1) were separated by 2D-PAGE in triplicate as described in section 4.6 and stained 
with Bio-Safe™ Coomassie stain (Bio-Rad). The gels were then analysed by PDQuest 
V8.0 and Progenesis SameSpots V1.01. 
 
The first problem highlighted was that Progenesis SameSpots had no manual as it was 
comparatively new software so the manufacturer’s technical support department guided 
us through the programme. PDQuest did have a manual and wizard guide to allow for 
ease of use. As with most new pieces of software, other problems followed with 
Progenesis SameSpots such as crashes and freezes in the software which were reported 
to technical support. But ultimately the decision for which analysis to use was based on 
reliability of results and speed. 
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PDQuest requires the analyst to intervene and manually match and edit spots (see 
section 4.9.1) which takes up to one week to complete, however it became apparent that 
Progenesis SameSpots also requires this intervention, but because the manufacturers say 
that no intervention is needed, the editing tools in the software are inadequate. Figure 
5.9 shows the poor spot detection of Progenesis SameSpots and how manual 
intervention is needed to split the spots.  
 
 
Figure 5.9: Picture to show poor spot splitting in Progenesis SameSpots 
The picture shows an example of spot detection done automatically using Progenesis 
SameSpots V1.01 (Nonlinear Dynamics). The area highlighted in blue (left) is clearly 
two spots which require splitting (right). 
 
The spot editing problem was seen throughout the gels (Figure 5.10). It took longer than 
one week to manually edit all the gels due to the inadequate editing tools and because 
not all the gel was accessible for editing. As all the 6 gels are overlaid in this software, 
only one gel needed editing, but accurate results relied greatly on the gels being 
correctly aligned. The manufacturers of the software do not recommend editing the gels 
as state that it will affect the reliability of the results. 
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Figure 5.10 Pictures to show spot detection by Progenesis SameSpots 
A: An example of spot detection on a gel done automatically by Progenesis SameSpots 
V1.01 (Nonlinear Dynamics).  
B: An enlarged area from picture A. It clearly shows the poor spot splitting and also the 
poor spot detection. 
 
PDQuest did require manual intervention which took one week (Figure 5.11), however, 
the editing tools were easy to use and the programme did not suffer from freezes and 
A 
B 
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crashes. PDQuest also uses crosshairs to mark the centre of the spot making editing 
easier than trying to select the area of the spot. 
 
 
Figure 5.11: Picture to show spot editing using PDQuest 
The picture shows in a zoomed in area of the gel where editing is needed. There is a 
spot which needs adding because the automatic detection has not picked it up, a spot 
that needs deleting because it is a speckle on the gel, and a large spot which need to be 
checked with the 3D viewer to see how many spots are overlapping. 
 
Previous 2D-PAGE studies in the laboratory, which have used PDQuest, have 
confirmed the fold changes (by immunoblotting) of proteins highlighted by PDQuest 
(Smith et al. 2007); however, studies which have used Progenesis SameSpots have not 
confirmed the fold changes of the proteins (Little. 2006).  
 
Because of its ease of use, accuracy and reliability of data, PDQuest V8.0 was chosen to 
analyse gels in this project, despite the lengthy time for analysis. 
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5.7 Optimisation of the Analysis of Protein Digests by MALDI-TOF MS 
 
Commercially available purified proteins were digested to gain experience in the 
methods and to obtain a MALDI-TOF-MS contaminants list (see section 4.11). 
 
5.7.1 Protein Digests 
 
Four purified proteins comprising of two phosphorylated proteins and two 
unphosphorylated proteins (PeppermintStick phosphoprotein molecular weight 
standards (#P33350; Invitrogen)),  were run on a 1D gel and stained with Bio-Safe™ 
Coomassie stain (Bio-Rad) (see section 4.8.1) (Figure 5.12). 
 
Two hundred and fifty ng of PeppermintStick phosphoprotein molecular weight 
standards (#P33350; Invitrogen) (see section 5.4) was run on a 1D gel (see section 4.7). 
Previous experiments show that the MALDI-TOF-MS system available in the 
department can analyse down to the sensitivity of coomassie stain, which, on a 1D gel is 
a band of 80ng of protein (see section 5.4). A 1D gel separation of 250ng of 
PeppermintStick marker results in all of the six proteins being visible when stained with 
coomassie (see Figure 5.12). It was important not to mask the contaminants with large 
amounts of protein sample; therefore the minimum amount of sample necessary to 
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 Beta galactosidase from E.coli (116KDa) 
 Bovine serum albumin (66KDa) 
 Phosphorylated ovalbumin from chicken egg (45KDa) 
 Phosphorylated beta casein from bovine milk (18KDa) 
 
 
Figure 5.12: 1D gel of proteins standards showing bands excised for MALDI-TOF-
MS optimisation 
The picture shows a 1D gel of four protein bands excised for MALDTI-TOF-MS 
analysis. Bands are of two phosphorylated proteins (P) and two unphosphorylated 
proteins which have been stained with coomassie stain. 
 
Proteins were excised and digested (see section 4.10) and peptides were analysed by 
MALDI-TOF-MS (see section 4.11). A blank piece of gel was also digested to obtain 
background contaminations. Because the proteins were derived from different species 
the MASCOT search was conducted under all taxonomy. 
 
Spectra were obtained for all four proteins; however, significant identifications could 
only be obtained for the two unphosphorylated proteins. Thus proving that modified 
proteins are difficult to identify by MALDI-TOF-MS. Bovine serum albumin was 
identified with a Mowse score of 74 (where >70 was significant) and a 30% sequence 
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coverage. Beta galactosidase (Figure 5.13) was identified with a score of 115 (where 
>60 significant) and a 38% peptide sequence coverage (see Appendix H: Mascot Search 
Results – Beta Galactosidase (LacZ Protein)). 
 
 
Figure 5.13: MALDI-TOF mass spectra of beta galactosidase 
Peptide mass fingerprint of beta galactosidase from E.coli. 
 
5.7.2 Keratin Contaminations 
 
Spectra generated from previous proteomic projects were combined with spectra from 
this project to comprise a list of MALDI-TOF-MS protein contaminants, which could 
be later excluded from 2D-PAGE work. The same methods were applied to all 
experiments (see sections 4.7, 4.8.1, 4.10, 4.11). 
Spectra acquired from previous proteomic projects included digests of myoglobin 
(7.3µg), cytochrome C (11.3µg), BSA (16.67µg) and transferrin (16µg). These proteins 
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were separated on a 1D gel (see section 4.7) (Figure 5.14). The bands were excised and 
digested (see section 4.10) and analysed by MALDI-TOF-MS (see section 4.11). 
 
 
Figure 5.14: 1D gel of pure proteins standards 
The 1D gel shows bands (red) excised for tryptic digestion from 11.3µg of cytochrome 
C (12KDa), 7.3µg of myoglobin (16.7KDa), 16µg of transferrin (77KDa) and 16.67µg 
of BSA (70KDa). The blue bands were also excised for tryptic digestion. 
 
Initially 20 spectra from 8 standard proteins were compared (Figure 5.12 and Figure 
5.14), but as more experiments were processed, more spectra were added. Peaks which 
appeared in more than one spectrum were cross checked with a contaminants list 
(Smith. 2005) and with the peaks from a blank piece of 2D gel (Figure 5.15). 
Contaminants were put into four groups: 
1. Peaks present in over 90% of spectra (Table 5.1) 
2. Peaks present in between 70-90% of spectra (Table 5.2) 
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3. Peaks present in over 60-70% of spectra (Table 5.3) 
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Figure 5.15: MALDI mass spectrum of a piece of 2D gel subjected to tryptic 
digestion 
A blank piece of 2D gel was subjected to tryptic digestion to obtain a peak list of keratin 
and trypsin contaminants. The spectra shows common contaminants such as keratin 1 
(m/z 1036, 1475, 1993) and trypsin autolysis peaks (m/z 2211, 2283). 
 
In future 2D-PAGE experiments, if a significant score had not been achieved the first 
set of contaminant peaks (Keller et al. 2008) were taken out and the search was 
submitted again (see section 4.11). If a significant protein still did not show then the 
second set of contaminant peaks were take out, and so on. After the fourth set of 






Hair Keratin 1 2211.472/2283.340 
Trypsin 
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protein spot was listed as unidentified. However, it is worth noting that slight variations 
can occur between each experiment, e.g. batch variations of consumables, environment 
variation etc, and so for every 2D-PAGE experiment, spectra were gathered from all the 
samples first, then interrogated in this way to account for new contaminant peaks. 
 
Table 5.1: Table showing group 1 MALDI-TOF-MS peptide contaminants 
M/Z Contaminant Modification Unmodified Peak M/Z 
993.5 Keratin 10 N/A N/A 
1036.5421 Type 1 Hair Keratin 1 N/A N/A 
1066.4986 Keratin 9 N/A N/A 
1179.6004 Keratin 1 N/A N/A 
1277.6332 Keratin 1 N/A N/A 
1475.7489 Keratin 1 N/A N/A 
1638.8598 Keratin 1 N/A N/A 
1837.9654 Keratin 9 N/A N/A 
1851.9269 Keratin 9 N/A N/A 
1993.9766 Keratin 1 N/A N/A 
2211.104 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2225.3 Background Peak N/A N/A 
2283.1801 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2367.2626 Keratin 10 N/A N/A 
2383.9518 Keratin 1 N/A N/A 
 
 
Table 5.2: Table showing group 2 MALDI-TOF-MS peptide contaminants 
M/Z Contaminant Modification Unmodified Peak M/Z 
1107.8 Background Peak N/A N/A 
1109.49 Keratin 10 N/A N/A 
2055.962 Type 1 Hair Keratin 1 CAM 1998.941 
2342.984 Keratin 10 CAM 2285.9628 
 
 
Table 5.3: Table showing group 3 MALDI-TOF-MS peptide contaminants 
M/Z Contaminant Modification Unmodified Peak M/Z 
1090.531 Keratin 10 N/A N/A 
1141.5194 Keratin 1 N/A N/A 
1165.5848 Keratin 10 N/A N/A 
1234.679 Keratin 10 N/A N/A 
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1262.5971 Keratin 10 N/A N/A 
1265.6372 Keratin 1 N/A N/A 
1307.6776 Keratin 9 N/A N/A 
1320.1 Background Peak N/A N/A 
1357.7182 Keratin 10 N/A N/A 
1434.7699 Keratin 10 N/A N/A 
1707.7503 Keratin 9 CAM 1650.7289 
1716.8511 Keratin 1 N/A N/A 
1794.9 Background Peak N/A N/A 
1941.9876 Keratin 1 N/A N/A 
2021.9886 Keratin 1 N/A N/A 
2082 Background Peak N/A N/A 
2095.0376 Keratin 9 CAM 2038.0161 
2171.0246 Keratin 9 N/A N/A 





A method to artificially stimulate the BCR in RAJI B-cells was established and a 
western blot BCR signaling assay was used to validate stimulation by probing for P-
ERK. A 2D-PAGE/MS method for the analysis of proteins was optimised. Krypton 
fluorescent total protein stain, coomassie visible total protein stain and Pro-Q Diamond 
fluorescent phosphoprotein stain were chosen to stain protein extracts separated in gels. 
PDQuest was chosen to identify differentially expressed proteins and peptide 




   
Chapter 6 - The Preliminary 





 To develop a 2D-PAGE/MS experiment based on methods optimised in sections 
5.4, 5.5, 5.6 and 5.7 to identify changes in phosphoprotein expression in 
artificially stimulated and unstimulated RAJI B-cells 
 
Publications and Presentations: 
 
 G. L. Eagle, D. Allsup, L. Cawkwell. Phosphoproteomic Analysis of B-Cell 
Receptor Signaling in Chronic Lymphocytic Leukaemia. The 4th Hull York 
Medical School Research Conference, York, UK (March 2007). Poster 
Presentation. 
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The Preliminary Phosphoproteomic Analysis of RAJI B-Cell Line 
 
Preliminary investigations were performed to try and identify differentially expressed 
phosphoproteins in stimulated and unstimulated RAJI B-cells, and thus pinpoint kinase 
cascade pathways activated by the BCR. 
 
6.1 Stimulation of RAJI B-Cells 
 
RAJI B-cells were cultured as described in 4. Cells were stimulated or exposed to an 
isotype control for 5mins (see section 4.4). Three biological replicates were produced by 
repeating the procedure on three consecutive days. Protein was extracted for western 
blot and for 2D-PAGE (see sections 4.4 and 4.5.1). A western blot of P-ERK was used 
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Figure 6.1: Western blot of P-ERK to confirm stimulation of the BCR in RAJI B-
cells 
The picture shows a western blot of P-ERK for three biological replicates of RAJI B-
cells. Replicates were stimulated or exposed to an isotype control for 5mins on three 
consecutive days. A PMA positive control was included to assess viability of cells. The 
blots confirm that the stimulation has been successful in all replicates. The stimulated 
cells are expressing P-ERK and the isotype controls are negative. 
 
6.2 2D-PAGE of RAJI B-Cells and Expression of Phosphoproteins 
 
When the stimulation had been confirmed, 80µg (as recommended by stain 
manufacturer) of protein extract from stimulated and unstimulated cells was prepared in 
triplicate, and compared by 2D-PAGE as described in section 4.6. IPG strips of pH3-10 
were used to obtain the widest range of proteins. Gels were then stained with Pro-Q 
Diamond fluorescent phosphoprotein stain and scanned (see section 4.8.5). 
 
The gels showed that expression of phosphoproteins in the cells greatly increased upon 
BCR stimulation (Figure 6.2 and Figure 6.3). PDQuest counted 60% more 
phosphoprotein spots on the stimulated gels compared to the isotype control gels. 
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Figure 6.2: 2D gel images of stimulated and unstimulated RAJI B-cells showing 
expression of phosphoproteins 
RAJI B-cells were stimulated for 5mins and protein was extracted from stimulated and 
isotype control cells. Eighty micrograms of protein was separated on non-linear pH3-10 
IPG strips and then separated by molecular weight onto a 2D gel. Gels were stained 
Pro-Q Diamond Phosphoprotein Gel Stain. The gels show the same area on the gel. A 
large increase in phosphoproteins can be seen in the protein extract from stimulated 
cells (B) compared to the protein extract from unstimulated cells (A), suggesting that 
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Figure 6.3: Areas on 2D gels from stimulated and unstimulated RAJI B-cells 
showing expression of phosphoproteins 
The pictures show two areas of the gels shown in Figure 6.2, the image has been edited 
to improve background. A large increase in phosphoproteins can be seen in stimulated 
cells in both regions, suggesting that cell signaling pathways are being activated and 
proteins are being phosphorylated as a result of BCR stimulation. 
 
6.3 Expression of Total Protein 
 
The gels were stained with Krypton total protein stain after being stained with Pro-Q 
Diamond to confirm that a similar amount of total protein had been loaded onto each gel 
(see section 4.8.3). The gels showed that protein loads were comparable between 
stimulated and unstimulated gels (Figure 6.4), confirming that the increase in 
phosphoprotein expression in the stimulated sample is due to the activation of signaling 
pathways and not due to incorrect protein loadings. 
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Figure 6.4: 2D gels of stimulated and unstimulated RAJI B-cells stained with 
Krypton fluorescent total protein stain 
The gels have been stained with Pro-Q Diamond phosphoprotein stain (Figure 6.2). To 
visually check protein loading they were then stained with Krypton total protein stain. 
The pictures shown are from one representative gel from each set of triplicate gels. 
They show that protein loads are similar between stimulated (B) and unstimulated gels 
(A), confirming that the increase in phosphoprotein expression in the stimulated sample 
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Unfortunately due to problems identifying phosphoproteins with the MALDI-TOF-MS 
(see section 5.7.1) and with problems excising spots stained with a fluorescent stain, 
differentially expressed spots could not be identified. Excision was attempted by 
exciting the fluorescent dye with a UV transilluminator, however, the stains were light 
sensitive and so UV rays bleached them within seconds. Excision was also attempted by 
overlaying the gel onto a picture of the scanned image, but this was not accurate enough 
to pick out the smaller fainter spots, thus making it impossible to excise the spots 
without a robotic spot picker. 
 
To attempt to solve the excision problems with fluorescently stained proteins gels were 
stained with Pro-Q Diamond, to identify differentially expressed phosphoproteins, and 
then stained coomassie visible total protein stain to excise. However, the amount of 
protein required for coomassie staining was too much for fluorescent staining and 
fluorescent phosphoprotein spots were streaky and undefined. 
 
It was therefore decided that gels would be stained with coomassie visible total protein 
stain alone, and differentially expressed unmodified proteins would be analysed. This 
would solve problems with excision and with MALDI-TOF-MS identification (see 
section 5.7.1). Signaling pathways activated by BCR stimulation could still be traced 
from proteins identified. 
 
 
   
Chapter 7 – The 2D-PAGE/MS Analysis of 





 To optimise a method to artificially stimulate the BCR in RAJI B-cells to 
produce changes in protein expression 
 To develop a 2D-PAGE/MS experiment based on methods optimised in sections 
5.4, 5.5, 5.6 and 5.7 to identify differentially expressed proteins in artificially 
stimulated and unstimulated RAJI B-cells 
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2D-PAGE/MS Analysis of RAJI B-Cell Line Following BCR Stimulation 
 
Because of the difficulties in excising fluorescent stains (see Chapter 6) and the 
problems identifying modified proteins with MALDI-TOF-MS (see section 5.7), it was 
decided that gels would be stained with a visible total protein stain. 
 




RAJI B-cells were cultured as described in section 4. Cells were stimulated in triplicate 
(three consecutive days) for 5mins (see section 4.4) and protein was extracted for 
western blot and for 2D-PAGE (see sections 4.4 and 4.5.1). A western blot of P-ERK 
was used to confirm stimulation; a PMA positive control was included to assess 
viability of cells (Figure 6.1). 
 
When the stimulation had been confirmed, 200µg of protein was prepared and analysed 
by 2D-PAGE as described in section 4.6. IPG strips of pH4-7 were used. Gels were then 
stained with Bio-Safe™ Coomassie stain and scanned (4.8.1). PDQuest was used to 
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Only one protein was found to be differentially expressed between stimulated and 
unstimulated gels (Figure 7.1). The protein was 24.6KDa with a pI >5.0 and was up-
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Figure 7.1: Histogram and picture of differentially expressed protein spot from 
stimulated vs. unstimulated cells (5mins stimulation) 
RAJI B-cells were stimulated in triplicate for 5mins and protein was extracted from 
stimulated and unstimulated cells. Two hundred µg of protein from each replicate was 
separated by 2D-PAGE. IPG strips of pH range 4-7 were used. Gels were then stained 
with Bio-Safe™ Coomassie stain and scanned. PDQuest was used to highlight any 
differentially expressed proteins. Only one protein was found to be differentially 
expressed between stimulated and unstimulated gels (highlighted in yellow). The figure 
shows the master gel (top left) and the gels from stimulated cells (top, red), and 
unstimulated cells (bottom, green). The histogram shows the three replicate groups from 
stimulated cells (red) and unstimulated cells (green). The protein is 24.6KDa with a pI 
>5.0. This protein could not be identified by MALDI-TOF-MS. 
 
The RAJI B-cells had been stimulated for 5mins originally to investigate 
phosphoproteins; however, proteins are phosphorylated very early in signaling 
pathways and only a short stimulation time is required to see changes in 
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phosphoproteins (see section 6.2). Results from this 2D-PAGE experiment suggest that 
a 5min stimulation time was not long enough to produce differences in the total protein 
in the cells. Therefore it was decided to increase the stimulation time in order to see if 
this result in a greater number of protein expression changes. 
 
7.2 Optimisation of Increased Stimulation Time for RAJI B-Cells 
 
The stimulation time needed to be increased to produce more protein expression 
changes, so a suitable stimulation time had to be found before proceeding with 2D-
PAGE. Unfortunately there was a lack of literature available on artificial B-cell 
stimulation times that were longer than 15mins, therefore a suitable time point had to be 





The test was performed on stimulated and unstimulated cells suspended in a 
concentration of 5x105cells/ml over a period of time. Cells were monitored for media 
exhaustion and stress. This was done to confirm that the stimulation at the time point 
chosen was due to artificial activation of the BCR and not due to cell signaling due to 
stress. The time point chosen for stimulation in the 2D-PAGE experiment would be the 
maximum time that the cells could remain stable and stress free. 
RAJI B-cells were stimulated as described in section 4.4 for 4hrs, 8hrs, 18hrs, and 
24hrs. An isotype control was included for each time point. To observe any negative 
affects from the cells being exposed to the antibody for longer periods, RAJI B-cells 
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that had been stimulated for 5mins, washed in tissue culture media and then rested for 
4hrs, 8hrs, 18hrs, and 24hrs were included in the assay. Flasks were gently agitated after 
each hour to avoid the suspension of RAJI B-cells sinking and clumping at the bottom 
of the flask, which would reduce exposure to the stimulant. The colour of the media was 
recorded, cells were observed under a microscope and cells were stained with trypan 
blue (see section 4.3) to check cell viability at the end of each time point. Protein was 
then extracted as described in section 4.5.1. Western blots (see section 4.5) were used to 
monitor levels of P-ERK, GAPDH, Cyclin D1 and BCL2 in cells. Cyclin D1 and BCL2 
were chosen as they are proteins further down the MAPK pathway. P-ERK was used to 
monitor the MAPK pathway (Kolch. 2000), Cyclin D1 is activated by the ERK/MAPK 
pathway (Lee et al. 1999; Stacey. 2003) and BCL2 is down regulated by the activation 




The first observation made from the Western blots was that Cyclin D1 was not 
expressed in the cells (Figure 7.2). No evidence could be found to confirm or refute that 
RAJI B-cells express Cyclin D1. 
 
The Western blots shown in Figure 7.2 show that the stimulant needed to be left on for 
the entire duration, cells which had the stimulant washed off after 5mins were 
comparable to the negative controls, i.e. no stimulation effects. P-ERK levels 
dramatically increase at 18hrs in both stimulated and unstimulated cells suggested that 
this time point is too long and the cells are becoming stressed. The colour of the media 
at this time point had changed from dark orange to intense yellow suggested a change in 
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pH and cell viability was poor. BCL2 is downstream of the P-ERK pathway and levels 
decrease as P-ERK levels increase. 
 
  
Figure 7.2: Western blots of protein extracts from RAJI B-cells stimulated over 
different time periods 
RAJI B-cells were stimulated for 4hrs, 8hrs, 18hrs, and 24hrs. Isotype controls (-ve) were 
included for each time point. RAJI B-cells that had been stimulated for 5mins, washed in 
tissue culture media and rested for the time points specified were also included (labelled 
5mins incubation). The Western blots show that the RAJI B-cells are negative for Cyclin 
D1. Cells which had the stimulant washed off after 5mins were comparable to the respective 
negative controls suggesting that the cells had to be incubated with the stimulant for the 
time period. P-ERK levels dramatically increased at 18hrs suggesting that this time point is 
too long and the cells were becoming stressed. The blots also show that BCL2 levels 
decreased as P-ERK levels increased. 
 
Figure 7.3 shows a Western blot of just the isotype controls. From this blot it is clear 
that the maximum time that the cells can be left without interference from signaling due 
to cells exhausting the media is 8hrs. At this time point the tissue culture media was still 
orange (i.e. no change in pH), cells looked healthy under a microscope and cell viability 
was still good. At 18hrs the P-ERK levels suggest that cells have been stimulated for 
too long and are becoming stressed due to the number of cells to the volume of media.  
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Figure 7.3: Western blots of protein extracts from negative control RAJI B-cells 
over different time periods 
RAJI B-cells were exposed to an isotype control for 4hrs, 8hrs, 18hrs, and 24hrs. RAJI 
B-cells that had been exposed to an isotype control for 5mins, washed in tissue culture 
media and rested for the time points specified were also included (labelled 5mins). The 
Western blot shows that the maximum time that the cells can be left without 
interference from signaling due to cells exhausting the media is 8hrs. At 18hrs the P-
ERK levels suggest that cells have been stimulated for too long and are becoming 
stressed due to the number of cells to the volume of media. 
 
Further tests could be done to find the absolute optimum time when the cells start to 
become stressed (6-8hrs). However, it was decided that 8hrs will be sufficient to induce 
BCR stimulation without causing the cells distress. It is worth noting that proteins found 
to be differentially expressed may vary with differing stimulation times. 
 
The 8hr stimulation time, chosen from this experiment, is the maximum time that the 
cells could be artificially stimulated without stress-related cell signaling interferences to 
allow protein expression changes. 
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RAJI B-cells were exposed to the stimulant or the isotype control (see section 4.4) for 
8hrs with the flask being gently agitated every hour. Stimulations were performed in 
triplicate and on consecutive days. Protein was extracted for 2D-PAGE (80%) and 
Western blot (20%) (see section 4.5.1). The 2D-PAGE protein extract was quantified, 
cleaned and 200µg from each replicate was separated by 2D-PAGE using pH4-7 IPG 
strips (see section 4.6). Gels were stained with coomassie protein stain and scanned (see 
section 4.8.1). PDQuest was used to highlight protein spots differentially expressed 
between stimulated and unstimulated cells by over 2-fold with p<0.05 (see section 
4.9.1). Protein spots found to be differentially expressed were excised, digested and 




PDQuest highlighted 22 proteins spots which were differentially expressed between 
stimulated and unstimulated cells by over 2-fold with p<0.05 (Figure 7.4). Eighteen 
protein spots were excisable and were analysed by MALDI-TOF-MS. Eleven of the 18 
were identified to significance (score 65).  
 
One protein was up-regulated and ten proteins were down-regulated. The protein which 
was up-regulated in stimulated cells was identified as heat shock 70KDa protein 
(NCBInr reference gi|16507237) (Figure 7.5). All proteins identified are listed in Table 
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7.1. The table shows protein spots which were not excised (green), and not identified 
(red). Proteins highlighted in blue had Mowse scores below the cut off for a significant 
identification (score 65). Increased (↑) or decreased (↓) protein expression changes in 
stimulated cells are indicated. Also shown are the estimated molecular weights (KDa) 




Figure 7.4: 2D gel of protein extracted from RAJI B-cells with spots found to be 
differentially expressed between cells stimulated for 8hrs and unstimulated cells 
The picture shows the 22 proteins spots highlighted by PDQuest, which were 
differentially expressed between stimulated and unstimulated cells by over 2-fold with 
p<0.05. Four of the protein spots (1, 2, 5 and 20) were not excised as they were either 
too faint, in a cluster of spots or in a streaky area of the gel. 
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Figure 7.5: Peptide mass fingerprint of a protein identified as heat shock 70KDa 
protein 
MALDI-TOF spectra of spot 4, identified to significance as heat shock 70KDa protein 
gi|16507237 (72.4KD), which was found to be up-regulated in RAJI B-cells stimulated 
for 8hrs when compared with unstimulated cells. The peaks highlighted in green 
correspond to HSP70 peptides, the peaks highlighted in red are contaminant peptides. 
Many of the low abundant peaks (not shown) correspond to the protein of interest, 
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Table 7.1: Table to show proteins found to be differentially expressed between RAJI B-cells stimulated for 8hrs and unstimulated RAJI B-cells 

















1 2018 18 5.0 N/A Not Excised N/A N/A N/A N/A N/A N/A 
2 1112 23 5.0 N/A Not Excised N/A N/A N/A N/A N/A N/A 
3 2314 30 5.0 N/A Not Identified N/A N/A N/A N/A N/A N/A 
4 2715 70 5.5 ↑ Heat Shock 70KDa Protein Gi|16507237 72.402 5.07 111 26 44 
5 6716 70 6.0 N/A Not Excised N/A N/A N/A N/A N/A N/A 
6 7821 80 >6.5 ↓ Inner Membrane Protein, Mitochondrial  Isoform 1 Gi|154354964 84.025 6.08 94 21 37 
7 6714 70 >6.5 ↓ Glutaminyl-tRNA Synthetase, Isoform  CRA-a (QARS Protein) Gi|119585356 72.548 6.89 80 17 29 
8 7701 65 >6.5 ↓ SARM 1 Protein Gi|116063294 68.81 6.13 78 25 41 
9 5622 60 6.0 ↓ Chaperonin Containing TCP Subunit 8  (Theta) Gi|48762932 60.153 5.42 66 17 35 
10 6605 60 6.5 ↓ SARM 1 Protein Gi|3043572 67.386 6.33 74 13 30 
11 5617 50 6.0 ↓ Chimerin (Chimaerin) 1 Gi|119631525 50.046 6.45 68 15 43 
12 5526 50 6.0 N/A Not Identified N/A N/A N/A N/A N/A N/A 
13 6610 60 >6.5 ↓ Chaperonin Containing TCP Subunit 8 (Theta) Gi|48762932 60.153 5.42 69 13 28 
14 6505 55 >6.5 ↓ Keratin 14 - Epidermolysis Bullosa  Simplex, Dailing-Meara, Koeber Gi|12803709 51.905 5.09 72 25 54 
15 5421 45 6.0 N/A Not Identified N/A N/A N/A N/A N/A N/A 
16 6419 40 6.0 ↓ Unknown Protein Gi|62988628 33.711 5.52 69 12 43 
17 6410 40 6.5 N/A Not Identified N/A N/A N/A N/A N/A N/A 
18 7317 30 6.0 N/A Not Identified N/A N/A N/A N/A N/A N/A 
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19 8502 45 >6.5 ↓ 
Leukocyte Derived Arginine  
Aminopeptidase Isoform CRAb 
(LRAP) 
N/A 40.376 6.73 64* 13 34 
20 9401 40 >6.5 N/A Not Excised N/A N/A N/A N/A N/A N/A 
21 8115 25 >6.5 N/A Not Identified N/A N/A N/A N/A N/A N/A 
22 8212 28 >6.5 ↓ Nuclear Receptor Binding Protein 2 Gi|119602588 31.056 6.87 65 13 47 
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A stimulation time of 5mins was not long enough to show differential expression in 
proteins with only one protein being up-regulated in stimulated cells. However, after an 
8hr incubation with the stimulant, 22 proteins were found to be differentially expressed 
between stimulated and unstimulated cells. Eleven of these proteins were identified by 
MALDI-TOF-MS. Heat shock 70KDa protein (HSP70) was found to be over expressed 
in stimulated cells and is of particular interest as recent studies show that over 
expression indicates poor prognosis in chronic myeloid leukaemia (Nylandsted. 2009; 
Yeh et al. 2009). Chimerin, a protein related to GTPase activity, proliferation and cell 
cycle arrest, was found to be down regulated in stimulated cells. A decrease in 
expression of chimerin has also been observed in breast cancer (Yang et al. 2005). 
Western blot confirmation and further analysis is required on these target proteins. 
 
The 8hr stimulation time chosen in this experiment was the maximum time that the cells 
could be artificially stimulated without cell signaling interferences due to stress. This 
experiment gives a platform to base further 2D-PAGE experiments on (see section 9.1). 
It is clear that long stimulation times are needed to produce differential expression in 
proteins when using a total protein stain. Differentially expressed proteins may vary 
over different stimulation times. It was decided to stimulate the cells for the maximum 
time possible in this project to produce protein expression changes. 
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 Optimise western blot signaling assay for use in clinical CLL samples 
 To identify three “poor prognosis” clinical CLL samples, to be used as 
biological replicates in a 2D-PAGE/MS experiment in section 9.3, based on: 
 
i  IgVH mutational status 
ii BCR responsiveness 
iii B-cell population in sample 
iv WBC of patient  
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The Categorisation and Selection of Clinical CLL Samples 
 
8.1 CLL Sample Collection 
 
Samples were prospectively collected during the project from patients diagnosed with 
CLL (Binet stages A-C), who had not received chemotherapy treatment in the past 3 
months. PBMCs were stored as described in section 4.2. Samples from over 200 
patients have been collected and stored over a period of three years. 
 
Cells frozen at -80°C and in liquid nitrogen at a concentration of 1x107cells/ml per 
cryovial were tested for viability after thawing using trypan blue (see section 4.3). 
Results showed that over 90% of cells were viable on thawing when stored at this 
concentration. 
 
8.2 Clinical CLL Sample Classification 
 
Clinical samples were chosen for analysis based on their IgVH gene mutation status and 
the BCR responsiveness. All samples were analysed for IgVH mutational status and 
samples which showed a poor prognosis (<5% difference in standard germline 
sequence) were subjected to a BCR signaling assay to determine BCR responsiveness. 
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8.2.1 IgVH Gene Mutational Status 
 
Samples were analysed at HMDS for IgVH gene mutational status (see section 4.2.3). 
Less than 5% difference in standard germline sequence was classified as unmutated 
IgVH and more than 5% difference in standard germline sequence was classed as 
mutated IgVH (Allsup et al. 2005). Approximately half of samples (57 out of 115) have 
been classed as unmutated samples (see Appendix B) 
 
Figure 8.1 shows a Kaplan Meier plot of mutated vs. unmutated samples from the 
cohort of 115 patient samples stored. The plot shows the differing prognosis between 
patients with mutated IgVH genes and those with less than 2% difference in standard 
germline sequence. This corresponds with the discussion in section 2.3. A 5% 
difference in standard germline sequence is generally accepted as a “cut-off point” for 
determining mutated and unmutated samples (Allsup et al. 2005), however the exact 
point of division between mutated and unmutated samples has not yet been determined. 
Figure 8.1 shows that in Hull’s cohort of samples, a 2% cut off gives visible separation 
of the two groups, therefore samples with little difference in standard germline sequence 
were taken forward to 2D-PAGE. 
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Figure 8.1: Kaplan Meier to show effects of IgVH mutational status on survival 
The plot shows the differing prognosis between the two groups from the cohort of 
patient samples stored. A <2% difference in standard germline sequence was classified 
as unmutated IgVH. Patients with mutated IgVH genes (n=81) (blue) have a better 
prognosis than those with unmutated IgVH genes (n=34) (green). Median survival for 
patients with unmutated IgVH genes is 4000 days. For patients with mutated IgVH genes 
median survival is not yet reached (P<0.00 Mantel Cox log rank test). Plot courtesy of 
J. Bailey 2008. 
 
8.2.2 BCR Responsiveness 
 
To classify samples as BCR “responders” or “non-responders” (see section 2.4), clinical 
CLL samples were stimulated as described in section 4.4. Stimulation of the RAJI B-
cell line was optimised in section 5.1, however, to ensure that a 5min incubation with 
10g/ml of antibody fragment would be suitable for the clinical samples, the same 
optimisation experiment was conducted as described in sections 5.1.1 and 5.1.2 using 
CLL sample 010. This sample has germline concordance of 99% (IgVH unmutated), and 
was known to have a responsive BCR from preliminary western blot signaling assays. 
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8.2.3 Optimisation of Incubation Time 
 
After cell counting (see section 4.3) CLL cells from sample 010 were suspended in a 
concentration of 5x106cells/ml as recommended (Allsup et al. 2005). CLL cells are 
smaller than RAJI B-cells and so more were required if the amount of stimulant was to 
be kept the same (RAJI B-cells were stimulated in a concentration of 5x105cells/ml). 
Cells were incubated for 5, 15, 25 and 45mins with 10g/ml of AffiniPure F(ab’)2 
fragment goat anti-human IgM, Fc5 fragment specific. Cells incubated with 10g/ml of 
ChromPure Goat IgG F(ab’)2 fragment for 60mins were included as an isotype control. 
Incubations were performed at 37°C with 5% CO2. 
 
Protein was extracted as described in section 4.5.1 and western blots were performed as 
described in section 4.5. P-ERK was used as a primary antibody and GAPDH was used 
as a loading control (Table 4.1, Table 4.2). 
 
The western blot showed that 5mins incubation with 10g/ml of the anti-human IgM 
antibody was sufficient to activate the BCR and induce the MAPK pathway (Figure 
8.2).  
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Figure 8.2: Western blot to show optimisation of stimulation time for clinical 
CLL sample 010 
The western blot shows that 5mins incubation with 10g/ml of the anti-human IgM 
antibody is enough to activate the BCR and causing ERK to become phosphorylated 
in the MAPK pathway in a clinical CLL sample. The isotype control showed that after 
5mins the cells were negative for P-ERK, providing evidence that P-ERK levels were 
purely induced by the anti-human IgM antibody. 
 
8.2.4 Optimisation of Stimulant Concentration 
 
After cell counting (see section 4.3) CLL cells from clinical sample 010 were suspended 
in a concentration of 5x106cells/ml. Cells were incubated with 1.0, 10, 50 and 100 
g/ml of AffiniPure F(ab’)2 fragment goat anti-human IgM, Fc5 fragment specific for 
5mins. Cells incubated with 100nM PMA for 5mins were included as a positive control 
and cells incubated with 100g/ml of ChromPure Goat IgG F(ab’)2 fragment for 5mins 
were included as an isotype control. Incubations were performed at 37°C with 5% CO2. 
 
Protein was extracted as described in section 4.5.1 and western blots were performed as 
described section 4.5. P-ERK was used as a primary antibody and GAPDH was used as 
a loading control (Table 4.1 and Table 4.2). 
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The western blot showed that incubation with all the chosen concentrations of anti-
human IgM antibody activated the BCR and induced the MAPK pathway (Figure 8.3). 
 
 
Figure 8.3: Western blot to show optimisation of stimulant concentration for 
clinical CLL sample 010 
The western blot showed that incubation with all the chosen concentrations of anti-
human IgM antibody activated the BCR and induced the MAPK pathway. The PMA 
positive control shows that after 5mins the cells are viable. The isotype control showed 
that at a concentration of 10µg/ml the cells were negative for P-ERK, providing 
evidence that P-ERK levels were purely induced by the anti-human IgM antibody. 
 
The incubation time and stimulant concentration used to activate the BCR in CLL 
samples in this project was chosen as 5mins and 10µg/ml respectively. This time and 
concentration correspond with the literature (Allsup et al. 2005) and is a well 
established and widely accepted protocol. It also corresponds with the time and 
concentration optimised to stimulate RAJI B-cells in this project (see sections 5.1.1 and 
5.1.2). 
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8.3 BCR Signaling Assay in Clinical CLL Samples 
 
Clinical CLL samples were collected and stored as described in section 4.2. Samples 
from patients with a high white blood count (>40x109L), with cells classified as IgVH 
unmutated (see section 4.2.3) were stimulated as described in section 4.4 to assess BCR 
responsiveness. Selecting samples from patients a high white blood count was important 
to be able to extract enough protein for 2D-PAGE from the volume of blood available 
(50ml blood, see 4.2.1). Also, assuming lack of infections, a high white blood count is 
an indication of poor prognosis in CLL. Protein was extracted from these samples (see 
section 4.5.1) and a western blot signaling assay (see section 4.5) was used to determine 
BCR responsiveness. 
 
To quickly determine from the bank of clinical samples which ones were of interest, 
multiple samples were stimulated and screened to determine the status of P-ERK 
(Figure 8.4). Samples demonstrating very high levels would then be assayed again with 
an isotype control to determine levels of constitutive P-ERK in the cells. It is important 
to verify that ERK phosphorylation is due to the artificial stimulation of the BCR and 
not due to intrinsic cell signaling. Samples that had a 2-fold increase in P-ERK when 
stimulated (Allsup et al. 2005) were potential samples that could be used for 2D-PAGE 
investigations. 
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Figure 8.4: Examples of western blot signaling screening assay of clinical CLL 
samples 
To quickly determine from the bank of samples which ones were of interest, multiple 
samples were stimulated and screened to determine levels of P-ERK. The blots above 
show six examples of assayed samples, consisting of three IgVH mutated samples (029, 
041 & 059) and three IgVH unmutated samples (048, 054 & 056). Twenty µg of each 
protein sample was loaded. Very high P-ERK levels can be seen in clinical samples 
048, and 056. These samples are IgVH unmutated and could be of interest for further 
testing. They would be assayed again with an isotype control to determine levels of 
constitutive P-ERK and fold change in P-ERK upon stimulation of the BCR. Sample 
054 is also IgVH unmutated but the P-ERK level is weak upon BCR stimulation 
suggesting it is not as responsive as samples 048 and 056. 
 
8.4 Clinical CLL Sample Selection 
 
Samples chosen for 2D-PAGE were: 
 
 Samples with a WBC >50x109L 
 Samples with 2.5% deviation from the standard germline (IgVH Unmutated) 
 Samples showing >2-fold change in P-ERK expression upon BCR stimulation 
 Samples which contain >70% B-cells 
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From all the samples tested three stood out as being potential biological replicates for a 























Proteomic Analysis of Chronic Lymphocytic Leukaemia - The Categorisation and 
Selection of Clinical CLL Samples 
 
 169
8.4.1 Sample 003 
 
Patient 003 had a white blood count of 215X109L. The sample had 0% deviation from 
the standard germline IgVH sequence and was classified as unmutated. The sample 
responded to BCR stimulation and gave a P-ERK fold change of 10.4 in stimulated cells 
(Figure 8.5). The sample also has a large population of B-cells consisting of 77.6% of 





Figure 8.5 Western blot and optical density data on signaling assay of sample 003 
Western blot and optical density data to show increase in P-ERK upon stimualtion. 
GAPDH has been used as a loading control. The results show a 10.4 fold increase in P-
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Figure 8.6: FACS plot of CD19 positive cells in sample 003 
The picture shows a fluorescence-activated cell sorting (FACS) plot of CD19 postive 
cells in sample 003. CD19 is a B-cell specific maker. This sample consist of 77.6% B-
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8.4.2 Sample 078 
 
Patient 078 had a white blood count of 55X109L. The sample had 0% deviation from 
the standard germline IgVH sequence and was classified as unmutated. The sample 
responded to BCR stimulation and gave a P-ERK fold change of 15.9 in stimulated cells 
(Figure 8.7). The sample also has a large population of B-cells consisting of 91.39% of 





Figure 8.7: Western blot and optical density data on signaling assay of sample 078 
Western blot and optical density data to show increase in P-ERK upon stimualtion. 
GAPDH has been used as a loading control. The blot shows some consitutive P-ERK 
activity in the isotype control sample, however, the results show a 15.9 fold increase in 
P-ERK upon stimulation of the BCR. 
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Figure 8.8: FACS plot of CD19 positive cells in sample 078 
The picture shows FACS plot of CD19 postive cells in sample 078. CD19 is a B-cell 
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8.4.3 Sample 089 
 
Patient 089 had a white blood count of 72X109L. The sample had 2.5% deviation from 
the standard germline IgVH sequence and was classified as unmutated. The sample 
responded to BCR stimulation and gave a large change in P-ERK expression with a fold 
change of 216.1 upon stimulation of the BCR (Figure 8.9). The sample also has a large 





Figure 8.9: Western blot and optical density data on signaling assay of sample 089 
Western blot and optical density data to show increase in P-ERK upon stimualtion. 
GAPDH has been used as a loading control. The results show a 216.1 fold increase in P-
ERK upon stimulation of the BCR. 
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Figure 8.10: FACS plot of CD19 positive cells in sample 089 
The picture shows a FACS plot of CD19 postive cells in sample 089. CD19 is a B-cell 





From all the clinical CLL samples tested, three matched the criteria for potential 
biological replicates for a 2D-PAGE experiment. The criteria were:  
 
 WBC >50x109L 
 2.5% deviation from the standard germline (IgVH Unmutated) 
 >2-fold change in P-ERK expression upon BCR stimulation confirmed by 
western blot and by P-ERK ELISA (data not shown) (Bailey. 2007) 
 >70% B-cells 
 
Table 8.1 summarises the three samples selected for further analysis by 2D-PAGE and 
shows WBC, IgVH mutational status, P-ERK fold change upon BCR stimulation and B-
cell population in each sample. 
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Table 8.1: Table to show the three clinical CLL samples which matched the criteria 






P-ERK Fold Change 
Upon BCR Stimulation 
B-Cells 
in Sample 
003 215x109L 0% 10.4 77.6% 
078 55x109L 0% 15.9 91.4% 
089 57x109L 2.5% 216.1 80.1% 
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 To optimise a method to artificially stimulate the BCR in clinical CLL samples 
to produce changes in protein expression 
 To assess the efficacy of using the 2D-PAGE/MS method developed in section 
7.3 for the identification of potential prognostic markers in clinical CLL samples 
 To identify changes in protein expression between stimulated and unstimulated 
cells in the three clinical samples selected in section 8.4 
 To validate proteins identified using western blot analysis 
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The 2D-PAGE/MS Analysis of CLL Clinical Samples 
 
CLL clinical samples were initially stimulated for 8hrs as optimised with RAJI B-cells 
lines in section 7.2. 
 
9.1 8hr Stimulation of CLL Clinical Sample 003 
 
CLL sample 003 was stimulated as described in section 4.4 for 8hrs (see section 7.2) at 
a concentration of 5x106cells/ml with a total volume of 10ml. However, clinical CLL 
samples can not be cultured and after 6hrs in culture the media had turned from orange 
to yellow (indicating media exhaustion and a change in pH) and cell viability was poor 
at 8hrs. This was not consistent with the 8hr RAJI B-cell line stimulation as described in 
section 7.3. Protein was extracted for 2D-PAGE (see section 4.5.1) from these cells 
however there was not enough protein for an experiment (need >800µg/ml, obtained 
<1µg/ml) (see section 4.6.2). This was probably because the majority of the cells had 
died during the long stimulation and were washed out in the washing steps. Therefore it 
was not practical to use the stimulation time previously optimised for the RAJI B-cell 
line in section 7.2 for clinical CLL samples. An optimum stimulation time for CLL 
samples needed to be found. 
 
9.2 Optimisation of Stimulation Time for CLL Clinical Samples 
 
The test was performed on stimulated and unstimulated (isotype control) CLL cells 
suspended in a concentration of 5x106cells/ml over a period of time. Cells were 
monitored for media exhaustion and stress. This was done to confirm that the 
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stimulation at the time point chosen was due to artificial activation of the BCR and not 
due to cells signaling due to stress. As in section 7.2, the time point chosen for 
stimulation in the 2D-PAGE experiment would be the maximum time that the cells from 
the clinical sample could remain stable and when the cells could be artificially 
stimulated without stress-related cell signaling interfering with the assay.  
 
As the media was exhausted after 6hrs in the 8hr stimulation of clinical sample 003 (see 
section 9.1), it was decided that the longest stimulation period should be 5.5hrs. CLL 
cells from clinical sample 063 (good responder to BCR stimulation, known from 
previous western blot analysis) were stimulated as described in section 4.4 for 1hr, 2hrs, 
4hrs, and 5.5hrs. An isotype control was included for each time point. Because the 
media had been exhausted in the 8hr stimulation of cells from clinical sample 003 (see 
section 9.1), a sample was included which was stimulated for 5.5hrs but the media and 
stimulant were replaced after 3hrs. Flasks were gently agitated after each hour to avoid 
the suspension of CLL cells sinking and clumping at the bottom of the flask, which 
would reduce exposure to the stimulant. The colour of the media was recorded, cells 
were observed under a microscope and cells were stained with trypan blue (see section 
4.3) to check cell viability at the end of each time point. Protein was then extracted as 
described in section 4.5.1. Western blots (see section 4.5) were used to monitor levels of 
BCL2 in cells (see Table 4.1 and Table 4.2). GAPDH was used as a loading control (see 
Table 4.1 and Table 4.2). BCL2 is down regulated by the activation of ERK (Tamura et 
al. 2004) making it a good marker of downstream MAPK activity. 
At 5.5hrs cells viability was good (see section 4.3) and the media had not changed 
colour. The optical densities of the BCL2 and GAPDH bands were measured (see 
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section 4.5.8) and BCL2 fold differences were calculated. Figure 9.1 shows changes in 
expression of BCL2 in stimulated cells compared with the isotype control. 
 
   
Figure 9.1: Graph to show fold changes of BCL2 in CLL clinical cells stimulated over 
increasing time periods 
CLL cells were stimulated for 1hr, 2hrs, 4hrs and 5.5hrs. One sample was stimulated for 5.5hrs 
and had fresh media and stimulant added after 3hrs (B). Cells were also exposed to an isotype 
control for each time point. Western blots were used to monitor expression of BCL2 in cells; 
GAPDH was used as a loading control. The graphs shows changes in expression of BCL2 in 
stimulated cells compared with the isotype control. Cells stimulated for 5.5hrs with no media 
change (A) saw a fold change of >2 with a decrease in BCL2 in stimulated cells, suggesting that 
ERK had been phosphorylated and the MAPK pathway was activated. Between 1-2hrs BCL2 
levels are lower than the isotype control indicating an increase in P-ERK and activation of the 
MAPK pathway. Changing the media after 3hrs on the 5.5hr stimulation (B) increases levels of 
BCL2. This suggests that P-ERK levels are down at these time points and that cells have not 
been stimulated. 
 
Cell viability was good after 5.5hrs. The results showed that changing the media after 
3hrs, affects stimulation. A rise in BCL2 levels (and therefore a decrease in P-ERK 
levels) suggests that changing the media results in vital environmental stimuli being 
washed out, and thus the MAPK pathway has not been activated. It is worth noting that 
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One hundred ml of blood was taken from each patient (See section 8.4) and PMBCs 
were stored at -80°C (see section 4.2.2). CLL cells were thawed (see section 4.1.3) and 
rested for 3hrs before being resuspended to a concentration of 5x106cells/ml (see section 
4.3) and split into six flasks. Three flasks contained the stimulant and three flasks 
contained the isotype control (see section 4.4). The same volume of cells was placed 
into each replicate flask. A minimum volume of 15ml of cells in a concentration of 
5x106cells/ml was required to extract enough protein for 2D-PAGE. Cells were 
incubated for 5.5hrs and the flasks were gently agitated every hour. Protein was 
extracted from each flask for 2D-PAGE (80%) and western blot (20%) (see section 
4.5.1). The 2D-PAGE protein extracts were quantified, cleaned and 200µg from each 
replicate was separated individually by 2D-PAGE using pH4-7 IPG strips (see section 
4.6). Gels were stained with coomassie protein stain and scanned (see section 4.8.1). 
PDQuest was used to highlight protein spots differentially expressed between the three 
stimulated and three unstimulated extracts. Protein spots found to be differentially 
expressed (2-fold difference with p<0.05 (see section 4.9.1)) were excised, digested and 
analysed by MALDI-TOF-MS (see sections 4.10 and 4.11). 
 
9.3.2 CLL Sample 003 (see Table 8.1) 
 
PDQuest highlighted 19 proteins spots (Figure 9.2) which were differentially expressed 
between stimulated and unstimulated cells by over 2-fold with p<0.05, two of these 
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differentially expressed spots are shown in detail in Figure 9.3 and Figure 9.4. All 19 
protein spots were excisable and were analysed by MALDI-TOF-MS. Ten were 
identified with a significant score (score >66). Figure 9.5 shows the peptide mass 
fingerprint of protein spot 5 (see Figure 9.2) which was identified to significance (score 
66, 52% sequence coverage) as interferon alpha 1/13 precursor. Table 9.1 shows 19 
protein spots which were excised (see Figure 9.2). Spots which were not identified are 
shown in red. Proteins highlighted in blue were not identified to a significance (score 
>66). The increased (↑) or decreased (↓) expression of protein in stimulated cells is 
indicated. Also shown are the sequence coverage, estimated weights (KDa) and pI from 
the spot location in the 2D gel, and the theoretical weights and pI according the NCBInr 
database. Figure 9.6 shows histograms from PDQuest illustrating the expression of 
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Figure 9.2: 2D  gel showing differentially expressed proteins between stimulated 
and unstimulated cells from CLL clinical sample 003 
The picture shows the 19 proteins spots (arrows) which were identified by PDQuest 
with differential expression between stimulated and unstimulated cells by over 2-fold 
(p<0.05). 
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Figure 9.3: Gel pictures of protein spot 10 identified as Glyoxalase domain 
containing 4, which is down-regulated in stimulated CLL 003 cells 
The spots highlighted in yellow on the gel are the spot of interest. The electronically 
generated master gel is shown top left. The three gels from stimulated cells are shown 
on the top (red) and the three gels from unstimulated cells are shown on the bottom 
(green). The protein spot is darker and larger in the three unstimulated gels (bottom). 
PDQuest identified this spot as having a >2-fold increase (p<0.05) in unstimulated cells. 
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Figure 9.4: Gel pictures of protein spot 11 identified as DARS, which is down-
regulated in stimulated CLL 003 cells 
The spots highlighted in yellow on the gel are the spot of interest. The electronically 
generated master gel is shown top left. The three gels from stimulated cells are shown 
on the top (red) and the three gels from unstimulated cells are shown on the bottom 
(green). The protein spot is barely visible in the three stimulated gels (top). PDQuest 
identified this spot as having a >2-fold increase (p<0.05) in unstimulated cells. 
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Figure 9.5: Peptide mass fingerprint of protein identified as interferon alpha 1/13 
precursor 
MALDI-TOF spectra of a protein found to be down-regulated in 003 CLL stimulated 
cells when compared to unstimulated cells. The protein was identified to significance by 
searching the NCBInr database using the Mascot search engine with a score of 66, as 
interferon alpha 1/13 precursor (21.7KDa). The peaks highlighted in green correspond 
to interferon alpha 1/13 precursor peptides. Many of the low abundant peaks (not 
shown) correspond to the protein of interest, whereas many of the higher abundant 
peaks are contaminants. 
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Table 9.1: Table showing identifications of differentially expressed proteins between stimulated and unstimulated cells from CLL clinical sample 003 















1 2222 27.3 ~5.0 ↓ Unnamed Protein Product 28.101 5.65 75 15 64% 
2 5017 13 <6 ↓ Not Identified N/A N/A N/A N/A N/A 
3 7014 15.6 >6.5 ↓ Not Identified N/A N/A N/A N/A N/A 
4 7114 17.6 >6.5 ↓ Fatty Acid Binding Protein 5 15.155 6.6 68 21 100% 
5 3111 20.9 ~5.5 ↓ Interferon Alpha-1/13 Precursor 21.711 5.32 66 15 52% 
6 2512 56.1 ~5.0 ↑ Tripartite Motif Protein (TRIM19 Zeta) 69.953 5.17 73 32 39% 
7 3418 43.9 ~5.5 ↓ Not Identified N/A N/A N/A N/A N/A 
8 4504 52.5 ~5.5 ↑ Astrotactin 2 (ASTN2 Protein) 49.557 5.53 73 28 56% 
9 4517 54.5 ~5.5 ↓ Astrotactin 2 Isoform d 44.532 5.57 68 27 60% 
10 4210 29.9 ~5.5 ↓ Glyoxalase Domain Containing 4 33.228 5.4 70 25 55% 
11 5531 56.4 ~6 ↓ Aspartyl-tRNA Synthetase (DARS) 57.088 6.11 68 26 51% 
12 6617 64.4 <6.5 ↑ Erythrocyte Membrane Protein Band 4.1 (EPB41) 69.847 6.32 59 31 43% 
13 6323 32.4 <6.5 ↑ KNG1 Protein (Kininogen 1) 33.034 6.27 67 11 54% 
14 5116 26.2 ~6 ↓ Not Identified N/A N/A N/A N/A N/A 
15 5104 25.5 ~6 ↓ Phosphatidylinositol Transfer Protein Beta 22.23 5.89 70 21 64% 
16 6218 26.6 <6.5 ↓ Coenzyme Q7 Homolog Ubiquinone (Yeast) 22.839 6.45 61 23 62% 
17 6216 26.6 <6.5 ↓ Not Identified N/A N/A N/A N/A N/A 
18 6116 24.9 <6.5 ↓ TatD Dnase Containing 3 (TATDN3 Protein) 30.314 6.67 47 12 37% 
19 8408 44.2 >6.5 ↓ DnaJ (HSP40) Homolg Subfamily C Member 7 56.405 6.565 58 24 44% 
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Figure 9.6: PDQuest histograms of the 10 proteins identified by MADLI-TOF-MS 
showing differential expression between stimulated and unstimulated cells in CLL 
clinical sample 003 
The histograms show protein expression in the three test replicates (stimulated cells, red) and 
three control replicates (unstimulated cells, green). The protein spots had a >2-fold change in 
expression between stimulated and unstimulated cells (p<0.05) and were identified by 
MALDI-TOF-MS (Table 9.1). Protein spots 6, 8 and 13 were over expressed in stimulated 
cells and spots 1, 4, 5, 9, 10, 11 and 15 were over expressed in unstimulated cells. 
 
9.3.3 CLL Sample 078 (see Table 8.1) 
 
PDQuest highlighted 15 proteins spots which were differentially expressed between 
stimulated and unstimulated cells by over 2-fold with p<0.05 (Figure 9.7). All 15 
protein spots were excisable and were analysed by MALDI-TOF-MS. Only two spots 
were identified to significance (score >66). Table 9.2 shows the 15 protein spots which 
were excised (see Figure 9.7). Spots which were not identified are shown in red. 
Proteins highlighted in blue were not identified to a significance (score >66). The 
increased (↑) or decreased (↓) expression of protein in stimulated cells is indicated. Also 
shown are the sequence coverage, estimated weights (KDa) and pI from the spot 
location in the 2D gel, and the theoretical weights and pI according the NCBInr 
Spot 1 Spot 4 Spot 5 Spot 6 Spot 8 
Spot 9 Spot 10 Spot 11 Spot 13 Spot 15 
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database. Figure 9.8 shows histograms from PDQuest illustrating the expression of 
proteins identified to significance in the stimulated and unstimulated replicates. 
 
 
Figure 9.7: 2D gel showing differentially expressed proteins between stimulated 
and unstimulated cells from CLL clinical sample 078 
The picture shows the 15 proteins spots (arrows) which were identified by PDQuest 
with differential expression between stimulated and unstimulated cells by over 2-fold 
(p<0.05). 
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1 1323 30.3 5.5 ↓ Adenylate Kinase Isoenzyme 5 22.07 5.38 70 15 72 
2 1820 70.8 5.3 ↑ Not Identified N/A N/A N/A N/A N/A 
3 5810 65.9 6 ↑ RABGAP1L 67.96 5.36 36 11 20 
4 6809 74.5 6.5 ↓ Not Identified N/A N/A N/A N/A N/A 
5 6707 71.9 6.5 ↓ RAS Homolog Gene Family Member T1 74.17 6.31 44 14 23 
6 7720 59.5 6.5 ↓ HCG29146 53.44 6.15 34 16 37 
7 6604 61.7 6.5 ↓ Putative Ribonucleus III 62.84 6.75 60 11 25 
8 6609 47.7 6.3 ↓ Not Identified N/A N/A N/A N/A N/A 
9 5517 38.1 6.2 ↓ Unknown Protein 35.84 5.69 29 N/A 39 
10 5313 27.7 6.2 ↓ Programmed Cell Death 2 25.52 5.99 45 10 33 
11 7315 28.7 6.7 ↑ Kininogen 1 47.87 6.29 76 26 41 
12 6206 28.4 6.7 ↓ Not Identified N/A N/A N/A N/A N/A 
13 8201 24.5 6.7 ↓ Unknown Protein 27.77 6.12 41 13 50 
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Figure 9.8: PDQuest histograms of the 2 proteins identified by MADLI-TOF-MS 
showing differential expression between stimulated and unstimulated cells in CLL 
clinical sample 078 
The histograms show protein expression in the three test replicates (stimulated cells, 
red) and three control replicates (unstimulated cells, green). The protein spots had a >2-
fold change in expression between stimulated and unstimulated cells (p<0.05) and were 
identified by MALDI-TOF-MS (Table 9.2). Protein spot 1 was over expressed in 
unstimulated cells and spot 11 was over expressed in stimulated cells. 
 
9.3.4 CLL Sample 089 (see Table 7.1) 
 
PDQuest highlighted 17 proteins spots which were differentially expressed between 
stimulated and unstimulated cells by over 2-fold with p<0.05 (Figure 9.9). Fourteen 
spots were excisable and were analysed by MALDI-TOF-MS. Eight spots were 
identified to significance (score >66). Table 9.3 shows the 17 protein spots which were 
differentially expressed (Figure 9.9). Spots highlighted in blue were not excised and 
spots which were not identified are shown in red. The increased (↑) or decreased (↓) 
expression of protein in stimulated cells is indicated. Also shown are the sequence 
coverage, estimated weights (KDa) and pI from the spot location in the 2D gel, and the 
theoretical weights and pI according the NCBInr database. Figure 9.10 shows 
histograms from PDQuest illustrating the expression of proteins identified to 
significance in the stimulated and unstimulated replicates. 
 
Spot 1 Spot 11 
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Figure 9.9: 2D gel showing differentially expressed proteins between stimulated and 
unstimulated cells from CLL clinical sample 089 
The picture shows the 17 proteins spots (arrows) which were differentially expressed 
between stimulated and unstimulated cells by over 2-fold (p<0.05). Three of the protein 
spots (spots 3, 7 and 15) were not excised as they were either too faint, in a cluster of 
spots or in a streaky area of the gel. 
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Table 9.3: Table showing identifications of differentially expressed proteins between stimulated and unstimulated cells from CLL clinical sample 089 















1 0020 14.8 <5.5 ↓ Not Identified N/A N/A N/A N/A N/A 
2 0118 16.5 <5.5 ↓ Tropomyosin 4-anaplastic Lymphoma Kinase Fusion Protein 12.295 5.2 69 13 88% 
3 0308 31 <5.5 ↓ Unable to Excise N/A N/A N/A N/A N/A 
4 1515 38.2 <6 ↓ Not Identified N/A N/A N/A N/A N/A 
5 1615 43.8 <6 ↓ FYVE-Ring Finger Protein Sakura (Rififylin) 39.687 5.51 69 27 52% 
6 1712 67.8 <6 ↑ Not Identified N/A N/A N/A N/A N/A 
7 5715 56.9 ~6 ↓ Unable to Excise N/A N/A N/A N/A N/A 
8 5713 51.2 ~6 ↑ Kazrin 46.738 6.31 74 18 44% 
9 6716 68.6 ~6 ↑ Leukotriene A4 Hydrolase 69.109 5.87 143 32 57% 
10 7725 67.7 <6.5 ↑ RAS Homolog Gene Family Member T1 79.496 6.46 69 26 32% 
11 8504 49.6 <6.5 ↑ Kininogen 1 47.871 6.29 65 24 49% 
12 6516 55.4 ~6 ↑ Protein Similar to CG 5439-PA 51.557 6.31 103 31 55% 
13 6118 24.2 ~6 ↓ Not Identified N/A N/A N/A N/A N/A 
14 4118 22.3 ~6 ↓ Thiopurine S-Methyltransferase 28.215 6.01 66 15 53% 
15 6116 21.6 ~6 ↓ Unable to Excise N/A N/A N/A N/A N/A 
16 5008 11.7 ~6 ↓ Not Identified N/A N/A N/A N/A N/A 
17 6009 11.7 ~6 ↓ Not Identified N/A N/A N/A N/A N/A 
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Figure 9.10: PDQuest histograms of the 8 proteins identified by MADLI-TOF-MS 
showing differential expression between stimulated and unstimulated cells in CLL 
clinical sample 089 
The histograms show protein expression in the three test replicates (stimulated cells, 
red) and three control replicates (unstimulated cells, green). The protein spots had a >2-
fold change in expression between stimulated and unstimulated cells (p<0.05) and were 
identified by MALDI-TOF-MS (Table 9.3). Protein spots 2, 5 and 14 were over 
expressed in unstimulated cells and spots 8, 9, 10, 11 and 12 were over expressed in 
stimulated cells. 
 
9.4 Western Blot Confirmations 
 
Western blots were used to confirm the change in expression of proteins identified by 
mass spectrometry (see section 9.3). Proteins were prioritised for western blot 
confirmation based on occurrence in the three biological replicates, availability of 
antibody, MASCOT score and % sequence coverage matched. Table 9.4 shows the 
identified proteins found to be differentially expressed between stimulated and 
unstimulated CLL clinical samples. Proteins highlighted in red had no western blot 
antibody commercially available. Proteins highlighted in blue were differentially 
expressed in more than one CLL clinical sample. 
Spot 2 Spot 5 Spot 8 Spot 9 
Spot 10 Spot 11 Spot 12 Spot 14 
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Table 9.4: Table to show differentially expressed proteins identified in all three CLL clinical samples 
Sample Spot PDQuest Number 
Stimulated 







089 9 6716 ↑ Leukotriene A4 Hydrolase 69.1 5.9 143 57% 
078 11 7315 ↑ Kininogen 1 47.9 6.3 76 41% 
078 1 1323 ↓ Adenylate Kinase Isoenzyme 5 22.1 5.4 70 72% 
089 2 0118 ↓ Tropomyosin 4-anaplastic Lymphoma Kinase Fusion Protein 12.3 5.2 69 88% 
003 4 7114 ↓ Fatty Acid Binding Protein 5 15.2 6.6 68 100% 
003 11 5531 ↓ Aspartyl-tRNA Synthetase (DARS) 57.1 6.1 68 51% 
003 13 6323 ↑ KNG1 Protein (Kininogen 1) 33.0 6.3 67 54% 
089 14 4118 ↓ Thiopurine S-Methyltransferase 28.2 6.0 66 53% 
089 11 8504 ↑ Kininogen 1 47.9 6.3 65 49% 
089 12 6516 ↑ Protein Similar to CG 5439-PA 51.6 6.3 103 55% 
003 1 2222 ↓ Unnamed Protein Product 28.1 5.7 75 64% 
089 8 5713 ↑ Kazrin 46.7 6.3 74 44% 
003 8 4504 ↑ Astrotactin 2 (ASTN2 Protein) 49.6 5.5 73 56% 
003 6 2512 ↑ Tripartite Motif Protein (TRIM19 Zeta) 70.0 5.2 73 39% 
003 15 5104 ↓ Phosphatidylinositol Transfer Protein Beta 22.2 5.9 70 64% 
003 10 4210 ↓ Glyoxalase Domain Containing 4 33.2 5.4 70 55% 
089 5 1615 ↓ FYVE-Ring Finger Protein Sakura (Rififylin) 39.7 5.5 69 52% 
089 10 7725 ↑ RAS Homolog Gene Family Member T1 79.5 6.5 69 32% 
003 9 4517 ↓ Astrotactin 2 Isoform d 44.5 5.6 68 60% 
003 5 3111 ↓ Interferon Alpha-1/13 Precursor 21.7 5.3 66 52% 
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The proteins prioritised for western blot confirmation based on Table 9.4 were: 
 
1. Kininogen 1 
2. Leukotriene A4 hydrolase 
3. Adenylate kinase isoenzyme 5 
4. Tropomyosin 4-anaplastic lymphoma kinase fusion protein 
5. Fatty acid binding protein 5 
6. Aspartyl-tRNA synthetase 
7. Thiopurine s-methyltransferase. 
 
Two of the seven antibodies have been fully optimised; these are adenylate kinase 
isoenzyme 5 (see section 9.4.2) and aspartyl-tRNA synthetase (see section 9.4.3). Five 
of the antibodies (including kininogen - see section 9.4.1) have been purchased and 




Kininogen 1 was prioritised as it was found to be up-regulated by 2D-PAGE by >2-fold 
in all three clinical CLL biological replicates. Clinical sample 003 showed differential 
expression of the 33KDa form of kininogen, whilst samples 078 and 089 showed 
differential expressions of the 47.9KDa form. Samples were screened using a mouse 
monoclonal antibody to kininogen (Abcam) (see Table 4.1 and Table 4.2). 
 
Unfortunately, after a series of optimisation steps the antibody was still not reliable 
enough to be able to measure an accurate fold change (Figure 9.11). Western blots were 
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performed using different blocking solution (BSA and milk), incubating with the 
primary antibody for different times (2-16hrs) and using different dilutions (1:150-
1:1000) of the primary antibody. To be able to confirm kininogen expression in the 




Figure 9.11: Western blots analysis of kininogen expression in clinical CLL sample 
089 
Western blots showing separate attempts at a kininogen screening assay. Western blots 
were tried using different blocking solution (BSA and milk) and incubating with the 
primary antibody for different times (2-16hrs) and different dilutions (1:150-1:1000). The 
blot on the left shows a membrane which had been incubated in BSA with an incubation of 
16hrs with 1:1000 dilution of kininogen. The blot shows non-specific binding and the 
expected bands at 47KDa can barely be seen and cannot be used to determine a fold 
change. The blot on the right shows a membrane which had been incubated in milk with an 
incubation of 2hrs with 1:150 dilution of kininogen. No protein bands are visible.  
 
9.4.2 Adenylate Kinase Isoenzyme 5 
 
Adenylate kinase isoenzyme 5 (AK5) was prioritised as it was found to be down-
regulated by 2D-PAGE by >2-fold in clinical sample 078 with a score of 70 and a 
sequence coverage of 72%. A rabbit polyclonal antibody to AK5 (Abgent) (see Table 
4.1 and Table 4.2) was used to screen clinical sample 078. The membrane was blocked 
in milk and incubated for 16hrs in the primary antibody in BSA.  
Proteomic Analysis of Chronic Lymphocytic Leukaemia – The 2D-PAGE/MS Analysis 
of CLL Clinical Samples 
 
 197
Results show a decrease in AK5 in stimulated cells from clinical sample 078, which 
correlates with the results obtained from 2D-PAGE (see Table 9.2). Replicate 1 did not 
transfer well (possibly due to an air bubble between the gel and membrane) and could 
not be included in the assay; however the two technical replicates, on average, show a 
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Figure 9.12: Western blot of adenylate kinase isoenzyme 5 (AK5) expression in 
clinical CLL sample 078 
Sample 078 was screened for AK5 expression (22KDa) by Western blot. AK5 was 
found to be down-regulated by over 2-fold in stimulated cells by 2D-PAGE. Beta actin 
(47KDa) was used as a loading control. Replicate 1 on the Western blot did not transfer 
well so only two replicates could be included in the assay. The blot and graph show a 
decrease in AK5 expression in stimulated cells in replicate 2 and 3 by 1.3-fold and 1.9-
fold respectively. The Western blot technique is not as sensitive as 2D-PAGE/PDQuest 
therefore it can be expected that fold changes may be a little lower. 
 
AK5 was not identified as being differentially expressed by 2D-PAGE in clinical 
sample 089; however, a western blot was performed to assess AK5 expression in this 
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clinical sample. The three technical replicates show decreased expression (average 2.6-
fold) of AK5 in stimulated cells (Figure 9.13). This correlates with the results from 




Figure 9.13: Western blot of adenylate kinase isoenzyme 5 (AK5) expression in 
clinical CLL sample 089 
Sample 089 was screened for AK5 (22KDa) expression by western blot. Beta actin 
(47KDa) was used as a loaing control. The results show a down-regulation of AK5 in 
stimulated cells with an average fold change of 2.6. 
 
9.4.3 Aspartyl-tRNA Synthetase 
 
Aspartyl-tRNA synthetase (DARS) was found to be down-regulated by 2D-PAGE by 
>2-fold in clinical sample 003 with a score of 68 and sequence coverage of 51%. A 
mouse monoclonal antibody to DARS (Abova) (see Table 4.1 and Table 4.2) was used 
in a dilution of 1:200 in BSA for 16hrs. The membrane was blocked in milk. Results 
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show a decrease in DARS in stimulated CLL 003 cells, which correlates with the results 
obtained from 2D-PAGE (Table 9.1). The three technical replicates show an average 




Figure 9.14: Western blot of aspartyl-tRNA synthetase (DARS) expression in 
clinical CLL sample 003 
Sample 003 was screened for DARS (57KDa) expression by Western blot. Beta actin 
(47KDa) was used as a loading control. The results show a down-regulation of DARS in 
stimulated cells with an average fold change of 2.1. This correlates with the results from 
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Table 9.5 shows all of the proteins found in the three clinical CLL 2D-PAGE 
experiments and the RAJI B-cell 2D-PAGE experiment (see sections 7.3 and 9.3). 
Twenty seven proteins have shown a change in expression between stimulated and 
unstimulated cells and have been identified by MALDI-TOF-MS. Of the 27 proteins, 7 
were up-regulated and 20 were down-regulated. 
 
The molecular class (Figure 9.15), molecular function (Figure 9.16), biological process 
(Figure 9.17) and location (Figure 9.18) of all the proteins found in the 2D-PAGE 
experiments were sourced from the Human Protein Reference Database (HPRD) 
(Mishra. 2006). The HPRD shows post-translational modifications, interaction networks 
and disease association for each protein in the human proteome. All the information in 
HPRD has been manually extracted from the literature by expert biologists who read, 
interpret and analyse the published data. The majority of the proteins found to be up-
regulated were located in the cytoplasm and nucleus (Figure 9.18) and involved in 
protein metabolism (Figure 9.17). The majority of the proteins found to be down-
regulated were enzymatic proteins (Figure 9.15) which were located in the cytoplasm 
(Figure 9.18) and involved in metabolism energy pathways (Figure 9.17). 
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Table 9.5: Table showing differentially expressed proteins between stimulated and unstimulated cells in all 2D-PAGE experiments 
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Figure 9.15: Pie charts showing molecular class of proteins found to be 
differentially expressed using 2D-PAGE. 
The chart shows the molecular classes of the 7 up-regulated proteins (left) and the 20 
down-regulated proteins (right). Proteins which were up-regulated had an equal 
distribution of protein molecular class; however the majority of the down-regulated 
proteins are enzymatic proteins. 
 
  
Figure 9.16: Pie charts showing molecular function of proteins found to be 
differentially expressed using 2D-PAGE. 
The chart shows the molecular functions of the 7 up-regulated proteins (left) and the 20 
down-regulated proteins (right). Proteins which were up-regulated had an equal 
distribution of protein molecular functions; however, the majority of the down-regulated 
proteins have unknown functions. 
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Figure 9.17: Pie charts showing biological process of proteins found to be 
differentially expressed using 2D-PAGE. 
The chart shows the biological processes of the 7 up-regulated proteins (left) and the 20 
down-regulated proteins (right). The majority of up-regulated proteins are involved in 
protein metabolism and the majority of down-regulated proteins are involved in 
metabolism energy pathways. 
 
  
Figure 9.18: Pie charts showing localisation of proteins found to be differentially 
expressed using 2D-PAGE. 
The chart shows the localisations of the 7 up-regulated proteins (left) and the 20 down-
regulated proteins (right). The majority of up-regulated proteins are cytoplasmic 
proteins and nucleic proteins, and the majority of down-regulated proteins are 
cytoplasmic. 
 
Two of the 27 proteins which had changed in expression between stimulated and 
unstimulated cells from clinical CLL samples were confirmed by western blot. These 
were AK5 (see section 9.4.2) and DARS (see section 9.4.3).  
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AK5 was found to be down-regulated in stimulated cells from clinical samples 078 and 
089 (see Figure 9.8 and section 9.4.2). AK5 is the cytosolic form of adenylate kinase 
which plays an important role in homeostasis of cellular energy (Stanojevic et al. 2008). 
It is a phosphotransferase enzyme which catalyses the reaction: 
 
2ADP  ATP + AMP 
 
Where:  
ADP = adenosine diphosphate 
ATP = adenosine triphosphate 
AMP = adenosine monophosphate 
 
AK5 was found to be down-regulated by 2D-PAGE by >2-fold in stimulated cells from 
clinical sample 078. However, expression of AK5 in clinical sample 089 was also 
shown to be down-regulated in stimulated cells by western blot (see section 9.4.2), 
despite the change in expression not being shown by 2D-PAGE. This shows that a 
change in expression of a protein can be missed by 2D-PAGE, and a protein that has 
shown an expression change in only one clinical CLL sample may still be relevant and 
further samples would need screening by western blot.  
 
DARS was found to be down-regulated in stimulated cells from clinical sample 003 (see 
Figure 9.6 and section 9.4.3). DARS is part of the aminoacyl-tRNA synthetases which 
are essential for the translation of mRNA into proteins (Hausmann et al. 2008). Studies 
have shown that removal of fatty acids alters the structure and function of aminoacyl-
tRNA synthetase complexes (Sivaram et al. 1990). 
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One protein, kininogen, was shown to be up-regulated by >2-fold in stimulated cells in 
all three clinical CLL samples by 2D-PAGE (see Table 9.4). Kininogen is the critical 
regulator of the plasma kallikrein-kinin system (Schmaier. 2002) which plays roles in 
inflammation, blood pressure control, coagulation and pain. It has also been suggested 
that kinins (a family of octato-decapeptides arisen from kininogen) influence cells of the 
immune system such as T-cells and B-cells, by modulating the activation, proliferation, 
migration and effector functions of these cells (Schulze-Topphoff et al. 2008). No 
references to CLL have been published. 
 
Other proteins which showed a >2-fold change in expression by 2D-PAGE and were 
prioritised (based on Table 9.4) but not yet confirmed by western blot were leukotriene 
A4 hydrolase, tropomyosin 4-anaplastic lymphoma kinase fusion protein, fatty acid 
binding protein 5 and thiopurine s-methyltransferase. 
 
Leukotriene A4 hydrolase was found to be up-regulated in stimulated cells from clinical 
sample 089 (Table 9.4). Leukotriene A4 hydrolase catalyses the final step in the 
biosynthesis of leukotriene B4 (Haeggstrom. 2000). Leukotriene B4 had been shown to 
interact with the B-cell differentiation process, and amplify activation (Yamaoka et al. 
1989), suggesting that cells which show high levels of leukotriene A4 hydrolase could 
be hyper-active to stimulation. 
 
Tropomyosin 4-Anaplastic Lymphoma Kinase Fusion Protein was found to be down-
regulated in stimulated cells from clinical sample 089 (Table 9.4). Anaplastic 
lymphoma kinase (ALK) is a receptor tyrosine kinase identified in a chromosomal 
translocation associated with some anaplastic large cell lymphomas. In cancers, all 
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translocations involving ALK produce fusion proteins with constitutive tyrosine kinase 
activity (Chiarle et al. 2008). Fusion proteins of ALK are oncogenic and strongly linked 
to out-of control cell proliferation (Morris et al. 1994) suggesting that the cells that 
show an increase in tropomyosin-ALK could show pro-survival characteristics. 
However, tropomyosin-ALK was found to be down-regulated in stimulated cells. 
 
Fatty Acid Binding Protein 5 was found to be down-regulated in stimulated cells from 
clinical sample 003 (Table 9.4). The exact physiological role of fatty acid binding 
proteins is still unknown (Krieg et al. 1993), however, studies have indicated that fatty 
acid binding proteins may stabilise leukotriene A4 hydrolase in leukaemia cells and are 
important in trans-cellular biosynthesis where leukotriene A4 hydrolase is transferred 
from one cell to another (Zimmer et al. 2004). This suggests that cells with a decrease 
in expression of fatty acid binding proteins may be unable to stabilise leukotriene A4 
hydrolase. Leukotriene A4 hydrolase was found to be up-regulated in stimulated cells in 
this study. 
 
Thiopurine s-methyltransferase was found to be down-regulated in stimulated cells from 
clinical sample 089 (Table 9.4). Deficiency in thiopurine s-methyltransferase (TPMT) is 
linked to toxicity and lack of response in cancer treatment as it is the main enzyme 
responsible for inactivating the toxic products of the immunosuppressant azathioprine 
(A. Ansari. 2002) suggesting that these cells could show therapy resistance. 
 
Seven proteins which showed a >2-fold change in expression by 2D-PAGE and which 
may be of potential interest were TRIM19 zeta, astrotactin 2, glyoxalase domain 
containing 4, phosphatidylinositol transfer protein beta, rififylin, kazrin and RAS 
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homolog gene family member T1. However, a commercially available antibody was not 
available for these proteins and western blot confirmation was not possible (see Table 
9.4). 
 
TRIM19 zeta was found to be up-regulated in stimulated cells from clinical sample 003 
(Table 9.4). TRIM19 zeta is also known as promyelocytic leukaemia protein. It is a 
tumour suppressor induced by interferons, involved in multiple apoptosis pathways. 
Studies have shown that cells that are deficient in promyelocytic leukaemia protein are 
resistant to apoptosis (Wu et al. 2002), while cells over expressing promyelocytic 
leukaemia protein activate caspase 8 (Kuwayama et al. 2008). Caspase 8 is involved in 
the initiation of apoptosis; however, it can also initiate signals that protect the cell from 
autophagic or necrotic cell death (Maelfait et al. 2008) suggesting that these cells could 
show pro-survival characteristics. 
 
Astrotactin 2 was found to be up-regulated and astrotactin 2 isoform d was found to be 
down-regulated in stimulated cells from clinical sample 003 (Table 9.4). Astrotactin is a 
neuron cell surface antigen, named because of its role in mediating neuron-astroglial 
contacts. It binds granule neurons to astroglia (cells found  in the brain and spinal cord) 
and maintains the cerebellar astroglial form (Edmondson et al. 1988). No references to 
oncology or haematology have been published. 
 
Glyoxalase domain containing 4 was found to be down-regulated in stimulated cells 
from clinical sample 003 (Table 9.4). The glyoxalase system catalyses the conversion of 
methylglyoxal to D-lactic acid via the intermediate S-D-lactoylglutathione. Addition of 
S-D-lactoylglutathione to HL60 leukaemia cells in culture induced growth arrest and 
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toxicity (Thornalley et al. 1988), suggesting that a lack of S-D-lactoylglutathione could 
promote cell survival. 
 
Phosphatidylinositol transfer protein beta was found to be down-regulated in stimulated 
cells from clinical sample 003 (Table 9.4). Phosphatidylinositol transfer protein beta 
regulates pathways involved in proliferation, apoptosis and cell survival (Snoek. 2004). 
Studies have shown that an over expression of phosphatidylinositol transfer protein beta 
results in the inhibition of anti-apoptotic pathways,  stimulating apoptosis (Schenning et 
al. 2007), suggesting that down-regulation may result in anti-apoptotic characteristics. 
 
Rififylin was found to be down-regulated in stimulated cells from clinical sample 089 
(Table 9.4). Rififylin is a novel protein characterised in 2004 which is reported to be 
involved in endocytosis (a fundamental cellular process, whereby extracellular material 
as well as plasma membrane proteins and lipids are internalised and transported to 
various intracellular compartments) (Coumailleau et al. 2004). Studies show that when 
rififylin is over-expressed in HeLa cells, it localized to and induced the condensation of 
endosomal structures (Coumailleau et al. 2004). 
Kazrin was found to be up-regulated in stimulated cells from clinical sample 089 (Table 
9.4). Karin is a novel protein reported in 2004 and is described as a periplakin 
interacting protein (Groot et al. 2004). Periplakin is a 195KDa membrane associated 
protein found in keratinocytes (Ruhrberg et al. 1997) which suggests that kazrin may 
have other functions which are not yet reported. 
 
RAS homolog gene family member T1 was found to be up-regulated in stimulated cells 
from clinical sample 089 (Table 9.4). RAS homolog gene family member T1 (RhoT) is 
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a homolog of Tc10 (Abe et al. 2003) which regulates cell signaling of the actin 
cytoskeleton and processes associated with cell growth (Murphy et al. 1999) suggesting 
that an over-expression could result in irregular cellular signaling. 
 
 
   
Chapter 10 - The Proteomic Analysis of 





 To identify changes in protein expression between stimulated and unstimulated 
cells in a clinical CLL sample selected in section 8.4 using The Panorama® 
Antibody Microarray – XPRESS Profiler725 
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The Proteomic Analysis of CLL Clinical Samples Using Antibody Microarrays 
 
The Panorama® Antibody Microarray – XPRESS Profiler725 (Sigma-Aldrich) was 
used to determine differentially expressed proteins between stimulated and unstimulated 
CLL cells (see section 3.3). Clinical CLL sample 003 was used in this experiment (see 
8.4.1). The XPRESS Profiler725 was chosen because of the large number of antibodies 
represented and also the selection of antibodies representing proteins from a variety of 
different biological pathways (see section 4.12). Results obtained from the antibody 
array experiment should be complementary to the results obtained from 2D-PAGE/MS. 
 
Ideally three technical replicates would be run, including one where the fluorescent dyes 
labelled on the test and control samples are swapped around. However, since 2D-
PAGE/MS data was available for the same clinical sample and the antibody microarray 
slides were expensive, only one microarray was used. This would serve as a preliminary 
screening method and any proteins shown to be of interest could be verified by a more 
economical method such as western blotting. All the antibodies spotted on the 
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CLL sample 003 was used for this experiment because; 
 
 It showed differential expression of numerous proteins in the 2D-PAGE 
experiment (9.3.2) 
 There was a sufficient number of cells left in the sample for further analysis 
 A large quantity of protein could be extracted due to the high WBC of the 
patient (antibody microarrays require a minimum of 1mg of protein from each 
test sample) 
 
Approximately 2.4x108 cells were stimulated or exposed to an isotype control in a 
concentration of 5x106cells/ml for 5.5hrs (see section 4.4) and the protocol as described 
in section 4.12 was used to extract and quantify protein, and analyse the Panorama 
XPRESS Profiler725 antibody microarray. 
 
One ml of protein at a concentration of 1µg/µl was needed for the array. Stimulated and 
unstimulated extracts were quantified as 4.9µg/µl and 3.2µg/µl respectively. Stimulated 
cells were labelled with a Cy5 dye (red) and unstimulated cells were labelled with a Cy3 
dye (green). A dye to protein ratio of >2 was needed for the array (see section 4.12.4). 
Stimulated and unstimulated extracts were labelled with a ratio of 3.5 and 4.86 
respectively. Fifty micrograms of each labelled protein extract was loaded onto the 
array. 
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Of the 725 antibodies on the array, 686 antibody spots were classed as; 
 
 Less than 3% saturated pixels 
 Not flagged as bad or absent 
 Uniform intensity 
 Uniform background  
 Detectable above background 
 
Of the 686 spots, 70 showed a 2-fold change in expression in the stimulated (test) 
sample when compared to the unstimulated (control) sample (see Figure 10.1). Twenty 
eight proteins were up-regulated (see Table 10.1) and 42 were down-regulated (Table 
10.2) in the stimulated cells. Protein spots which appeared red were up-regulated in 
stimulated cells and protein spots which appeared green were down-regulated in 
stimulated cells (Figure 10.2). 
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Figure 10.1: Panorama® Antibody Microarray – XPRESS Profiler725 slide image 
with labelled protein extracts from stimulated and unstimulated cells from clinical 
CLL 003 sample 
On the Panorama® Antibody Microarray – XPRESS Profiler725 (Sigma-Aldrich), 686 
antibodies were classed in the experiment. Of the 686, 70 proteins were differentially 
expressed between stimulated and unstimulated 003 CLL cells. 
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Table 10.1: Table showing proteins identified using the Panorama® Antibody Microarray – XPRESS Profiler725 which were up-
regulated in stimulated cells from clinical sample 003 
Protein Antibody Alternate Name Lowess M Log Ratio 
Fold Change 
(2n) 
PUMA bbc3 #P4818 BCL2 binding component 2 3.067 8.4 
TRAIL #T9191 TNF-related apoptosis inducing ligand 2.922 7.6 
PUMA bbc3 #P4743 BCL2 binding component 2 2.664 6.3 
Siah2 #S7945 Seven in absentia homlog 2 2.483 5.6 
MyD88 #M9934 Myeloid differentiation primary response protein 2.23 4.7 
P53R2 #P4993 Ribonucleotide reductase M2 B 1.69 3.2 
CtBP1 #C8741 C-terminal binding protein 1 1.637 3.1 
Chk1 #C9358 Cell cycle checkpoint kinase 1.613 3.1 
ILP2 #I4782 Baculoviral IAP repeat containing 8 1.608 3.0 
TSG101 #T5826 Tumour susceptibility gene 101 1.585 3.0 
ARP3 #A5979 Actin related protein 3 1.579 3.0 
iASPP #A4605 Inhibitor of apoptosis stimulating protein of p53 1.55 2.9 
Bim #B7929 BCL2-like 11 (apopotosis facilitator) 1.512 2.9 
Nuf2 #N5287 Cell division cycle associated 1 1.464 2.8 
p115 TAP #P3118 Vesicle docking protein p115 1.42 2.7 
bCOP #G6160 Coatomer protein complex, subunit beta 1.42 2.7 
Caspase 13 #C8854 N/A 1.305 2.5 
Ubiquitin Cterminal Hydrolase L1 #U5258 Ubiquitin carboxyl terminal hydrolase isozyme L1 1.175 2.3 
Cortactin #C6987 Oncogen EMS1 1.163 2.2 
FXR2 #F1554 Fragile X mental retardation syndrome related protein 2 1.15 2.2 
FADD #F8053 FAS associating protein with death domain 1.146 2.2 
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Sir2 #85313 Sirtuin 2 1.141 2.2 
TRAIL #T3067 TNF-related apoptosis inducing ligand 1.089 2.1 
Spectrin a & b #S3396 Spectrin 1.077 2.1 
p53DINP1SIP #P4868 p53-Dependent damage-inducible nuclear protein 1 1.074 2.1 
dCatenin NPRAP #C4864 Catenin (cadherin associated protein) delta 2 (neural plakophilin related arm repeat protein) 1.048 2.1 
Glutamate receptor NMDAR 2a #G9038 Glutamate receptor ionotropic, N-methyl D-aspartate subunit 2A 1.016 2.0 
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Table 10.2: Table showing proteins identified using the Panorama® Antibody Microarray – XPRESS Profiler725 which were down-regulated in 
stimulated cells from clinical sample 003 
Protein Antibody Alternate Name Lowess M Log Ratio 
Fold Change 
(2n) 
BACE 1 #B0806 Beta site App cleaving enzyme 1 -2.754 -6.7 
PIASx #P9498 Protein inhibitor of activated STAT X -2.393 -5.3 
Rad17 #R8029 RAD1 homolog -2.253 -4.8 
hBRM hSNF2a #H9787 SWI/SNF related matrix associated actin dependent regulator of chromatin a2 -2.053 -4.1 
Smad4 #S3934 Deletion target in pancreatic carcinoma 4 -1.97 -3.9 
SLIPR MAGI3 #S4191 Membrane associated guanylate kinase related 3 (scaffolding protein) -1.832 -3.6 
Tropomyosin #T9283 TPM1 -1.78 -3.4 
RhoE #R6153 Ras homolog gene family, member E -1.755 -3.4 
BACH1 #B1310 Transcription regulator protein BACH1 -1.686 -3.2 
RALAR #R8529 Ras related protein Ral A -1.639 -3.1 
Rab7 #R8779 Ras associated protein Rab7 -1.634 -3.1 
Zyxin #Z0377 P83 -1.81 -3.5 
Importin a3 #I9783 Karyopherin alpha3 -1.56 -2.9 
SKM1 #S9568 Sodium channel, voltage gated, type IV, alpha subunit -1.55 -2.9 
Protein Kinase C PKC #P5704 Protein Kinase C -1.522 -2.9 
Caldesmon #C6542 Caldesmon 1 -1.386 -2.6 
E6AP #E8655 Ubiquitin protein ligase E3A -1.374 -2.6 
Paxillin #P1093 FLJ16691 -1.367 -2.6 
hABH1 #A8103 Alpha/beta hydrolase domain containing protein 1 -1.354 -2.6 
Growth Factor Independence1 #G6670 Zinc finger protein Gfi 1 -1.336 -2.5 
Slipr MAGI3 #S1190 Membrane associated guanylate kinase related 3 (scaffolding protein) -1.331 -2.5 
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AOP1 #A7674 Peroxiredoxin 3 (antioxidant protein 1) -1.324 -2.5 
FBI1 POKEMON #F9429 Zinc finger and BTB domain containing 7 -1.322 -2.5 
NBS1 #N3037 Nibrin -1.276 -2.4 
MRP2 #M3692 ATP binding cassette, sub family C, member 2 (Multidrug resistance associated protein 2) -1.267 -2.4 
p34cdc2 #C3085 CDC2 -1.263 -2.4 
LIS1 #L7391 Nude like protein -1.238 -2.4 
Vimentin #V6389 N/A -1.192 -2.3 
ING1 #I3659 Inhibitor of growth 1 -1.189 -2.3 
DNASE I #D0188 Deoxyribonuclease I -1.182 -2.3 
aInternexin #I0282 Alpha internexin -1.145 -2.2 
Mad2 #M8694 MAD2 mitotic arrest deficient like 1 -1.143 -2.2 
Cytokeratin CK5 #C7785 N/A -1.13 -2.2 
gParvin #P5746 Parvin gamma -1.113 -2.2 
BUB1 #B0561 Budding uninhibited by benzimidazoles 1 homolog -1.053 -2.1 
MAP1 #M4278 Microtubule asociated protein 1 -1.051 -2.1 
GRP94 #G4420 Tumor rejection antigen 1 -1.051 -2.1 
Nitric Oxide Synthase bNOS #N2280 Nitric oxide synthase 1 -1.031 -2.0 
Heat Shock Factor 1 #H4163 N/A -1.016 -2.0 
Nitrotyrosine #N0409 N/A -1.015 -2.0 
Cyclin A #C4710 N/A -1.003 -2.0 
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Figure 10.2: Picture showing down-regulation of PIASx and up-regulation of 
MYD88 on the XPRESS Profiler725 microarray 
Stimulated cells were labelled with a Cy5 dye (red) and unstimulated cells were labelled 
with a Cy3 dye (green). Antibodies were spotted onto the array in duplicate. The picture 
shows down-regulation of PIASx (Sigma-Aldrich #P9498) (top) in stimulated cells, so 
the spot appears green and up-regulation of MYD88 (Sigma-Aldrich #M9934) (bottom), 
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Seventy proteins were shown to have 2-fold change in expression in stimulated 003 
CLL cells when compared to unstimulated cells on an XPRESS Profiler725 microarray. 
The molecular class, molecular function, biological process and location of the proteins 
was sourced from the Human Protein Reference Database (Mishra. 2006). 
 
The majority of the proteins found to be up-regulated were cytoskeletal proteins (Figure 
10.3) related to receptor signaling complex scaffold activity and ubiquitin specific 
protease activity (Figure 10.4), involved in cell communication and signal transduction 
(Figure 10.5) and found in the cytoplasm (Figure 10.6). The majority of the proteins 
found to be down-regulated were cytoskeletal proteins (Figure 10.3) involved in cell 
communication and signal transduction (Figure 10.5) and found in the nucleus (Figure 
10.6). The majority of the proteins found to be down-regulated in the 2D-PAGE/MS 
experiment (see section Error! Reference source not found.) were also located in the 
nucleus (Figure 9.18). 
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Figure 10.3: Pie charts showing molecular class of proteins found to be 
differentially expressed on the XPRESS Profiler725 microarray 
The chart shows the molecular classes of the 28 up-regulated proteins (top) and the 42 
down-regulated proteins (bottom). The majority of differentially expressed proteins are 
cytoskeleton protein. 
 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - 





Figure 10.4: Pie charts showing molecular function of proteins found to be 
differentially expressed on the XPRESS Profiler725 microarray 
The chart shows the molecular functions of the 28 up-regulated proteins (top) and the 42 
down-regulated proteins (bottom). The majority of up-regulated proteins are a mixture of 
proteins related to receptor signaling complex scaffold activity, ubiquitin specific 
protease activity and proteins with unknown functions (top). The majority of down-
regulated proteins have unknown functions (bottom). 
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Figure 10.5: Pie charts showing biological process of proteins found to be 
differentially expressed on the XPRESS Profiler725 microarray 
The chart shows the molecular functions of the 28 up-regulated proteins (top) and the 
42 down-regulated proteins (bottom). The majority of differentially expressed proteins 
are involved in cell communication, signal transduction. However, 21% of up-regulated 
proteins are related to apoptosis (top) and 20% of down-regulated proteins are involved 
in cell growth and/or maintenance (bottom). 
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Figure 10.6: Pie charts showing localisation of proteins found to be differentially 
expressed on the XPRESS Profiler725 microarray 
The chart shows the molecular functions of the 28 up-regulated proteins (top) and the 
42 down-regulated proteins (bottom). The majority of up-regulated proteins are 
cytoplasmic proteins (top) and the majority of down-regulated proteins are nucleic 
proteins (bottom). Twenty-four percent of up-regulated proteins were also nucleic and 
20% of down-regulated proteins were cytoplasmic proteins. 
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Several proteins were shown to be differentially expressed on two occasions on the 
microarray. This is because some protein targets had two different antibodies referenced 
on the slide. For example, PUMA bbc3 was shown to be up-regulated in stimulated 
cells by 8.4-fold (#P4618) and 6.3-fold (#P4743). Antibody #P4618 is an anti-PUMA 
bbc3, C-terminal antibody produced in rabbit and #P4743 is an anti-PUMA bbc3, N-
terminal antibody produced in rabbit. TRAIL was shown to be up-regulated in 
stimulated cells by 7.6-fold (#T9191) and 2.1-fold (#T3067). Antibody #T9191 is an 
anti-TRAIL antibody produced in rabbit and #T3067 is a monoclonal anti-TRAIL 
antibody produced in mouse. SLIPR MAGI3 was found to be down-regulated in 
stimulated cells by 3.6-fold (#S4191) and 2.5-fold (#S1190). Antibody #S4191 is a 
monoclonal anti-SLIPR MAGI3 antibody produced in mouse and #S1190 is an anti-
SLIPR MAGI3 antibody produced in rabbit.  
 
These three proteins are therefore of specific interest and confirmation by western blot 
should be prioritised as they have shown differential expression by over 2-fold in more 
than one type of antibody. 
 
PUMA bbc3 is a BCL-2 family protein and is activated by P53 in cells undergoing P53 
induced apoptosis (Yu et al. 2003). PUMA bbc3 is said to be silenced in many human 
malignancies resulting in anti-apoptotic effects (Garrison et al. 2008). However, it was 
shown to be up-regulated in stimulated cells from CLL clinical sample 003. 
 
TRAIL is known to induce apoptosis in cancer cells independent of P53 (Wang. 2008). 
However studies have shown that TRAIL also has survival and proliferation properties. 
TRAIL failed to induce apoptosis in small cell lung cancer cells in a study by 
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Belyanskaya et al, and instead resulted in a 40% increase in proliferation. In the same 
study it was shown that TRAIL-induced cell proliferation was mediated by extracellular 
signal-regulated kinase 1 and 2 (Belyanskaya et al. 2008). TRAIL was shown to be up-
regulated in stimulated cells from CLL clinical sample 003 suggesting that these cells 
could show pro-survival characteristics. 
 
SLIPR MAGI3 is part of the MAGUK (Membrane-Associated Guanylate Kinase) 
family proteins. It has been shown to interact with tumour suppressor phosphatase, 
phosphatase and tensin homolog (phosphatase PTEN) (Wu et al. 2000). SLIPR MAGI3 
was shown to be down-regulated in stimulated cells from CLL clinical sample 003. 
Loss of phosphatase PTEN results in enhanced AKT/PKB kinase activation and 
resistance to apoptosis (DiCristofano et al. 2000), suggesting that these cells could show 
anti-apoptotic characteristics. 
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11.1 Aims of Project 
 
The aim of this project was to identify potential biomarkers which could be used in a 
clinical test to predict patient prognosis. IgVH gene mutational status has proven to be a 
good prognostic marker but the test is expensive and time consuming and can not be 
used routinely in clinical practice. If the B-cell has not been sensitised to a specific 
antigen (i.e. unmutated IgVH genes on BCR) it is hyper-responsive to stimulation 
through the BCR by antigen. Stimulation of the BCR may prevent apoptosis of 
malignant cells; therefore a hyper-responsive BCR is linked to poor prognosis. 
Proteomics was used to investigate the signaling pathways activated by the BCR to gain 
a greater understanding of the anti-apoptotic nature of the malignant B-cells and to find 
potential prognostic biomarkers related to a hyper-active BCR. 
 
11.2 Concluding Remarks 
 
This project generated a list of candidate proteins (see Table 11.1) which may be related 
to prognosis in CLL. Further western blot confirmation remains to be completed but the 
results give a greater understanding of the mechanisms of the BCR and therefore, why 
an over-active BCR is related to poor prognosis and survival of malignant B-cells.  
 
The BCR signaling pathways, rather than the individual protein targets, are important in 
the determining the prognosis of a patient with CLL. The cascades of signals activated 
by the BCR are related to anti-apoptotic characteristics and malignant cell survival. The 
cellular pathways of the BCR are not yet fully understood, which makes it difficult to 
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determine pathway links between the protein targets found in this project. However, we 
have shown connections between some of the proteins targets found. For example 2D-
PAGE/MS showed a decrease in a fatty acid binding protein and an increase in 
leukotriene A4 hydrolase - fatty acid binding proteins stabilise leukotriene A4 
hydrolase, a decrease in a fatty acid binding protein would result in a change of 
expression of leukotriene A4 hydrolase (see section Error! Reference source not 
found.). It is very possible that many of the targets found act in concert in specific 
pathways which are not yet understood. The list of proteins targets generated from this 
project may bring us a step closer to solving the puzzles of the BCR signaling cascades 
and making those links. Targets found have been ranked in order of their importance to 
prioritise for further study (Table 11.1) Level of importance was based on confirmation 
status, the number of clinical samples the target was found in and level of expression 
change. 
 
Table 11.1: Protein targets ranked in order of importance for further study showing fold 
change in stimulated cells 





Kininogen 003 ↑ >2-fold     
  078 ↑ >2-fold     
  089 ↑ >2-fold     
AK5 078 ↓ >2-fold ↓ 1.6-fold   
  089   ↓ 2.6-fold   
DARS 003 ↓ >2-fold ↓ 2.1-fold   
PUMA bbc3 003     ↑ 8.4-fold 
  003     ↑ 6.3-fold 
TRAIL 003     ↑ 7.6-fold 
  003     ↑ 2.1-fold 
SLIPR MAGI3 003     ↓ 3.6-fold 
  003     ↓ 2.5-fold 
BACE1 003     ↓ 6.7-fold 
SIAH 003     ↑ 5.6-fold 
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PIASx 003     ↓ 5.3-fold 
Leukotriene A4 Hydrolase 089 ↑ >2-fold     
Tropomyosin 4-anaplastic 
Lymphoma Kinase Fusion Protein 089 ↓ >2-fold     
Fatty Acid Binding Protein 5 003 ↓ >2-fold     
Thiopurine S-Methyltransferase 089 ↓ >2-fold     
Rad17 003     ↓ 4.8-fold 
MyD88 003     ↑ 4.7-fold 
hBRM hSNF2a 003     ↓ 4.1-fold 
Smad4 003     ↓ 3.9-fold 
Zyxin 003     ↓ 3.5-fold 
RhoE 003     ↓ 3.4-fold 
Tropomyosin 003     ↓ 3.4-fold 
P53R2 003     ↑ 3.2-fold 
BACH1 003     ↓ 3.2-fold 
Chk1 003     ↑ 3.1-fold 
CtBP1 003     ↑ 3.1-fold 
Rab7 003     ↓ 3.1-fold 
RALAR 003     ↓ 3.1-fold 
ARP3 003     ↑ 3-fold 
ILP2 003     ↑ 3-fold 
TSG101 003     ↑ 3-fold 
Bim 003     ↑ 2.9-fold 
iASPP 003     ↑ 2.9-fold 
Importin a3 003     ↓ 2.9-fold 
Protein Kinase C PKC 003     ↓ 2.9-fold 
SKM1 003     ↓ 2.9-fold 
Nuf2 003     ↑ 2.8-fold 
bCOP 003     ↑ 2.7-fold 
p115 TAP 003     ↑ 2.7-fold 
Caldesmon 003      ↓ 2.6-fold 
E6AP 003     ↓ 2.6-fold 
hABH1 003     ↓ 2.6-fold 
Paxillin 003     ↓ 2.6-fold 
Caspase 13 003     ↑ 2.5-fold 
AOP1 003     ↓ 2.5-fold 
FBI1 POKEMON 003     ↓ 2.5-fold 
Growth Factor Independence1 003     ↓ 2.5-fold 
LIS1 003     ↓ 2.4-fold 
MRP2 003     ↓ 2.4-fold 
NBS1 003     ↓ 2.4-fold 
p34cdc2 003     ↓ 2.4-fold 
Ubiquitin Cterminal Hydrolase L1 003     ↑ 2.3-fold 
DNASE I 003     ↓ 2.3-fold 
ING1 003     ↓ 2.3-fold 
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Vimentin 003     ↓ 2.3-fold 
Cortactin 003     ↑ 2.2-fold 
FADD 003     ↑ 2.2-fold 
FXR2 003     ↑ 2.2-fold 
Sir2 003     ↑ 2.2-fold 
aInternexin 003     ↓ 2.2-fold 
Cytokeratin CK5 003     ↓ 2.2-fold 
gParvin 003     ↓ 2.2-fold 
Mad2 003     ↓ 2.2-fold 
dCatenin NPRAP 003     ↑ 2.1-fold 
p53DINP1SIP 003     ↑ 2.1-fold 
Spectrin a & b 003     ↑ 2.1-fold 
BUB1 003     ↓ 2.1-fold 
MAP1 003     ↓ 2.1-fold 
Glutamate receptor NMDAR 2a 003     ↑ 2-fold 
Centrin 003     ↑2-fold 
GRP94 003     ↓ 2.1-fold 
Cyclin A 003     ↓ 2-fold 
Heat Shock Factor 1 003     ↓ 2-fold 
Nitric Oxide Synthase bNOS 003     ↓ 2-fold 
Nitrotyrosine 003     ↓ 2-fold 
Kazrin 089 ↑ >2-fold     
Astrotactin 2 (ASTN2 Protein) 003 ↑ >2-fold     
Tripartite Motif Protein 
(TRIM19 Zeta) 003 ↑ >2-fold     
Phosphatidylinositol Transfer 
Protein Beta 003 ↓ >2-fold     
Glyoxalase Domain Containing 4 003 ↓ >2-fold     
FYVE-Ring Finger Protein 
Sakura (Rififylin) 089 ↓ >2-fold     
RAS Homolog Gene 
Family Member T1 089 ↑ >2-fold     
Astrotactin 2 Isoform d 003 ↓ >2-fold     
Interferon Alpha-1/13 Precursor 003 ↓ >2-fold     
 
 
Many of the protein targets found have no previous connection to CLL or BCR 
signaling (e.g. astrotactin, kazrin and kininogen). In both 2D-PAGE/MS and antibody 
microarray experiments, more proteins were found to be down-regulated in the 
stimulated cells suggesting that BCR activation not only activates signaling pathways 
but also inhibits cellular pathways resulting in decrease in expression of proteins. Some 
of the proteins found to be increased in expression are anti-apoptotic or cell survival 
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proteins (e.g. TRIM19 zeta and iASPP) and some proteins found to be decreased in 
expression are related to cell death (e.g. phosphatidylinositol transfer protein beta and 
glyoxalase domain containing 4) suggesting that activation of the BCR is resulting in 
malignant cell survival. 
 
11.3 Antibody Microarray vs. 2D-PAGE/MS 
 
2D-PAGE/MS is a global proteomic technique and remains the gold standard for the 
analysis of protein expression. However there are several drawbacks associated with the 
technique. It is very time consuming and requires highly experienced analysts to 
perform experiments reproducibly. Many differentially expressed proteins are lost in the 
numerous stages of 2D-PAGE/MS; 
 
 Proteins may not enter the gel due to hydrophobic nature or pH 
 Protein spots may not get excised if they are in a cluster, a streak or are they too 
faint 
 Proteins may not be identified by MS if there are too many contaminating 
peptides, too little sample or if the protein isn’t in the database 
 
The antibody microarray is a promising new technology which is designed to overcome 
these problems. However, the antibody microarray is not a global proteomic technique 
and results are limited to what antibodies are referenced on the slide. The two 
techniques therefore cannot not be compared, but may work complimentary to one 
another, both providing information on protein expression. 
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11.4 Future Work 
 
Table 11.1 shows protein targets highlighted in this project which require further 
validation. Due to the time implications with 2D-PAGE, only three clinical CLL 
samples were analysed with this technique. However, protein targets generated can be 
used to develop a fast screening assay for the other clinical samples. For example, an 
enzyme-linked immunosorbent assay (ELISA) can be used to detect an antibody in 
numerous samples in a 96-well microtitre plate format, resulting in many samples being 
screened for one protein target at the same time. This technique would be particularly 
useful when screening for a target protein such as kininogen, which was found to be up-
regulated in all three clinical CLL sample by 2D-PAGE/MS. The prognostic value of 
kininogen could be determined by screening the bank of CLL samples for kininogen, 
using an ELISA technique, and relating the expression of kininogen in each sample to 
the classifications of the sample, based on IgVH mutational status and BCR 
responsiveness. Western blots can also be used to determine protein target levels in 
clinical samples. Sigma-Aldrich have released a “Prestige” set off antibodies for 
commercial use. These antibodies have been designed and validated by the Human 
Proteome Resource and are supplied with standardised universal protocols. The Human 
Protein Atlas (proteinatlas.org) is publicly available and shows approximately 1600 
human proteins which have been screen for protein profiling. Kininogen is one of the 
antibodies offered by Sigma Prestige (#HPA001616) and could be used in the future for 
validation and identifying clinical significance in the CLL clinical samples. 2D-PAGE 
targets can also be confirmed by MALDI-TOF-MS/MS analysis. Some of the 
differentially expressed proteins found in this project have been analysed by MALDI-
TOF-MS/MS (data not shown). Pilot studies were used to determine methods and 
techniques to identify and validate future protein extracts (collaboration with the 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Conclusion 
 
 235
Institute of Cancer Therapeutics, the University of Bradford). The antibody microarray 
results can be validated by western blot, and the clinical relevance of the proteins found 
can be assessed by screening numerous clinical samples for the target proteins. 
 
To date there is over 215 CLL samples stored in Hull (with 155 already characterised) 
and access to further CLL samples via collaborations with Cardiff, Birmingham, 
Liverpool and Newcastle. A large collection of samples (750) from around the UK 
could be screened for the potential prognostic biomarkers found in this investigation. 
Blood samples continue to be collected in Hull from CLL patients and new samples will 
require classifying into “good and poor prognosis” based on IgVH mutational status and 
BCR responsiveness. 
 
Additional prognostic biomarkers could be discovered by further 2D-PAGE/MS and 
antibody microarray experiments on CLL clinical samples. Results from these 
experiments would give more pieces to add to the BCR signaling pathway puzzle. 
 
The maximum stimulation time was used in this project. This was defined as the 
maximum time that the stimulant could remain on the cells without causing cellular 
stress. For RAJI B-cells this was 8hrs (see section 7.2) and for CLL clinical samples this 
was 5.5hrs (see section 8.2.3). In future experiments this time point could be reduced to 
identify protein changes at shorter stimulation times. A stimulation time of 5mins shows 
changes in expression of phosphoproteins (see Chapter 6) but not of unphosphorylated 
proteins (see section 7.1.2). The time point at which total protein expression changes are 
seen could be determined. Changes in expression at the proteome level could then be 
determine for specific time points, working up to the maximum stimulation time. This 
Proteomic Analysis of Chronic Lymphocytic Leukaemia - Conclusion 
 
 236
would create a greater understanding of the mechanism of the BCR from pathways and 




In conclusion, some of the proteins found to have changed in expression between 
stimulated and unstimulated cells in this project are related to cell signaling pathways 
and have connections with other proteins targets found. Some targets found were novel 
proteins which have not previously been associated with CLL or BCR signaling. The 
project has provided some evidence that stimulation of the BCR in CLL results in cell 
survival proteins being up-regulated and cell death proteins being down-regulated. 
These potential prognostic biomarkers now need validating and assessing across a wider 
range of clinical samples. The identification of more proteins relating to BCR signaling 
will not only increase our understanding of the mechanisms of the BCR, but will also 
provide potential prognostic biomarkers for CLL allowing for earlier treatment for 
patients with a poor prognosis and peace of mind for patients with a good prognosis. 
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Appendix B – CLL Sample Database 
 




Age at C1 Binet Stage at C1 
IgVH Mutational Status 
(% Standard Germline 
Concordance) 
001 Male 01/12/1999 17/06/2005 74 B 93.5 
002 Male 01/10/2000 30/09/2005 70 A 93.9 
003 Male 01/01/2001 30/09/2005 80 C 100 
004 Male 29/01/2004 07/10/2005 64 B 93.7 
005 Male 07/05/2004 08/07/2005 81 A 98.3 
006 Female 03/05/2001 14/10/2005 61 A 90.5 
007 Male 13/02/2002 14/10/2005 78 A 93 
008 Female 26/04/1999 14/10/2005 74 A 96 
009 Male 21/08/2002 21/10/2005 71 A 94 
010 Female 31/10/2001 28/10/2005 83 A 99 
011 Male 30/01/2002 02/09/2005 59 A 98.3 
012 Female 04/11/2005 04/11/2005 73 A 95 
013 Male 03/02/1998 04/11/2005 79 A 96 
014 Female 20/05/2005 11/11/2005 58 A 93 
015 Female 05/01/1995 11/11/2005 84 A 96.6 
016 Female 07/01/2004 18/11/2005 77 A 99 
017 Male 23/02/2001 18/11/2005 69 A 92 
018 Female 01/01/1985 18/11/2005 82 A 92.6 
019 Male 16/04/2003 25/11/2005 61 A 92 
020 Female 05/05/1987 25/11/2005 71 A 94.4 
021 Male 15/03/2004 25/11/2005 50 A 94.2 
022 Male 11/11/2005 11/11/2005 55 A 90 
023 Female 09/05/1991 02/12/2005 68 A 89 
024 Male 20/06/2001 02/12/2005 69 A 99.6 
025 Male 11/08/2000 02/12/2005 65 A 97.8 
026 Female 23/07/2004 16/12/2005 59 A 91.6 
027 Female 23/04/2004 16/12/2005 81 A 99.5 
028 Female 02/09/1994 16/12/2005 66 A 90.9 
029 Male 26/06/2002 16/12/2005 79 C 87 
030 Male 18/06/2004 06/01/2006 66 A 99.4 
031 Male 12/12/2002 06/01/2006 67 B 92.7 
032 Male 10/12/2003 06/01/2006 68 A 90.8 
034 Male 11/06/2004 13/01/2006 80 A 97.2 
035 Male 24/05/1994 20/01/2006 80 A 92.3 
036 Female 19/06/1997 20/01/2006 77 A 95.3 
038 Female 23/09/2005 27/01/2006 56 A 99.4 
039 Female 01/01/1996 27/01/2006 70 A 89 
041 Female 01/02/2005 03/02/2006 73 A 89 
042 Female 19/01/2001 10/02/2006 76 A 90.4 
043 Female 08/12/2000 10/02/2006 66 A 96.5 
044 Male 09/01/2002 17/02/2006 63 B 96.4 
045 Female 28/05/2003 17/02/2006 76 A 93 
046 Female 29/08/1982 17/02/2006 77 B 92.1 
048 Male 14/02/2006 10/03/2006 100 C 99.6 
049 Female 26/05/1970 10/03/2006 85 A 94.7 
050 Male 10/04/2001 17/03/2006 69 A 97.2 
052 Male 16/01/2002 31/03/2006 73 A 97.6 
054 Male 21/08/2002 07/04/2006 39 C 99.6 
055 Female 02/12/1999 26/05/2006 76 C 96.7 
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056 Male 25/07/1997 28/04/2006 75 A 100 
057 Male 17/02/2006 12/05/2006 63 B 96.2 
058 Male 22/10/2004 12/05/2006 62 A 99.6 
059 Female 30/05/1996 19/05/2006 72 A 85 
060 Female 09/06/1994 19/05/2006 74 A 93.3 
062 Female 14/05/1986 07/07/2006 75 B 96 
063 Female 14/06/2004 07/07/2006 75 B 100 
064 Male 10/09/1986 14/07/2006 68 B 94.4 
066 Male 13/02/2004 25/08/2006 87 B 94.7 
069 Male 25/01/2006 01/09/2006 77 C 100 
070 Male 20/08/2004 02/03/2007 69 A 90 
071 Male 13/08/2004 08/09/2006 83 A 90.3 
072 Male 01/01/1987 08/09/2006 77 A 89.3 
073 Female 30/06/2006 15/09/2006 73 A 97.5 
074 Male 11/02/2005 22/09/2006 62 B 93.6 
076 Female 03/02/2006 29/09/2006 71 A 96.6 
077 Male 31/03/2006 06/10/2006 63 B 94.1 
078 Male 21/07/2006 13/10/2006 77 A 100 
080 Male 11/02/1999 10/11/2006 76 A 89.6 
081 Male 02/07/1992 17/11/2006 57 A 94.6 
082 Female 15/01/2003 17/11/2006 83 A 94.9 
086 Male 20/10/2006 01/12/2006 61 A 88.5 
088 Male 17/07/2002 12/01/2007 78 B 92.1 
089 Female 22/10/2004 15/12/2006 78 A 97.5 
090 Female 03/06/1998 11/11/2006 70 A 93.4 
091 Male 04/12/2002 28/09/2007 75 C 100 
092 Female 01/12/2006 12/01/2007 79 B 100 
093 Male 08/01/2007 19/01/2007 37 B 97.8 
096 Male 22/07/2005 16/02/2007 76 A 100 
099 Male 20/06/2001 09/03/2007 74 C 100 
100 Female 26/01/2007 02/03/2007 79 A 100 
101 Female 01/01/2003 09/03/2007 78 B 100 
103 Male 14/10/2005 16/03/2007 48 A 94.6 
104 Female 18/08/2006 16/03/2007 87 A 94.1 
107 Male 30/06/1998 30/03/2007 66 A 94 
111 Female 29/10/1998 20/04/2007 91 A 92.4 
112 Male 05/02/2003 27/04/2007 63 A 100 
113 Male 10/10/2001 27/04/2007 69 A 96.3 
114 Female 02/12/2005 27/04/2006 59 A 99.6 
115 Female 06/03/2002 27/04/2007 86   93.9 
116 Male 08/12/2006 11/05/2007 53 A 91.1 
117 Male 28/09/2000 18/05/2007 58 B 91 
118 Male 31/12/2003 18/05/2007 59 A 100 
120 Male 24/04/2007 25/04/2007 58 A 98 
121 Male 23/01/2002 01/06/2007 70 A 96.3 
122 Male 30/03/2007 01/06/2007 76 A 93.4 
123 Female 11/04/2001 01/06/2007 64 A 99.2 
124 Female 06/09/2000 08/06/2007 69 A 97.1 
131 Female 27/06/2001 13/07/2007 55   91.1 
132 Female 13/04/2007 27/07/2007 81 A 91.2 
133 Male 06/07/2007 20/07/2007 68 A 99.2 
134 Male 04/12/2000 20/07/2007 70 A 94 
135 Male 04/11/1994 20/07/2007 72 A 89.9 
139 Male 25/07/2007 10/08/2007 62 C 99.6 
140 Female 16/04/1999 10/08/2007 72 A 95 
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141 Male 16/04/2003 10/08/2007 73 C 94.5 
142 Male 25/07/2007 10/08/2007 64 A 100 
144 Male 20/07/2007 28/07/2007 59 A 100 
145 Male 11/07/2007 24/08/2007 75 A 95.5 
146 Female 04/12/2002 31/08/2007 81 A 97.6 
147 Male 07/09/2007 07/09/2007 87 C 100 
148 Female 08/06/2007 07/09/2007 44 A 100 
149 Female 24/08/2007 14/09/2007 75 A 91 
150 Female 17/08/2007 14/09/2007 73 C 100 
151 Male 18/05/2007 21/09/2007 71 A 92.4 
155 Male 21/09/2007 19/10/2007 70 A 99.6 
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Appendix C – Tissue Culture Solutions 
 
Tissue culture (TC) media/Washing Media 
 
 1 bottle RPMI 1640 media (Invitrogen), 50ml Foetal calf serum, 5ml Pen/Strep 
(Invitrogen), 5ml Glutamine (Invitrogen), 5ml Fungizone (Invitrogen). 
 20% freezing media as washing media + 20% filtered, sterile DMSO (Sigma-
Aldrich). 
 10% freezing media as washing media but + 10% filtered, sterile DMSO 
(Sigma-Aldrich). 
 
Phosphate Buffered Saline 
1 tablet PBS per 500ml DH2O 
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Appendix D – 2D-PAGE Solutions 
 
2D Lysis Buffer 
2.52g Urea, 0.912g Thiourea, 0.24g CHAPS, 46.2mg Dithiothreitol (DTT), 60l Biolyte 
(pH3-10), 12l 1% Bromophenol Blue (BPB), 3.3ml Distilled Water, 60l Protease 
Inhibitor (Sigma-Aldrich #P8340), 60l Phosphatase Inhibitor 1 (Sigma-Aldrich 
#P2850), 60l Phosphatase Inhibitor 2 (Sigma-Aldrich #P5726) 
 
Equilibration Buffer 
6.7ml 1.5M Tris-HCl (pH 8.8), 72.07g urea (60.06MW), 69ml 87% glycerol, 4.0g SDS, 
trace BPB. Made up to 200ml DH2O. 
 
Equilibration Buffer 1 
100mg DTT to 10ml equilibration buffer 
Equilibration Buffer 2 
250mg idoacetamide to 10ml equilibration buffer 
 
1% Agarose Solution 
1g Agarose, 100ml Running Buffer, trace of BPB 
 
Running Buffer 
1 part TGS (x10) (Bio-Rad) to 9 parts DH2O 
(10x TGS = 25mM Tris, 192mM Glycine, 0.1% (w/v) SDS (pH8.3)) 
 
0.1M AMBIC Solution 
0.16g Ammonium Bicarbonate, 20ml DH2O 
 
10mM DTT / 0.1M Ammonium Bicarbonate solution 
0.0077g DTT in 5ml 0.1M ammonium bicarbonate 
 
55mM Iodoacetamide / 0.1M Ammonium Bicarbonate 
0.051g IAA in 5ml 0.1M ammonium bicarbonate – protect from light 
 
50mM acetic acid 
Molarity = % solvent X 10 / MW 
Acetic acid = 16.6M = 16,600mM 
50mM / 16,600mM X 1000 = 3l 
3l acetic acid in 997l DH2O 
 
1mg/ml Trypsin Solution 
100g trypsin (Promega #V5280) + 100l 50mM Acetic Acid 
 
Digestion Buffer 1 
400l 0.1M Ammonium Bicarbonate 
100l ACN 
25l Trypsin Solution 
475l DH2O 
 
Digestion Buffer 2 
Proteomic Analysis of Chronic Lymphocytic Leukaemia – Appendices 
 
 251





10ml DH2O + 0.8g Ammonium Bicarbonate 
 
0.05M & 0.025M AMBIC 
5ml 0.1M AMBIC + 5ml DH2O = 0.05M 
5ml 0.05M AMBIC + 5ml DH2O = 0.025M 
 
DHB Matrix 
50% ACN:DH2O + 1% formic acid. Saturate with DHB (Sigma-Aldrich #85707) 
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Appendix E – Protein Staining Solutions 
 
Krypton Fixing Solution 
40% Ethanol + 10% Acetic Acid + 50% DH2O 
 
Krypton Destaining Solution 
5% Acetic Acid + 95% DH2O 
 
Pro-Q Diamond Fixing Solution 
50% Methanol + 10% Acetic Acid + 40% DH2O 
 
Pro-Q Diamond Destaining Solution 
50ml 1M Sodium Acetate (pH 4.0) + 200ml ACN +250ml DH2O 
 
Flamingo and Sypro Ruby Fixing Solution 
40% Ethanol + 10% Acetic Acid + 50% DH2O 
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Appendix F – Western Blot Solutions 
 
Laemmli Buffer 
4.0ml DH2O, 1ml 0.5M Tris-HCl pH 6.8, 0.8ml Glycerol, 1.6ml 10% SDS, trace of 
BPB.  
To every 190l add 10l 5% beta-mercapto ethanol (β-Me), 10l phosphatase inhibitor 
1 (Sigma-Aldrich #P2850) and 2 (Sigma-Aldrich #P5726) and 10l protease inhibitor 
mix (Sigma-Aldrich #P8340). 
 
Running Buffer 
1 part TGS (x10) (Bio-Rad) to 9 parts DH2O 
(10x TGS = 25mM Tris, 192mM Glycine, 0.1% (w/v) SDS (pH8.3)) 
 
Transfer Buffer 
200ml Methanol + 800ml DH2O + 3g Tris + 14.4g Glycine 
 
Tris Buffered Saline (TBS) (x20) 
121g Tris, 170g Sodium Chloride, made up to 1L in DH20, pH 7.6 with conc HCl 
 
TBS/TWEEN 
250ml TBS (x20) + 4750ml DH2O + 2ml TWEEN-20 
 
5% Blocking Solution 
2g Marvel non-fat dried milk powder 
40ml TBS/ 0.05% TWEEN-20 
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Appendix G – Antibody Microarray (XPRESS profiler725) solutions 
 
Protease inhibitor cocktail 
Add 0.3ml DH2O to the lyophilised vial (Store at -20C for long term) 
 
Benzonase working solution 




10ml labelling/extraction buffer 
50uL of protease inhibitor cocktail solution. 
100uL of phosphatase inhibitor cocktail 
1.2uL of benzonase working solution. 
 
Wash Buffer: 
Phosphate Buffered Saline, pH 7.4, with Tween 20 (from kit) + 1L of water. Filter 
through a 0.45µM filter. 
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Appendix H – MALDI-TOF-MS 
 




M/Z Contaminant Modification Unmodified Peak M/Z 
993.5 Keratin 10 N/A N/A 
1036.5421 Type 1 Hair Keratin 1 N/A N/A 
1066.4986 Keratin 9 N/A N/A 
1179.6004 Keratin 1 N/A N/A 
1277.6332 Keratin 1 N/A N/A 
1475.7489 Keratin 1 N/A N/A 
1638.8598 Keratin 1 N/A N/A 
1837.9654 Keratin 9 N/A N/A 
1851.9269 Keratin 9 N/A N/A 
1993.9766 Keratin 1 N/A N/A 
2211.104 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2225.3 Background Peak N/A N/A 
2283.1801 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2367.2626 Keratin 10 N/A N/A 





M/Z Contaminant Modification Unmodified Peak M/Z 
1107.8 Background Peak N/A N/A 
1109.49 Keratin 10 N/A N/A 
2055.962 Type 1 Hair Keratin 1 CAM 1998.941 





M/Z Contaminant Modification Unmodified Peak M/Z 
1090.531 Keratin 10 N/A N/A 
1141.5194 Keratin 1 N/A N/A 
1165.5848 Keratin 10 N/A N/A 
1234.679 Keratin 10 N/A N/A 
1262.5971 Keratin 10 N/A N/A 
1265.6372 Keratin 1 N/A N/A 
1307.6776 Keratin 9 N/A N/A 
1320.1 Background Peak N/A N/A 
1357.7182 Keratin 10 N/A N/A 
1434.7699 Keratin 10 N/A N/A 
1707.7503 Keratin 9 CAM 1650.7289 
1716.8511 Keratin 1 N/A N/A 
1794.9 Background Peak N/A N/A 
1941.9876 Keratin 1 N/A N/A 
2021.9886 Keratin 1 N/A N/A 
2082 Background Peak N/A N/A 
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2095.0376 Keratin 9 CAM 2038.0161 
2171.0246 Keratin 9 N/A N/A 





M/Z Contaminant Modification Unmodified Peak M/Z 
842.5094 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
847.4519 Keratin 10 N/A N/A 
847.4593 Type 1 Hair Keratin 1 N/A N/A 
874.4992 Keratin 1 N/A N/A 
881 Background Peak N/A N/A 
895.4592 Keratin 1 N/A N/A 
897.4135 Keratin 9 N/A N/A 
906.5043 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
910.4152 Keratin 1 N/A N/A 
913.4084 Keratin 9 MSO 897.4135 
932.5047 Keratin 1 N/A N/A 
935.4251 Keratin 10 N/A N/A 
945.4999 Keratin 1 N/A N/A 
948.4493 Keratin 10 N/A N/A 
951.42 Keratin 10 MSO 935.4251 
962.4901 Keratin 9 N/A N/A 
966.4567 Keratin 10 N/A N/A 
967.4519 Keratin 9 N/A N/A 
973.5313 Keratin 1 N/A N/A 
976.4231 Keratin 10 N/A N/A 
982.4233 Type 1 Hair Keratin 1 N/A N/A 
985.5789 Keratin 1 N/A N/A 
988.5309 Type 1 Hair Keratin 1 N/A N/A 
998.4836 Keratin 1 N/A N/A 
999.4451 Keratin 1 N/A N/A 
999.4966 Keratin 1 N/A N/A 
999.5833 Type 1 Hair Keratin 1 N/A N/A 
1003.5531 Keratin 10 N/A N/A 
1006.4296 Keratin 1 N/A N/A 
1006.4873 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1009.5313 Type 1 Hair Keratin 1 N/A N/A 
1014.4785 Keratin 1 MSO 998.4836 
1015.4401 Keratin 1 MSO 999.4451 
1033.516 Keratin 1 N/A N/A 
1045.5636 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1047.5754 Type 1 Hair Keratin 1 N/A N/A 
1048.5785 Keratin 10 N/A N/A 
1060.5633 Keratin 9 N/A N/A 
1063.5088 Porcine Trypsin (Sigma-Aldrich and Promega) CAM 1006.4873 
1064.6098 Keratin 10 N/A N/A 
1065.4993 Keratin 9 N/A N/A 
1065.5211 Keratin 1 N/A N/A 
1066.5163 Keratin 1 N/A N/A 
1071.5251 Keratin 10 N/A N/A 
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1073.5949 Keratin 1 N/A N/A 
1077.5245 Porcine Trypsin (Sigma-Aldrich and Promega) PAM 1006.4873 
1078.6255 Type 1 Hair Keratin 1 N/A N/A 
1079.5116 Keratin 10 N/A N/A 
1081.4942 Keratin 9 MSO 1065.4993 
1081.5133 Keratin 9 N/A N/A 
1082.4935 Keratin 9 MSO 1066.4986 
1087.52 Keratin 10 MSO 1071.5251 
1087.5279 Keratin 1 N/A N/A 
1092.5028 Keratin 1 N/A N/A 
1095.5469 Keratin 9 N/A N/A 
1096.4662 Type 1 Hair Keratin 1 CAM 982.4233 
1097.5082 Keratin 9 N/A N/A 
1104.596 Type 1 Hair Keratin 1 CAM 1047.5754 
1106.5259 Keratin 10 MSO 1090.531 
1118.6125 Type 1 Hair Keratin 1 PAM 1047.5754 
1121.5837 Keratin 9 N/A N/A 
1124.4976 Type 1 Hair Keratin 1 PAM 982.4233 
1125.5422 Keratin 1 N/A N/A 
1127.5401 Keratin 1 N/A N/A 
1131.5463 Keratin 10 N/A N/A 
1133.5 Background Peak N/A N/A 
1134.5935 Type 1 Hair Keratin 1 N/A N/A 
1138.5925 Keratin 9 N/A N/A 
1140.5354 Type 1 Hair Keratin 1 N/A N/A 
1143.535 Keratin 1 MSO 1127.5401 
1147.5412 Keratin 10 MSO 1131.5463 
1152.5531 Keratin 1 N/A N/A 
1153.5306 Type 1 Hair Keratin 1 N/A N/A 
1153.7 Background Peak N/A N/A 
1154.5874 Keratin 9 MSO 1138.5925 
1157.5143 Keratin 1 MSO 1141.5194 
1157.5909 Keratin 9 N/A N/A 
1158.6041 Keratin 10 N/A N/A 
1159.6542 Keratin 1 N/A N/A 
1169.5255 Type 1 Hair Keratin 1 MSO 1153.5306 
1175.6015 Keratin 1 N/A N/A 
1185.5229 Keratin 10 N/A N/A 
1186.6062 Type 1 Hair Keratin 1 N/A N/A 
1190.6085 Keratin 9 N/A N/A 
1191.615 Type 1 Hair Keratin 1 CAM 1134.5953 
1194 Background Peak N/A N/A 
1197.5568 Type 1 Hair Keratin 1 CAM 1140.5354 
1201.6171 Keratin 10 N/A N/A 
1203.6765 Type 1 Hair Keratin 1 N/A N/A 
1204.6419 Keratin 9 N/A N/A 
1205.6307 Type 1 Hair Keratin 1 PAM 1134.5953 
1206.6034 Keratin 9 MSO 1190.6085 
1206.6147 Keratin 9 N/A N/A 
1211.5725 Type 1 Hair Keratin 1 PAM 1140.5354 
1217.6161 Keratin 1 N/A N/A 
1218.6212 Type 1 Hair Keratin 1 N/A N/A 
1222.6096 Keratin 9 MSO 1206.6147 
1223.4 Background Peak N/A N/A 
1235.5287 Keratin 9 N/A N/A 
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1237.5847 Keratin 10 N/A N/A 
1238.6739 Type 1 Hair Keratin 1 N/A N/A 
1243.6641 Type 1 Hair Keratin 1 N/A N/A 
1260.698 Type 1 Hair Keratin 1 CAM 1203.6765 
1261.5668 Keratin 10 N/A N/A 
1274.7137 Type 1 Hair Keratin 1 PAM 1203.6765 
1277.5869 Keratin 9 N/A N/A 
1277.7099 Keratin 1 N/A N/A 
1280.6481 Keratin 1 N/A N/A 
1300.5296 Keratin 1 N/A N/A 
1302.7012 Keratin 1 N/A N/A 
1302.7151 Keratin 1 N/A N/A 
1309.6382 Type 1 Hair Keratin 1 N/A N/A 
1315.6852 Keratin 9 N/A N/A 
1323.6725 Keratin 9 MSO 1307.6776 
1324.6168 Keratin 10 N/A N/A 
1326.6396 Type 1 Hair Keratin 1 N/A N/A 
1332.5195 Keratin 1 MSO 1300.5296 
1340.6692 Keratin 1 N/A N/A 
1350.6284 Keratin 10 N/A N/A 
1350.6827 Keratin 9 N/A N/A 
1357.6957 Keratin 1 N/A N/A 
1367.6736 Type 1 Hair Keratin 1 N/A N/A 
1381.6481 Keratin 10 N/A N/A 
1383.6903 Keratin 1 N/A N/A 
1390.6808 Keratin 10 N/A N/A 
1391.7277 Keratin 9 N/A N/A 
1392.6502 Keratin 10 N/A N/A 
1393.7321 Keratin 1 N/A N/A 
1399.7652 Type 1 Hair Keratin 1 N/A N/A 
1421.7383 Keratin 1 N/A N/A 
1424.695 Type 1 Hair Keratin 1 CAM 1367.673 
1438.7107 Type 1 Hair Keratin 1 PAM 1367.673 
1450.7244 Keratin 10 N/A N/A 
1460 Background Peak N/A N/A 
1464.6821 Type 1 Hair Keratin 1 N/A N/A 
1465.7394 Type 1 Hair Keratin 1 N/A N/A 
1469.7304 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1469.8434 Keratin 1 N/A N/A 
1471.7499 Type 1 Hair Keratin 1 N/A N/A 
1475.7852 Keratin 1 N/A N/A 
1482.7143 Keratin 1 N/A N/A 
1494.5 Background Peak N/A N/A 
1495.6983 Keratin 10 N/A N/A 
1504.7754 Type 1 Hair Keratin 1 N/A N/A 
1520.7452 Keratin 10 N/A N/A 
1523.7886 Keratin 1 N/A N/A 
1526.7519 Porcine Trypsin (Sigma-Aldrich and Promega) CAM 1469.7304 
1530.6902 Type 1 Hair Keratin 1 N/A N/A 
1537.4 Background Peak N/A N/A 
1539.7835 Keratin 1 MSO 1523.7886 
1540.7676 Porcine Trypsin (Sigma-Aldrich and Promega) PAM 1469.7304 
1542.6675 Keratin 1 N/A N/A 
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1543.6996 Keratin 10 N/A N/A 
1546.6851 Type 1 Hair Keratin 1 MSO 1530.6902 
1546.8509 Type 1 Hair Keratin 1 N/A N/A 
1556.8391 Type 1 Hair Keratin 1 N/A N/A 
1574.6574 Keratin 1 MSO 1542.667 
1586.7656 Keratin 9 N/A N/A 
1599.8336 Keratin 1 N/A N/A 
1603.8723 Type 1 Hair Keratin 1 CAM 1546.8509 
1605.7431 Keratin 9 N/A N/A 
1617.888 Type 1 Hair Keratin 1 PAM 1546.8509 
1619.7156 Keratin 9 N/A N/A 
1622.8271 Keratin 10 N/A N/A 
1625.8493 Type 1 Hair Keratin 1 N/A N/A 
1636.8176 Keratin 10 N/A N/A 
1639.7 Background Peak N/A N/A 
1640.7735 Keratin 10 N/A N/A 
1644.7331 Type 1 Hair Keratin 1 CAM 1530.6902 
1650.7289 Keratin 9 N/A N/A 
1653.8152 Keratin 1 N/A N/A 
1657.7928 Keratin 1 N/A N/A 
1669.8101 Keratin 1 MSO 1653.8152 
1672.7644 Type 1 Hair Keratin 1 PAM 1530.6902 
1687.9701 Keratin 1 N/A N/A 
1707.7721 Keratin 10 N/A N/A 
1708.7132 Keratin 1 N/A N/A 
1712.8925 Type 1 Hair Keratin 1 N/A N/A 
1721.766 Keratin 9 PAM 1650.7289 
1730.9548 Keratin 1 N/A N/A 
1731.9136 Type 1 Hair Keratin 1 N/A N/A 
1736.8424 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1741 Background Peak N/A N/A 
1751.8266 Keratin 1 N/A N/A 
1765.7346 Keratin 1 CAM 1708.7132 
1768.7992 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1779.7503 Keratin 1 PAM 1708.7132 
1787.965 Type 1 Hair Keratin 1 N/A N/A 
1791.7276 Keratin 9 N/A N/A 
1793.8639 Porcine Trypsin (Sigma-Aldrich and Promega) CAM 1736.8424 
1797.0116 Keratin 10 N/A N/A 
1807.8796 Porcine Trypsin (Sigma-Aldrich and Promega) PAM 1736.8424 
1813.8939 Keratin 1 N/A N/A 
1830.9093 Keratin 1 N/A N/A 
1839.1 Background Peak N/A N/A 
1844.9461 Keratin 1 N/A N/A 
1848.9926 Type 1 Hair Keratin 1 N/A N/A 
1853.9 Background Peak N/A N/A 
1855.9218 Keratin 9 N/A N/A 
1867.9218 Keratin 9 MSO 1851.9269 
1869.0552 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
1871.9167 Keratin 9 MSO 1855.9218 
1880.9534 Keratin 10 N/A N/A 
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1881.8865 Type 1 Hair Keratin 1 N/A N/A 
1881.9705 Keratin 1 N/A N/A 
1882.8422 Porcine Trypsin (Sigma-Aldrich and Promega) CAM 1768.7992 
1896.9484 Keratin 10 MSO 1880.9534 
1910.8735 Porcine Trypsin (Sigma-Aldrich and Promega) PAM 1768.7992 
1938.9589 Keratin 9 N/A N/A 
1953.1127 Keratin 10 N/A N/A 
1954.9538 Keratin 9 MSO 1938.9589 
1957.9688 Type 1 Hair Keratin 1 N/A N/A 
1966.0603 Keratin 9 N/A N/A 
1973.9637 Type 1 Hair Keratin 1 MSO 1957.9688 
1985.8943 Keratin 1 N/A N/A 
1994.7 Background Peak N/A N/A 
1996.9709 Keratin 10 N/A N/A 
1998.941 Type 1 Hair Keratin 1 N/A N/A 
2005.0937 Type 1 Hair Keratin 1 N/A N/A 
2013.907 Keratin 10 N/A N/A 
2017.8841 Keratin 1 MSO 1985.8943 
2022.025 Type 1 Hair Keratin 1 N/A N/A 
2037.9876 Type 1 Hair Keratin 1 N/A N/A 
2038.0161 Keratin 9 N/A N/A 
2045.9637 Type 1 Hair Keratin 1 N/A N/A 
2047.0627 Type 1 Hair Keratin 1 N/A N/A 
2069.9781 Type 1 Hair Keratin 1 PAM 1998.941 
2070.9284 Keratin 10 CAM 2013.907 
2079.9146 Keratin 1 N/A N/A 
2084.9441 Keratin 10 PAM 2013.907 
2091.8822 Keratin 9 N/A N/A 
2102.9851 Type 1 Hair Keratin 1 CAM 2045.9637 
2104.0842 Type 1 Hair Keratin 1 CAM 2047.0627 
2105.0621 Type 1 Hair Keratin 1 N/A N/A 
2109.0532 Keratin 9 PAM 2038.0161 
2117.0008 Type 1 Hair Keratin 1 PAM 2045.9637 
2118.0998 Type 1 Hair Keratin 1 PAM 2047.0627 
2121.018 Keratin 1 N/A N/A 
2146.0159 Keratin 9 N/A N/A 
2150.0777 Keratin 1 N/A N/A 
2155.0812 Type 1 Hair Keratin 1 N/A N/A 
2158.0307 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2174.0256 Porcine Trypsin (Sigma-Aldrich and Promega) MSO 2158.0307 
2176.0992 Keratin 10 N/A N/A 
2203.0144 Keratin 9 MSO 2171.0246 
2205.0716 Keratin 9 N/A N/A 
2210.0472 Keratin 10 N/A N/A 
2212.0979 Keratin 10 N/A N/A 
2212.1026 Type 1 Hair Keratin 1 CAM 2155.0812 
2215.0522 Porcine Trypsin (Sigma-Aldrich and Promega) CAM 2158.0307 
2221.0666 Keratin 9 MSO 2205.0716 
2226.1183 Type 1 Hair Keratin 1 PAM 2155.0812 
2229.0678 Porcine Trypsin (Sigma-Aldrich and Promega) PAM 2158.0307 
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2234.1775 Type 1 Hair Keratin 1 N/A N/A 
2236.9536 Keratin 1 N/A N/A 
2247.1788 Type 1 Hair Keratin 1 N/A N/A 
2271.1291 Keratin 9 N/A N/A 
2283.0921 Keratin 10 N/A N/A 
2285.9628 Keratin 10 N/A N/A 
2286.1248 Keratin 1 N/A N/A 
2293.9751 Keratin 1 CAM 2236.9536 
2298.1506 Type 1 Hair Keratin 1 N/A N/A 
2299.1196 Keratin 9 N/A N/A 
2299.175 Porcine Trypsin (Sigma-Aldrich and Promega) MSO 2283.1801 
2304.2002 Type 1 Hair Keratin 1 CAM 2247.1788 
2307.1826 Type 1 Hair Keratin 1 N/A N/A 
2307.9907 Keratin 1 PAM 2236.9536 
2318.2159 Type 1 Hair Keratin 1 PAM 2247.1788 
2325.1577 Keratin 9 N/A N/A 
2329.1742 Keratin 1 N/A N/A 
2329.1816 Keratin 9 N/A N/A 
2331.1074 Type 1 Hair Keratin 1 N/A N/A 
2331.1094 Keratin 9 MSO 2299.1196 
2338.2361 Type 1 Hair Keratin 1 N/A N/A 
2340.1136 Keratin 10 CAM 2283.0921 
2341.1526 Keratin 9 MSO 2325.1577 
2345.1765 Keratin 9 MSO 2329.1816 
2349.2183 Keratin 1 N/A N/A 
2354.1292 Keratin 10 PAM 2283.0921 
2355.1721 Type 1 Hair Keratin 1 CAM 2298.1506 
2356.9999 Keratin 10 PAM 2285.9628 
2357.2306 Keratin 9 N/A N/A 
2369.1877 Type 1 Hair Keratin 1 PAM 2298.1506 
2377.1881 Keratin 9 N/A N/A 
2382.1792 Keratin 9 CAM 2325.1577 
2388.1288 Type 1 Hair Keratin 1 CAM 2331.1074 
2396.1948 Keratin 9 PAM 2325.1577 
2400.2115 Keratin 1 N/A N/A 
2402.1445 Type 1 Hair Keratin 1 PAM 2331.1074 
2409.164 Keratin 10 N/A N/A 
2416.2064 Keratin 1 MSO 2400.2115 
2457.2 Porcine Trypsin (Sigma-Aldrich and Promega) N/A N/A 
2463.2838 Type 1 Hair Keratin 1 N/A N/A 
2508.1453 Keratin 1 N/A N/A 
2510.1317 Keratin 9 N/A N/A 
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